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The paediatric, nephroblastoma Wilms' Tumour, affecting 1 in 10,000 children, is a disease
where the disruption in the normal events of kidney development leads to tumour formation.
The WT1 gene has been shown by knockout experiments to be crucial in kidney and gonadal
development. The structure of the protein, which contains four zinc fingers of the Kriippel-
type, together with in vitro work, suggests WT1 is a transcription factor. Other work however
also suggests that the protein may be involved in post-transcriptional regulation as WT1
localises and co-immunoprecipitates with splicing factors. The structure of the protein also
backs up this possible role as WT1 has a putative RNA recognition motif and the zinc fingers
can bind RNA in vitro.
The genuine functions of WT1 are thus not clear so this project set out to address what WT1
is doing at the molecular level. By looking for WT1-binding proteins, 1 aimed to investigate
which components of the cellular machinery WT1 is interacting with, as it is only once we
comprehend the molecular mechanism behind development that we will begin to understand
the link with tumourigenesis.
Using a yeast two hybrid screen I identified a protein that interacts with the C-terminus of
WT1. As this protein is novel, with no homologues found in the yeast or invertebrate
databases, it was called NAL (Novel Associating Ligand). NAL was mapped, using FISH, to
human chromosome 6q26-27, a location which possibly harbours a tumour suppressor gene.
The mouse homologue was cloned and, at the amino acid level, is 94% identical to the
human clone. This sequence conservation suggests that whatever the role of this novel
protein may be, its structure must be important for function. Using FISH and the EUCIB
resource, the mouse homologue was mapped close to the centromere on chromosome 17, a
region which has conserved synteny with human 6q26-27 and which maps close to the
murine T-locus.
In vitro assays showed that the interaction between NAL and WT1 could occur outside of the
yeast two hybrid system and in vivo co-immunoprecipitation experiments revealed that the
interaction is physiologically relevant as it occurs in WT1-expressing cells. Expression
studies using RT-PCR and whole mount in situ hybridisation showed that NAL is
ubiquitously expressed. The expression pattern of NAL during development of the kidney
and testis was also investigated to see if, like WT1, NAL is confined to the developing
nephron and Sertoli cells respectively. Immunohistochemistry revealed that NAL is
expressed in all cells of these organs and thus is not exclusively localised to cells expressing
WT1, suggesting that NAL may play a housekeeping role.
Immunofluorescence indicated that N AL is a nuclear protein and its distribution within the
nucleus was interesting as it resembled that of WT 1: a speckled pattern within an overall
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diffuse staining. Immunocytochemistry confirmed that this protein, like WT1, does indeed
co-localise with splicing factors. Thus it will be of interest to see if this protein really is
involved in splicing. Unfortunately no further functional assays could be carried out and so
future work needs to be carried out to determine its true role and the potential






Wilms' tumour (WT), or nephroblastoma, is a paediatric tumour of the kidney which
was first described by Max Wilms in 1899. It is one of the most common childhood
cancers occurring in 1 in 10,000 children (Matsunaga, 1981; Pritchard Jones and
Hastie, 1990). WT is a striking example of a tumour which has arisen due to
development gone wrong and thus serves as a model system for studying the link
between development and tumourigenesis.
1.1 Clinical Presentation
The initial clinical manifestation of WT is frequently as a large abdominal mass
detected by parents but it can manifest itself with several other symptoms. Most
cases of WT are unilateral, where the tumour affects only one kidney, but 5-10% of
children can be affected bilaterally. WT is usually diagnosed by the age of six, with
the median age of presentation being 3.5 years, although older children and even
adults have been known to be affected. Females have a higher incidence especially
for the bilateral cases and they are also usually older by an average of six months
when they are diagnosed (Breslow and Beckwith, 1988). WT occurs to the same
extent world-wide although it does seem to vary between different ethnic groups
even within the same geographical area, suggesting that there is a genetic component
leading to disease predisposition (Kramer et al., 1984).
WT often comes associated with other congenital diseases, especially in children
with bilateral tumours. The first association seen was that of WT arising together
with sporadic Aniridia (absence of the iris), Genitourinary abnormalities and mental
.Retardation, giving rise to the WAGR syndrome (Miller et al., 1964). Reckwith-
Wiedemann Syndrome (BWS) is a disease which leads to gigantism,
hemihypertrophy, large tongue, hyperplasia of the kidneys, gonadal abnormalities
and a predisposition to several neoplasms including WT (Beckwith, 1969). Denys-
Drash Syndrome (DDS) is associated with male pseudohermaphroditism,
progressive renal insufficiency and Wilms' Tumour (Denys et al., 1967; Drash et al.,
1970). The Perlman syndrome involves foetal gigantism, bilateral nephromegaly and
cryptorchidism (undescended testis) as well as WT (Perlman et al., 1973).
The treatment of WT has advanced dramatically compared to earlier days when the
disease was almost always fatal - there is now a 90% cure rate (Weiner et al., 1998).
This enhanced success rate is due to improved clinical management arising from
large multicentre trials which were first carried out in the USA by the National
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Wilms'Tumour Study (NWTS) (D'Angio et al., 1989). The NWTS classified the
extent of the disease into various stages according to the histopathology. The
multimodal therapy aims to decrease treatment intensity for the earlier stages, using
only surgery and chemotherapy, whilst the more aggressive tumours in later stages
will also be given radiotherapy.
1.2 Histology
The malignant transformation occurring in WT is thought to arise from cells within
the metanephric blastema which have lost developmental control. These
mesenchymal cells can undergo a switch to become epithelial cells and would
normally form the nephron after having been induced by the ureteric bud (see
section 1 7.1). However, in WT malignant mesenchymal cells have continued to
divide beyond their normal point in kidney development, and the progeny cells have
attempted to differentiate but cannot do so correctly. Due to this, WT is often
classified as triphasic as the tumour can contain blastemal, epithelial and stromal
components. WTs can vary according to which component predominates and some
even show further multilineage differentiation with the presence of skeletal muscle,
bone and cartilage (Hastie, 1994; Miyagawa et al., 1998),
It has been noted that islands of cells resembling metanephric blastema can persist
into postnatal life (Beckwith et al., 1990). These lesions, called nephrogenic rests,
have been found in only 1% of infant postmortems whereas the incidence in WT
kidneys increases to 40% in unilateral and 100% in bilateral cases, suggesting that
they are premaiignant and predispose to tumour development. The location of these
lesions varies among WT patients. One type of rest is called the perilobar
nephrogenic rest (PLNR) and this is found near the periphery of the renal lobe,
whereas the other type is called intralobar nephrogenic rest (ILNR) and is found
within the renal lobe. The ILNR are usually associated with early events occurring
in the developing kidney and are often found in children who are diagnosed with
WT at an early age, compared to the PLNR which is found in WT diagnosed at a
later stage. PLNRs are also found generally in patients that have BWS, whereas
ILNRs are normally found in WT from WAGR syndrome (Beckwith, 1997). This
observation may suggest that there are different predisposing genes to WT which
may be involved in distinct developmental pathways within the kidney and their
inactivation may disnipt kidney development at discrete time points.
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1.3 Genetic Loci Associated With WT.
1.3.1 The Knudson Model And WT1
WT are usually unilateral and sporadic but 5-10% are bilateral and a further 1-2%
familial (Breslow and Beckwith, 1988). WT is therefore likely to follow the
Knudson model of retinoblastoma, RB (Knudson, 1971), since the latter can also be
either unilateral or bilateral, familial or sporadic. Knudson predicted that for RB to
develop both alleles of a tumour suppressor gene would have to be mutated. Bilateral
cases would carry a germline mutation in one allele of the appropriate tumour
suppressor gene, therefore since all cells had a mutation, only one additional genetic
hit in the other allele would be required to allow for tumourigenesis. This would
explain the incidence of bilateral tumours and the early age of onset. Unilateral cases
have a higher incidence but a later age of onset as the child is not predisposed to the
tumour and requires two independent genetic mutations. A year later Knudson and
Strong proposed a similar "two-hit" model for WT which suggested that there was a
specific WT locus and therefore maybe WT, like RB, was caused by loss of function
of a tumour suppressor gene (Knudson and Strong, 1972).
Unfortunately the genetics of WT has turned out to be more complicated than that of
RB and the proposed model cannot account for all aspects of WT. Unlike the
situation with RB, which only has one predisposing gene, WT seems to have
multiple genes leading to the disease. One of the WT genes, WT1, was localised by
cytogenetic studies, which identified chromosome 11 alterations in patients with the
cancer. Molecular analysis of deletions associated with WAGR, as well as a
homozygous deletion in a WT, mapped the gene to 11 p 13 (see section 1.4). WT1
was shown to act as a classical tumour suppressor gene as introduction of various
WT1 isoforms into a WT cell line resulted in the suppression of both in vitro and in
vivo growth (Haber et ah, 1993). WT1 was therefore the gene involved in WT which
would follow the Knudson hypothesis. Loss of heterozygosity (LOH) studies, using
polymorphic markers to the short arm of chromosome 11, had also been used to
determine whether this chromosomal region was regularly disrupted in Wilms'
tumours. In chromosomal regions showing LOH, one allele of a particular locus is
lost and this can lead to tumour formation if the locus affected carries a tumour
suppressor gene and the other allele had already been mutated. LOH can arise due to
mitotic recombination; chromosome loss followed by re-duplication of the sister
chromosome; or deletion of a region of one of the two sister chromosomes. These
LOH studies only detected such allele losses in 30-40% of all WT cases studied, and
out of these, a few were restricted to the 11 pi3 region, but most involved the 11 p 15
-4-
Ch 1 Introduction
region (Henry et al., 1989; Koufos et al., 1989; Reeve et al., 1989). These two
chromosomal regions on lip must therefore carry two genes involved in WT.
1.3.2 The WT2 Locus
The WT2 gene at locus 1 lpl5 has still not been cloned although there are candidate
genes. As the BWS and the WT2 gene are present on the same chromosomal region,
it is not yet know whether they are the same gene or two separate genes which are
closely linked. Interestingly the LOH in the tumours all seem to be from the maternal
chromosome (Schroeder et al., 1987), raising the possibility that perhaps the gene
could be imprinted. Also of interest is the fact that some sporadic BWS patients
have chromosome anomalies where there is uniparental paternal disomy (UPD) for
11 p 15, and it is these patients that frequently go on to get embryonal tumours
(Henry et al., 1991). The insulin-like growth factor II gene, IGF2, has already been
mapped to 1 lpl5 and is therefore a good candidate, especially as it is known to be
imprinted with only the paternal copy of the gene active (DeChiara et al., 1991;
Ohlsson et al., 1993). IGF2 is a growth factor highly expressed during the
embryonic development of many organs, including the kidney. IGF2 has been
shown to have increased expression in WTs (Reeve et al., 1985) and this could be
because in cases where there is UPD there would now be two active copies of the
paternal gene thus leading to IGF2 overexpression and hence overgrowth symptoms.
There have also been reports where there is biallelic expression of IGF2 in WTs,
occurring due to loss of imprinting (LOI) (Ogawa et al., 1993). This again would
lead to overgrowth and tumours. There is, however, no direct evidence that IGF2 is
the second WT gene, and there have been no specific mutations of the IGF2 gene
reported in WTs.
There is another imprinted candidate gene at 1 lp 15, H19. This gene is maternally
active and can be transcribed to form RNA but it is not translated (Bartolomei et al.,
1991). It has been shown that overexpression of this RNA can suppress the
tumourigenicity of a rhabdomyosarcoma cell line (Harrington et al., 1993) and thus
may be a tumour suppressor gene. Therefore in UPD or in loss of the maternal copy
of 11 pi5 in tumours would mean that no HI9 is transcribed which would allow for
tumour formation. More recent findings, however, suggest that F119 is not a tumour
suppressor gene (Lustig-Yariv et al., 1997) and thus the role of H19 is not really
known There is no evidence to show that HI9 is the WT2 gene.
Another imprinted gene associated with BWS, is the p57kip2 gene. This gene maps
to 11 pi5.5 and is a cyclin-dependent kinase inhibitor that arrests cells in Gl. If the
-5-
Ch 1 Introduction
maternal allele is lost there would be a decrease in p57kip2 expression, due to the
gene being paternally imprinted, leading to an overgrowth phenotype as there would
no longer be negative regulation of the cell cycle. However, in WT there seems to be
no altered expression of p57kip2 compared to normal tissue, suggesting that this
gene is not the WT2 gene (Overall et al., 1996).
The efforts to clone the WT2 gene have been hampered because of the large size of
the locus, 10MB. However recently Kamik et al. have narrowed this locus down by
using high density marker LOH analysis of 1 lpl5.4-15.5, and have refined the WT2
locus to 800kb within 11 p 15.5, but they also think there is a second distinct locus in
that area predisposing to WT (Kamik et ah, 1998). The genetics at the 1 lp 15 locus
remain unclear and therefore the search for these genes continues.
1.3.3 Additional WT Genes
Significantly LOH at chromosome 11 only accounts for 30-40% of WT suggesting
that there must be more genes predisposing to the disease. There have been reports
on LOH for markers at 16q in approximately 20% of WT cases (Maw et ah, 1992),
and a further 12% of cases with LOH at lp. However there are other tumours which
also have LOH at these loci and therefore these loci may be associated with tumour
progression (Grundy et ah, 1994).
Familial WT is very rare, with only 1% of cases having hereditary transmission. It is
inherited as an autosomal dominant trait with incomplete penetrance (Breslow and
Beckwith, 1988; Breslow et ah, 1996). Out of these only 3 cases have been linked to
chromosome llpl3or llpl5, and further genetic linkage analysis excluded the
whole of chromosome 11 from transmission of disease susceptibility (Grundy et ah,
1988; Huff et ah, 1988), suggesting that there must be at least a third WT locus. The
fact that familial WT is so rare complicates the search for a familial WT gene.
However Rahman et al. described a family in Canada which showed linkage of WT
to chromosome 17ql2-21 (Rahman et ah, 1996). Surprisingly there is no LOH at
this locus and therefore FWT1 cannot be acting as a tumour suppressor gene in the
classical sense. Perhaps a mutation in FWT1 may be sufficient to start some familial
WTs but then the maintenance of the neoplasm becomes independent of the FWT1
(Rahman et ah, 1997). Further work has shown that in other pedigrees, there is
exclusion of linkage to 17ql2-q21 (Huff et ah, 1997), and therefore maybe there is
more than one gene which predisposes to WT in large pedigrees. Subsequently
McDonald et al. found linkage of familial WT to chromosome 19q in five families
studied, and they have called this the FWT2 locus. However they show that there is
-6-
Ch 1 Introduction
another site on 19q different to FWT2 which may be acting in two different families
(McDonald et al., 1998), This work taken together shows that the etiology of WT is
genetically heterogenous.
1.4 Cloning The Wilms' Tumour Gene, WT1
As discussed in section 1.3, cytogenetic studies on patients who had the WAGR
syndrome were crucial in starting to pinpoint the WT1 locus, as it was noted that
these patients had deletions at 11 p 13 (Francke et al., 1979; Riccardi et al., 1978).
Molecular analysis of a large number of WAGR-associated deletions allowed the
WT1 gene to be mapped to a region within 1 lpl3 (Compton et al., 1988; Rose et al.,
1990). It was then shown that the WT1 locus was separate to that causing aniridia as
there were cases of sporadic aniridia which did not have WT, and these patients were
not associated with the WT1 locus but instead the one lying next to it, PAX6, (Davis
et al., 1988). A homozygous deletion in a sporadic WT eventually narrowed the
WT1 region to 350 kb (Lewis et al., 1988). The WT1 gene, within this deleted region
of 1 lpl3, was positionally cloned independently by two different groups. Call et al.
used a library of human genomic DNA deri ved from a somatic cell hybrid to identify
clones that were homozygously deleted in sporadic WTs. The genomic clones were
then used to isolate cDNAs encoding the WT1 gene (Call et al., 1990). The gene
was also isolated by Gessler et al. but they used a different technique called
chromosome jumping based on the presence of CpG islands which occur at 5' ends
of transcription units (Gessler et al., 1990).
1.5 Structure Of WT1
The WT1 gene spans 50kb of DNA and has 10 coding exons (Call et al., 1990;
Gessler et al., 1992; Haber et al., 1991). Northern blot analysis using a WT1 cDNA
showed that the transcript formed is 3kb (Call et al., 1990; Pritchard Jones et al.,
1990) which can encode up to 16 different isoforms (Schedl and Hastie, 1998) by
means of an alternative start site (Bruening and Pelletier, 1996), alternative splicing
(Haber et al., 1991; Hsu et al., 1992) and RNA editing (Sharma et al., 1994), figure
1.1. These different isoforms therefore produce proteins that range from 50-55kD
(Bruening and Pelletier, 1996; Morris et al., 1991) depending on which combination
of start and splice sites are present. The same reading frame is maintained for each
of the different isoforms. There are two alternative splice sites: the first
includes/excludes 17 amino acids (17aa) encoding exon five; and the second
adds/removes the three amino acids lysine, threonine and serine (KTS) between
exons 9 and 10. The resulting isoforms will be named according to which
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combination of splice sites are selected such that if exon 5 and the KTS do not get
spliced out, the protein will have the +17aa and the +KTS and will be called +/+. If
exon 5 and the KTS do get spliced out, the protein will be -17aa and -KTS therefore
named -/-. If the protein has +17aa but -KTS it will be called +/- and if it has the
17aa spliced out but contains +KTS it will be called -/+. The ratio of each of the
four transcripts in the developing mouse kidney is 8.3 +/+; 3.8 +/-; 2.5 -/+; 1 -/-
(Brenner et al., 1992), and the ratio seems to remain constant throughout
development (Haber et al., 1991). It is not yet known whether these isoform ratios
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Figure 1.1: Schematic of the WT1 gene and protein structure. Adapted from
Huff and Saunders, 1993 and Menke et al 1998.
By studying the conservation of the WT1 cDNA throughout evolution, the
importance of the different isoforms and domains seen in the protein can be
determined. Kent et a/, isolated full length cDNAs from chickens and alligators and
partial clones from fish and amphibia. The zinc finger region between all vertebrates
studied, including human, mouse and rat are 99% identical, even to the extent of the
+/- KTS site being conserved. Recently Miles et al. have shown that in the
pufferfish, Fugu rubripes, the 3 amino acids are KPS not KTS, but they can still be
spliced out (Miles et al., 1998). This suggests that the alternative splice site and the
zinc fingers have a very important role for the function of WT1 in all these animals.
The rest of the protein has 87% homology but interestingly the 17aa alternative
splice site, the proline rich domain and the RNA editing are not conserved between
-8-
Ch 1 Introduction
all vertebrates, only among mammals (Kent et al., 1995; Miles et al,, 1998), The
other vertebrates therefore do not have as many isoforms of WT1 as mammals and
this could reflect the fact that mammals have a different, more complex
genitourinary system.
The predicted protein sequence shows that WT1 has several motifs which could help
in the functional characterisation of the protein. The most obvious motif is that of 4
zinc fingers (ZF) of the Kriippel type at the C-terminus (Call et al., 1990). The last
three ZFs show close homology to those found in the EGR1 family of transcription
factors and therefore possibly form a DNA binding domain. The N-terminus has a
proline-glutamine rich domain which has also been found to be common to
transcription factors (Mitchell and Tjian, 1989). Another motif which has been
found in the WT1 protein is a potential leucine zipper (Madden et al., 1993) and this
motif is frequently associated with protein-protein interactions. Finally using
structural modelling Kennedy et al. have recognised a possible RNA recognition
motif (RRM) suggesting that WT1 may bind RNA (Kennedy et al., 1996). From
these motifs it seems that WT1 possibly acts as a transcription factor, but since there
is a likely RRM domain there could be other potential roles.
1.6 Functions OfWTl
1.6.1 WT1 As A Transcription Factor
DNA-binding specificity ofWTl
The structure of the WT1 protein has helped tremendously in trying to ascertain its
function. The zinc fingers of WT1 are of the type where a zinc ion is co-ordinated
by two cysteine and two histidine residues (C2H2 class). This motif has been found
in site-specific DNA binding proteins, and the most highly homologous protein to
WT1 in the zinc finger region is EGR1. Structural analysis of EGR1 showed that
the protein fits into the major grooves of DNA and each of the fingers interact with
specific nucleotides within the 9 base pair sequence GCG GGG GCG (Pavletich and
Pabo, 1991). As the last three zinc fingers of WT1 are so homologous to the EGR1
protein, Rauscher et al. investigated whether the same consensus sequence could be
bound by WT1 Using bacterially expressed WT1 -KTS zinc fingers and gel
retardation assays they showed that this zinc finger region of WT1 could indeed bind
to this sequence but they also showed that W'Tl could bind to slightly different
sequences (Rauscher et al., 1990). As WT1 can bind to the same consensus
sequence as EGR1, it may seem likely that these two proteins compete for the same
binding site However, Hamilton et al. have shown that the presence of the first zinc
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finger in WT1, which is not so closely homologous to the EGR1 zinc fingers,
apparently affects the DNA binding properties of WT1, generating a GC-rich 12bp
consensus recognition site (Hamilton et al., 1995).
The presence of the three amino acids, KTS, between zinc fingers three and four
causes the spacing between these two fingers to alter such that the EGR1 consensus
sequence can no longer be bound with such high affinity. There is therefore a
difference in DNA binding specificity between the + and - KTS isoforms. The
+KTS fingers can however still bind to DNA but the sequences they bind to differ to
those bound by -KTS fingers (Bickmore et al., 1992). Hence it seems likely that by
producing alternative isoforms, WT1 can bind to different target sequences and
therefore potentially to different target genes. However, it remains unclear as to
what the real consensus sequences are for the different WT1 isoforms.
Potential target genes for WT1
The structure of WT1 and the fact that it can bind to DNA suggests that WT1 acts as
a transcription factor. With this in mind it was then shown that WT1 expressed from
a cytomegalovirus (CMV) expression vector could repress transcription from a
synthetic chloramphenicol acetyltransferase (CAT) reporter construct containing
three Egrl sites (Madden et al., 1991). The repressor domain of WT1 was mapped to
amino acids 85-124 and Madden et al. showed that if they fused this domain to the
zinc fingers of EGR 1, the heterologous protein would now function as a
transcriptional repressor too. Thus unlike EGR1 which activates transcription, WT1
seems to act as a transcriptional repressor. The 17aa of exon five also seem to have
a function in increasing the degree of repression, as it was shown that the WT1 +/+
protein suppresses the activity of the WT1 promoter about 25 fold better than the
WT1 -/+ protein (Rupprecht et al., 1994).
In an attempt to identify authentic cellular targets, the IGF2 promoter was also used
in these experiments. IGF2 had been reported to be overexpressed in WT and the
BWS, which has paternal duplications of the chromosomal region containing IGF2,
also has a predisposition for WT. The promoters that drive IGF2 expression are GC
rich and contain several potential WT1 binding sites and for all these reasons, it was
thought that perhaps the IGF2 gene could be a target for WT1 transcriptional
repression. In these in vitro experiments, WT1 did repress transcription directed
from the IGF2 promoter (Drummond et al., 1992). DNase I footprinting and gel




WT1 (Hofmann et al., 1993)
EGR1 (Rauscher et al., 1990)
IGF2 (Drummond et al., 1992)
IGF1R (Werner et al.s 1993)
PDGF-A (Wang et al., 1992)
EGFR (Englert et al., 1995a)
RARa (Goodyer et al., 1995)
PAX2 (Ryan et al., 1995)
Inhibin-a (Hsu et al., 1995)
Bcl2 (Hewitt et al., 1995)
c-myc (Hewitt et al., 1995)
ODC (Moshier et al., 1996)
CSF-1 (Harrington et al., 1993)
TGF(3 (Dey et al., 1994)
Nov (Martinerie et al., 1996)
Midkine (Adachi et al., 1996)
p21 (Englert et al., 1997)
Table 1.1: Potential target genes regulated by WT1
Since then, there have been several other potential target genes whose expression can
be regulated by WT1 as shown in the table 1.1. For a full review of potential targets
and WT1 DNA-binding sequences see Menke et al., 1998(b). Although it seems that
there is a large list of potential targets for WT1, care must be taken because all of
these assays have been carried out in vitro and not under physiological relevant
conditions. Also it may be misleading to suggest that WT1 is always acting a
repressor because it has been found that under certain conditions WT1 can activate
transcription For example the reporter constructs used seems to affect the activity
of WT1, as has been highlighted by the case of the PDGF-A gene. If the 5'residues
to the start site of the PDGF-A gene were used, WT1 acted as a activator but if the 5'
and 3'residues of the PDGF-A promoter were used, WT1 now seemed to repress
transcription (Wang et al., 1993). The activation domain of WT1 seems to map to
position 181-250 and it can act independently of the repression domain. The activity
of WT1 also seems to depend on the cell line used (Moshier et al., 1996) as well as
on the expression vectors used to drive expression of WT1 (Reddy et al, 1995a).
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WT1 therefore seems to be able to both activate some target genes and repress
others. This could reflect the role WT1 plays in kidney development, as it may
repress genes involved in proliferation and activate those that instead cause the cell
to differentiate into epithelial cells. WT1 also seems to regulate genes that are
involved in apoptosis, and so it appears that loss of WT1 function deregulates
multiple pathways that maintain cell growth in check and the loss of this regulation
can result in tumour formation.
1.6.2 WT1 As A Post-Transcriptional Regulator
WT1 is associated with splicing factors
The initial experiments carried out all pointed towards WT1 being a classical tumour
suppressor gene whose function was to regulate the transcription of genes involved
in proliferation. It has since been discovered that perhaps there is a further function
for WT1 as a post-transcriptional regulator. The initial studies came from Larsson et
al. where the subnuclear localisation of WT1 was examined. They looked at the
nuclear staining pattern of WT1 in a mesonephric cell line (Ml5) which expresses
WT1 endogenously. They found that WT1 staining not only gave a diffuse pattern,
as is found for other transcription factors, but there was also a characteristic
speckled pattern (Charlieu et al., 1995; Larsson et al., 1995). These 20-50 distinctly
stained irregular foci, which exclude the nucleolus, have been previously
documented for the subnuclear localisation of splicing factors (Spector et al., 1991).
These speckles are interchromatin granule clusters, and it is believed that they are
either storage sites for splicing factors, or sites where the splicing factors are pre-
assembled into spliceosomes, a multicomponent complex involved in splicing.
Splice factors are then recruited from these speckles to the perichromatin fibrils,
which are the sites where active transcription occurs, where they then remove the
introns from the nascent pre-mRNA (Misteli et al., 1997; Spector, 1996). By
transfecting each isoform in turn into COS cells Larsson et al. found that it was
mainly the -KTS isoforms that produced the diffuse pattern whereas the +KTS
isoforms went predominantly into the speckles. By using double labelling
experiments they showed that the speckles where WT1 was present overlapped with
the speckles stained by splicing factors, and so the idea that WT1 might play a role
in splicing arose.
Englert et al. carried out similar experiments and they seem to disagree with the idea
that WT1 has a role in splicing as they think that the speckled structures for WT1 are
different to the structures that contain pre-mRNA splicing factors. They showed,
using an inducible cell line, that some of WT1 +KTS did co-localise with a
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spliceosome assembly factor, SC35, but a lot of the WT1, as well as the mutant
forms of the protein, seemed to go into other large foci which did not co-localise
with SC35 (Englert et ah, 1995b). They suggest that these sites are merely storage
sites for mutant WT1 protein or for the WT1 protein that has a decreased DNA-
binding affinity. Although it is possible that they may act as storage sites, as it is
known that both active and inactive splice factors are stored in the speckles (Gama-
Carvalho et ah, 1997), it seems unlikely that all the +KTS isoforms, which are the
most abundant forms of WT1, would be stored due to its decreased DNA-binding
affinity and for it not to have any other function. Further evidence to suggest that at
least some of the WT1 present in the speckles may have a role in splicing came from
showing that WT1 could directly interact with splicing factors as an antibody
directed against splicing factors could co-immunoprecipitate WT1 in vivo (Larsson
et ah, 1995).
There is other evidence to suggest that WT1 is indeed involved in splicing.
Continuing on from Larsson's work, Davies et at. wanted to investigate whether
WT1 does directly interact with the splicing machinery and if so with which
components. They have now shown that, both in the yeast two hybrid system and in
vivo, WT1 can bind to U2AF65, a protein required for the binding of the U2 snRNP
to the intron branch point adjacent to the 3' splice site (Zamore et ah, 1992), and
may therefore have a role in 3' splice site selection (Davies et ah, 1998). Furthermore
they showed that the +KTS isoform bound to this splicing factor with the greatest
affinity, supporting the idea that the WT1 +KTS isoform, which is the predominant
form found in speckles, functions in splicing. They also provide evidence that WT1
can become incorporated into spliceosomes in vitro.
WT1 can bind to RNA
It has been suggested that WT 1 can not only contact DNA through its zinc fingers,
but it can also bind to RNA. WT1 has been shown to bind to the promoter sequence
of the lgf2 gene and also to sequences within exon 2, which is one of three
alternative 5' untranslated leader exons, at the RNA level (Caricasole et al., 1996).
They demonstrated that for this RNA binding, it was the zinc finger region which
was contacting the transcript and they showed that it was specific to WT1 as the
closely related EGR1 protein could not do so. More specifically they established
that it was zinc finger 1 that had a more significant role in RNA binding, compared
to zinc finger 4. Bardeesy et al. also showed that WT1 could bind to RNA. Using an
RNA selection method, they pulled down 3 groups of RNA ligands which are
specifically recognised by WT1 but they show that zinc fingers 2-4 and not zinc
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finger 1, were important for binding (Bardeesy and Pelletier, 1998). Thus it seems
that different combinations of fingers can again select for different RNA binding
sites. There have been other reports showing that WT1 may have the potential to
bind to RNA. Kennedy et al. used molecular modelling to show that WT1 has an
RNA recognition motif (RRM) mapping at the N-terminus of the protein (Kennedy
et al., 1996). This region is totally separate from the zinc fingers, suggesting that
WT1 can contact RNA by more than one mechanism. These findings that WT1 can
bind to RNA are carried out in vitro and it is not known how this reflects the in vivo
situation. However this is not the first example of a protein binding to both DNA
and RNA. TFIILA, which is another zinc finger protein can also regulate gene
expression by both transcriptional and post-transcriptional mechanisms (Ladomery,
1997). Nevertheless further work needs to be carried out to determine what the real
RNA targets for WTl are, and the consequences of such an interaction.
1.6.3 WT1 is involved in cell growth regulation and apoptosis
The importance of the WT1 function in suppression of cell growth was shown when
WT1 was identified as a tumour suppressor gene. In these experiments, wild type
WT1 was reintroduced into a Wilms' tumour cell line expressing an aberrantly
spliced WT1 transcript, and shown that it could suppress cell growth (Haber et al.,
1993). Kudoh et al. also showed that microinjection of a WT1 cDNA into cells that
were at early G[ stage, blocked cell cycle progression into S phase (Kudoh et al.,
1995). This cell cycle arrest by WT1 seems to be associated by the induction of p21,
independent of p53 (Englert et al., 1997). WT1 and p21 are found in the same
developing structures within the kidney and perhaps they work together to stop cells
from proliferating and start differentiating (see section 1.7.1).
Some cells undergo apoptosis after their Gi arrest by WT1, as shown by the
induction of WT1 (especially the -KTS isoforms) in U20S and Saos-2 cells (Englert
et al., 1995a). They also showed that the induction of cell death by WT1 was
associated with reduced expression of EGFR. The role of WT1 in apoptosis is
important as it is part of the developmental programme of the kidney (Koseki et al.,
1992; see section 1.7.1).
If, however, WTl is expressed at lower levels, it represses p53-mediated apoptosis.
At these lower levels, WTl cannot repress EGFR and so does not induce apoptosis,
but instead binds to p53 and inhibits p53-mediated apoptosis due to ionising
radiation (Maheswaran et al., 1995). This could explain why mesenchymal cells in
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the developing kidney which normally undergo an epithelial transition (see section
1.7.1) actually undergo apoptosis in wtl-null mice (Kreidberg et al., 1993).
Whether a cell undergoes apoptosis depends on several signals it receives, and the
levels of WT1 seem to influence whether apoptosis will occur. Apart from the
pathways already mentioned, the regulation of bcl-2 and c-myc by WT1 will also
determine whether a cell goes into apoptosis (Hewitt et al., 1995). The role of WT1
in growth arrest and apoptosis is known to be important as it was shown that the
adenovirus can transform cells by expressing the E1B 55 K protein which sequesters
WT1, along with p53, within a cytoplasmic body thus not allowing them to carry
out their function (Maheswaran et al., 1998a).
1.6.4 WT1 Can Interact With Several Cellular Proteins
In order for WT1 to carry out its various roles it must interact with the cellular
machinery. Whether WT1 activates or represses transcription; is involved in post-
transcriptional modifications; or represses cell growth and induces or inhibits
apoptosis will depend to a certain extent on its interaction with other cellular
proteins. This was first seen with p53, which was shown to bind to WT1 by
immunoprecipitation experiments and by doing so affecting the transcriptional
activity of WT1 as shown by transfection assays. In the absence of p53, WT1
activates an EGR1 reporter but in the presence of p53 it acts as a repressor of EGR1
transcription (Maheswaran et al., 1993). The binding of WT1 to p53 also affects
apoptosis as described earlier.
It has also been shown that WT1 can bind to more proteins than just p53. WT1
itself can dimerise as shown using the yeast two hybrid system. The domain required
for this self-association has been mapped to position 1-182 (Englert et al., 1995b).
The human prostrate apoptosis response-4 (par-4) protein also binds to WT1, as
shown by in vitro and in vivo experiments (Johnstone et al., 1996). Par-4 is a novel
protein required for apoptosis in prostatic cells. By binding to WT1, par-4 inhibits
its transcription activation and augments the repression activity as shown by
transient transfection studies. Par-4 does not affect the DNA-binding activity of
WT1 so it has been suggested to function by bringing another repressor domain to
the promoter. Par-4 also seems to be able to rescue the growth suppression caused
by WT1 and sensitises cells to apoptosis (Sells et al., 1997). Thus WT1 is a protein
partner to par-4 and attenuates its function to block cell growth and apoptosis.
Increased par-4 expression would reverse the WT1 effects.
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WT1 can also bind to UBC9, the human ubiquitin conjugating enzyme (Wang et al.,
1996). The exact effect this has on the function of WT1 is not clearly understood
but it may affect the role WT1 plays in the cell cycle. WT1 (-/+) and (+/+) can block
the cell cycle progression into S-phase by downregulating the activities of CDK2
and CDK4. This block can be overcome by overexpression of cyclin E/CDK2 as
well as cyclin D1/CDK4 (Kudoh et al., 1995). UBC9 probably acts by the
degradation of S- and M-phase cyclins (Seufert et al., 1995) and so has a role in cell
cycle progression. Therefore if WT1 binds to UBC9 it may impose a cell cycle
block by affecting the fate of the S- and M-phase cyclins that are degraded by
ubiquitination.
The inducible heat shock protein 70, Hsp70, is another protein that WT1 binds to, as
shown by co-immunoprecipitation experiments (Maheswaran et al., 1998b). Hsp70
binds to the extreme amino terminus of WT1, and it may ensure correct folding of
this domain, enhancing the functional properties of WT1. Binding of Hsp70 by
WT1 appears to be necessary for the latter to be able to induce p21 expression and
mediate a G] phase cell cycle arrest.
Ciaol, identified by its ability to bind to WT1, is another protein that can mediate
the transcriptional activation of WT1 (Johnstone et al., 1998). Unlike par-4 though,
it does not affect the repression activity. Ciao 1 is a novel protein and is a member of
the WD40 family. Proteins containing the WD40 repeats have several functions
including cell cycle regulation, RNA splicing, and transcription. Thus although it
has been shown by transient transfections that Ciao 1 can affect the transcriptional
activity of WT1, it may also affect some of the other roles of WT1.
The steroidogenic factor 1 (SF-1) protein has also been shown to bind to WT1, and
the binding is isoform specific as SF-1 only binds to the -KTS isoforms. Together
they are involved in promoting Miillerian inhibiting substance (MIS) expression
which determines the fate of the gonad (Nachtigal et al., 1998; see section 1.7.2) and
thus their interaction is vital for gonadal development.
It is clear that there must be other cellular proteins with which WT1 interacts for it to
carry out its many roles in transcriptional control, splicing, apoptosis and cell cycle
regulation.
1.7 Expression Pattern Of WT1
The expression pattern of WT1 has been looked at in detail to try to gain further
insights into its role in development and tumourigenesis. Northern blot analysis
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initially showed that WT1 could be detected in foetal kidney, spleen, testis, ovary
and some weak expression in the brain (Pritchard Jones et ah, 1990). More detailed
analysis examined the spatial and temporal expression pattern of wtl in situ
(Armstrong et ah, 1993). They showed that wtl is first expressed in the intermediate
mesoderm but is then more strongly expressed in the urogenital system during
organogenesis. Wtl is also expressed in the mesothelium, an epithelial tissue which
surrounds the internal organs of the body. There is also some expression of wtl
along the spinal cord and a region of the brain; adult bone marrow (Fraizer, 1995);
lymph nodes; and peripheral blood (King-Underwood et ah, 1996). Apart from the
latter regions, wtl is present in tissues of mesodermal origin that undergo a
mesenchyme to epithelial transition. This expression pattern seems to fit in with the
tissues affected when WT1 is mutated.
1.7.1 The Expression Of WT1 In The Developing Kidney And The Wtl
Knockout Mouse
The expression pattern of WT1 has been studied extensively in the developing
kidney (Armstrong et ah, 1993; Pelletier et ah, 1991b; Pritchard Jones et ah, 1990).
Its pattern of expression suggests that WT1 has a role in at least three stages of renal
development: both at the onset and during progression of nephrogenesis and also in
the maintenance of mature podocyte function.
The development of the kidney has been studied in both humans and mice and they
follow similar pathways. A brief description of mouse kidney development will be
described to show the importance of the different areas where wtl is expressed. For
reviews on kidney development see Davies, 1996; Davies and Bard, 1996; Lechner
and Dressier, 1997; Saxen, 1987.
During embryonic day 8 and 10 (E8 and E10) the pronephros and mesonephros are
formed, and these are transient precursors for the permanent kidney. These
rudimentary kidneys consist of the nephric, or Wolffian, duct and some tubules. By
E10.5 the ureteric bud (which is the primordium of the renal collecting duct)
evaginates from the most caudal end of the duct and invades the blastema of the
metanephric mesenchyme. At this stage, the mesenchyme are the only cells that
express wtl albeit at a low level (figure 1.2). The metanephric kidney then starts to
form through the reciprocal interactions of these two tissues. The interaction
induces the formation of a metanephric mass over the growing ureteric bud, which
in turn causes the latter to branch within the metanephric blastema. The blastema is
induced to condense at the tip of each branch, which in turn causes further
branching and thus a wave of nephrogenesis occurs throughout the developing
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kidney. The expression of wtl is upregulated in the condensing mesenchyme. The
condensed mesenchyme then undergoes a burst of proliferation before differentiating
into epithelial cells that form the renal vesicle, which continues to express wtl. At
this stage there is a wave of regression which removes the pro- and mesonephros.
The renal vesicle then undergoes morphological changes and first forms a comma
shaped body, so called because cells further from the collecting duct become
elongated and a slit forms within the vesicle. Another slit is then formed but this
time at the distal end, near the collecting tubules and this structure is now called an
S-shaped body. At this point wtl expression is confined to the proximal end of the
vesicle. The distal end of the S-shaped body then joins the collecting duct and a
series of collecting tubules are formed. The proximal end of the vesicle becomes the
Bowman's capsule, the inner cells of which form the glomerular podocytes and this
is where wtl expression is confined to. Wtl expression in the glomerulus will
remain postnatally but at a lower level. This is the only place in the mature kidney
where wtl is expressed as any remaining mesenchyme which has not been induced
by the ureteric bud undergoes apoptosis (Koseki et ah, 1992).
As can be seen from these expression studies, WT1 must have an important function
in the formation of the nephron. Mutations in WT1 do lead to developmental
abnormalities within the kidney, but there are no known humans with a null
mutation for WT1 which would prove that WT1 is essential for early stages of
nephrogenesis. Kreidberg et al. therefore used gene targeting to produce wtl null
mice (Kreidberg et ah, 1993). These mice, which die at mid-gestation due to heart
defects, have no metanephric kidneys at all as the metanephric mesenchyme fails to
differentiate and therefore undergoes apoptosis. The ureteric bud does not grow out
and degenerates. This therefore proves that wtl must be essential for kidney
development and suggests it may have a role in producing the signal which is
thought to be secreted to induce the ureteric bud. The exact nature of this signal is
not yet known and in fact there are many gene products produced during kidney
development but it is not known how they all function and interact with each other
to form the kidney (Davies and Brandli, 1994). One potential candidate signalling
molecule required for ureteric bud formation and branching is the glial cell line
derived neurotrophic factor (GDNF). GDNF is expressed by the mesenchyme and it
binds, via the receptor tyrosine kinase Ret, to the tip of the ureteric bud, causing
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Figure 1.2: Diagram illustrating the expression pattern of WT1 during
nephrogenesis. WT1 is expressed at low levels in the mesenchyme (light
shading), and the expression is then upregulated during the condensing of the
mesenchyme around the ureteric bud (stronger shading). WT1 expression then
remains on in the comma-shaped bodies, as well as the S-shaped bodies except
that it becomes localised to the proximal end. The expression of WT1 finally







1.7.2 WT1 Expression in the Gonads
The wtl knockout mouse showed that WT1 was also essential for gonad
development as the gonads failed to develop (Kreidberg et al., 1993). This is not
surprising as gonad development is linked to kidney development. Initially gonadal
development is the same for both sexes and starts as a thickening of the coelomic
epithelium to form the primary sex cords. The gonad rapidly grows out from the
urogenital ridge into the coelomic cavity forming the genital ridge which continues
to express wtl. The genital ridge runs the full length of the mesonephros. As this is
occurring a second duct is formed, called the Miillerian duct, and like the
mesonephric duct it does not express wtl.
At around El3 the differentiation programme for the female and male gonads differ.
In the testis the seminiferous cords form within the mesenchyme and they consist of
epithelial Sertoli cells (McLaren, 1998). The cords themselves enclose the germ
cells, which give rise to spermatogenesis and it is only the Sertoli cells surrounding
the cysts with the early spermatogonia that express WT1 (Rio-Tsonis et al., 1996).
This suggests that WT1 may be involved in germ cell maturation. In the Sertoli cells
SF-1 and WT1 associate in vitro to promote expression of the Miillerian inhibiting
substance (MIS) to inhibit the development of the Miillerian duct (Nachtigal et al.,
1998) which would otherwise, through a default pathway (Ramkissoon and
Goodfellow, 1996), form the fallopian tubes of the ovaries. The germ cells produce
testosterone which causes the mesonephric duct to differentiate into the Vas
Deferens, which at the level of the gonad becomes convoluted to form the
epididymis.
For the ovaries to form, Dax-1 antagonises the interaction between SF-1 and WT1 in
the Sertoli cells (Nachtigal et al., 1998) so that MIS is not expressed and the default
pathway can proceed. In the ovary there are no seminiferous tubes and germ cells
become surrounded by granulosa cells which express wtl. The germ cells of the
ovary produce oestrogen which causes regression of the entire mesonephric duct. It
also causes the Miillerian duct to differentiate into the oviduct. The caudal ends of
the oviducts then fuse to form the uterus.
WT1 therefore plays an important role in gonad development and this can be seen
both in humans, where if WT1 is mutated gonadal dysgenesis such as that found in
DDS occurs, and in the knockout mouse where no gonads develop. However
because after gonad development has occurred WT1 is still expressed both in Sertoli
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cells and in granulosa cells, it suggests it may also play a role in both sperm and
follicle development (Hsu et al., 1995; Rio-Tsonis et al., 1996).
1.7.3 Regulation of WT1 Expression
Unlike many other ubiquitously expressed tumour suppressor genes, WT1 has a
specific expression pattern which is temporally and spatially restricted (Armstrong et
al., 1993). The expression of WT1 has to be tightly regulated as its misexpression
could lead to disastrous consequences. For instance WT1 can increase the tumour
growth rate of adenovirus-transformed baby rat kidney cell line (Menke et al., 1996)
and if WT1 is expressed from a CMV promoter in transgenic mice such that it would
be ubiquitously expressed, it causes embryonic lethality (Menke et al., 1998a).
The upstream regulatory elements of the WT1 gene control region have been
characterised and the promoter seems to be TATA-less and GC-rich (Hofmann et al.,
1993), and it has multiple transcription start sites present (Pelletier et al., 1991b). A
far upstream cis-element, approximately 15kb upstream of the transcription start
site, has been identified. This element is necessary but not sufficient for wtl
expression in human foetal kidney cells in culture (Scholz et al., 1997). Hofmann et
al. (1993) have also shown by DNase I footprinting that there are several sites within
the promoter where Spl binds and by transient transfections they showed that the
WT1 promoter was activated in response to Spl. Initially it seemed strange that Spl
could regulate the expression of WT1 as Spl is ubiquitously expressed and therefore
would not be able to produce the specific expression pattern seen for WT1.
However a more detailed study of Spl showed that the levels of Spl expression are
not constant but that it is expressed most highly in the areas where there is WT1
expression (Cohen et al., 1997). Hofmann et al. also found WT1 binding sites
within the WT1 promoter and it seems that WT1 itself can regulate its own
expression in a negative feedback loop.
Other genes which seem to affect WT1 expression are Pax2 and Pax8 both belonging
to the paired box family of genes and involved in kidney development. The WT1
promoter has two Pax2 binding sites and transient transfections show that WT1
expression is upregulated by Pax2 (Dehbi et al., 1996). Pax2 expression is induced
in the condensing mesenchyme and it is after this, in the formation of the renal
vesicle that WT1 expression increases. Interestingly it is then that the Pax2
expression falls. As mentioned earlier, WT1 can repress the expression of Pax2
(Ryan et al., 1995), and therefore when Pax2 expression peaks, it activates WT1
expression, which in turn turns off Pax2 expression via a feedback loop. Pax8
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which is expressed at its highest level during renal vesicle formation has been shown
to activate the WT1 promoter (Dehbi and Pelletier, 1996) and it is at this stage that
WT1 expression peaks too. When levels of Pax8 decrease so do the levels of WT1,
which may also be due to WT1 inhibiting expression at its own promoter (Rupprecht
et al., 1994).
It has been noted that WT1 expression can be specifically regulated in
haematopoietic cell lines as the promoter has a cell-line specific enhancer within the
3' end of the gene (Fraizer et al., 1994) which is transactivated by GATA-1 (Wu et
al., 1995). This is of interest because WT1 is thought to be expressed in organs
involved with haematopoiesis.
Although we are beginning to understand a little more about how the expression of
WT1 is regulated it is still not understood how the precise temporal and spatial
expression is achieved. It is also not known whether the factors affecting WT1
expression work together or whether they compete for sites on the promoter.
Following isolation of the genomic WT1 from pufferfish Fugu rubripes (Miles et al.,
1998) work is in progress to examine the promoter region. As the genome of the fish
is a lot more compact, it should highlight those regions which are most important for
proper expression. Transgenic mice containing this fish WT1 can be used to
investigate whether the fish genomic WT1 clone contains all the regulatory elements
in the promoter region for it to be expressed in the appropriate areas in the
mammalian kidney, an organ which is very primitive in the lower vertebrates.
1.8 WT1 Involved In Disease
Mutations in WT1 have been shown to be involved in the development of WT, and it
was thought that WT1 was acting as a classical tumour suppressor gene, and patients
with the WAGR syndrome would have both copies of the WT1 gene inactivated.
However, extensive studies have shown that fewer than 15% of WT cases actually
have WT1 mutations and that therefore there are other genes, such as the WT2 and
the FWT1 and FWT2 (see section 1.3), which predispose to this disease to a greater
extent than WT1 (Gessler et al., 1994). The studies carried out however cannot
guarantee that all mutations in WT1 are detected and therefore the precise
percentage of WT in which WT1 is involved in is not known.
There are also cases where only one WT1 allele is mutated and thus WT1 would not
be acting as a classical tumour suppressor gene. Heterozygosity could, however, still
predispose to WT as there may be haploinsufficiency leading to tumourigenesis.
However mice lacking one allele of wtl do not develop WT (Kreidberg et al., 1993)
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which suggests that haploinsufficiency of wtl does not lead to WT. On the other
hand, there are cases where WTI is known to be heterozygously mutated, such as in
some cases of DDS. A large proportion of DDS patients have a missense mutations
within exon 9 resulting in a replacement of an arginine for a tryptophan at position
394 (Pelletier et al., 1991a). Most other patients have mutations somewhere in the
zinc finger region and all of these cause the WT1 protein to lose its ability to bind to
DNA (Little et ah, 1995). This would suggest that the mutant protein must actively
be involved in bringing about the disease because it is known from the mice studies
that reduced levels of WT1 alone do not lead to WT. It has been shown that the
mutant WT1 protein, which cannot bind to DNA, dimerises to the wild type WT1
protein and inhibits its transcriptional activation (Moffett et ah, 1995; Reddy et ah,
1995b). The mutant protein therefore acts in a dominant negative fashion.
Frasier syndrome (FS) is a disease which shows the importance of maintaining the
correct isoform ratio of WT1 for normal development. FS is a rare, dominant
heterozygous disease defined by male pseudohermaphroditism and progressive
glomerulopathy but no WT. This disease is thought to arise through a mutation in
the intron of exon 9 which would lead to the loss of +KTS and an imbalance of the
WT1 ratios, thus showing the importance of all the WT1 isoforms (Barbaux et al.,
1997). The phenotype of this disease suggests that the -KTS isoforms, and not the
+KTS isoforms, are involved in acting as tumour suppressor genes, as patients with
FS do not develop WT,
Apart from these syndromes, mutations in the WTI gene are also thought to be
involved in other tumour types. The types of tumours that have WTI mutations
correlate with the expression pattern seen for WTI. For example, WTI is expressed
in the mesothelium and WTI mutations have been found in non-asbestos related
mesothelioma (Park et al., 1993). However, it should be noted that only 1
mesothelioma out of 100 had WT1 mutations (Langerak et al., 1995). Mutations in
WTI are also thought to be involved in leukemias as WTI is highly expressed in a
range of acute leukemias and haematopoietic cell lines and mutations in the gene
have been found to be present in this disease (King-Underwood et al., 1996; Miwa et
al., 1992). Ovarian tumours have also been found to contain WTI mutations
(Bruening et al., 1993). Thus a picture is emerging where WTI is not just involved




1.9 Summary and aim of project
Wilms' tumour is a good model to study the link between cancer and development.
There are several genes predisposing to the disease, but only the WT1 gene has been
cloned and shown to be directly involved in urogenital development. The gene
encodes 16 different isoforms of a protein that has a structure resembling other
transcription factors as it has four zinc fingers, three of which are highly
homologous to the EGR1 family. The protein also has a proline-glutamine rich
domain which again is found in other transcription factors. Indeed, transient
transfections have shown that WT1 can either activate or repress certain target
genes. It has been noted that WT1 can have different effects in different cell lines
and this must depend on the presence of other cellular components which WT1 can
interact with.
The structure of the protein, however, also points to a role in post-transcriptional
regulation as the zinc fingers are also capable of binding to RNA and there is a
possible RNA recognition motif at the N-terminus. The +KTS isoform of WT1 has
been found in speckled structures of the nucleus, which are often associated with
splicing factors, and WT1 has been shown to bind to splicing factors in vivo. Thus
the various isoforms seem to play different roles in the cell, although it is not known
how much each isoform contributes to the various functions.
Detailed expression studies have shown that WT1 is expressed mainly in cells that
are undergoing a mesenchyme to epithelial transition, although there are other
pockets of expression. The main areas where WT1 is found are in the developing
kidney and gonads and it shows a highly regulated spatial and temporal expression
pattern. Although the wtl knockout mice show that WT1 is essential for urogenital
development, the expression of WT1 continues on in some adult structures, such as
the Sertoli cells and the follicular cells of the male and female gonads respectively as
well as in the podocytes, suggesting that WT1 may play a further role in these
structures.
It is thought that WT1 may function by controlling the expression of genes involved
in cell proliferation and apoptosis. From the expression pattern seen in the kidney, it
is likely that WT1 represses these genes and activates other genes involved in
differentiation, thus allowing for the mesenchyme to epithelial transition. WT1
mutations may lead to tumour formation due to mutant WT1 having lost the ability
to bind to DNA and thus it would not be able to repress those genes involved in
cellular proliferation leading to mass cellular production without any differentiation.
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Although a lot of progress has been made in trying to understand the role of WT1
there is still a lot to learn. It is not yet clear how WT1 brings about its functions and
why there are so many isoforms. How does WT1 bring about both activation or
repression of certain genes? Which genes are targeted by WT1? Are all isoforms
involved in transcription? The environment WT1 is in seems to affect its function.
However, it is not yet known how WT1 interacts with other cellular components to
bring about the required activity. The potential role of WT1 in splicing is still very
controversial. It is not really known if WT1 causes post-transcriptional regulation -
does it bind to certain transcripts, and if so which? What happens to any of the
transcripts which are bound by WT1? Does WT1 affect the splice site selection?
These are all questions that still need to be addressed. It is very important to find out
with which other components of the cellular machinery WT1 is interacting. By
identifying other proteins which WT1 binds to, we may start to shed some light as to
how WT1 acts at the molecular level. This project will therefore use the yeast two
hybrid system as a tool to identify WT1-interacting proteins. By knowing the
function of the proteins WT1 binds to we may gain some insight into how WT1 can
apparently have so many different activities. The different isoforms can be looked at
to see if they all bind similar proteins. For example the +KTS isoforms might tend to
bind to proteins involved in splicing whereas the -KTS isoforms may bind to
proteins which could affect their transcriptional activity. Proteins involved in cell
cycle regulation and apoptosis may also emerge as indeed may new proteins which
may suggest that WT1 also has further roles other than those already documented. It
is only once we know the function of WT1 at the molecular level that we will be able
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Chapter 2: Materials and Methods
2.1 Bacterial Work




TGI supE, hsdA5, thiA(lac-proAB), F'[traD36, proAB+, lacIqZAM15]
Y1090 supF, hsd R, araD 139Alon, AlacU169rpsL,
trpC22::TnlO(tetr)pMC9
XL-1 Blue supE44, hsdR17, recAl end Al, gyrA46, thi rel Allac
F'[proAB+, lacf1, lacZAM15,TnlO(tetr)]
2.1.2 Media and Additives
All bacterial media was provided by in house stores, unless otherwise stated.
L-Broth - lOg tryptone, 5g yeast extract, lOg NaCl, and 2.46g MgS04 in 1 litre H20.
L-Agar - lOg tryptone, 5g yeast extract, lOg NaCl, 2.46g MgS04 and 15g agar
(Oxoid Ltd) in 1 litre H20.
CY-TOP - lOg casamino acid, 5g yeast extract, 3g NaCl, 2g KC1 and 6g agarose.
Ampicillin (Amp, Sigma)- This antibiotic was added to agar and broth in order to
select for bacteria carrying the ampicillin resistance gene on a plasmid. A stock
solution of ampicillin was made up at a concentration of 50mg/ml in dH20. The
solution was filter sterilised and stored at -20°C. It was added to broth and agar to a
final concentration of 60pg/ml.
Chloramphenicol (CA, Sigma)- This antibiotic was added to agar and broth to select
for bacteria carrying the chloramphenicol resistance gene. A stock solution is made
to a concentration of 34mg/ml in ethanol and stored at -20°C. Use at a final
concentration of 170(lg/ml.
5-Bromo-4-Chloro-3-Indolyl|3 -D-Galacopyranoside (X-gal) (Sigma)- X-gal is the
substrate for (3-galactosidase which when metabolised turns blue. It is added to agar
to allow for blue/white colour selection of colonies carrying the plasmid with the p-
galactosidase gene. If the plasmid is recombinant, the P-galactosidase gene will be
disrupted and the colonies will turn white as the X-gal will not be broken down.
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Blue colonies will have the intact plasmid. Stock solution was made at a
concentration of 20mg/ml in dimethylformamide (DMF, Sigma). It was stored
protected from light at ~20°C and used at a final concentration of 40pg/ml.
Isopropyl [3-D Thiogalactopyranoside (IPTG, Sigma) - IPTG is a derepressor of the
Lac operon. It was added to agar to induce the (3-galactosidase gene and thus in
conjunction with the X-gal could be used for the blue/white selection of colonies.
Stock solutions were made at a concentration of lOOmM. It was stored at -20°C and
used at a final concentration of 0.5mM.
2.1.3 Bacterial Glycerol Stocks
lOmls of bacterial culture were grown in a 37°C shaker for 4 hours, until opaque
Cells were pelleted at 3500rpm for 10 minutes and then re-suspended in 2mls of
15% glycerol in L-Broth. They were then frozen in liquid nitrogen and stored at -70
°C.
2.1.4 Preparing Bacterial Competent Cells
Bacterial cells were streaked out from glycerol stocks onto an L Agar plate and
incubated at 37°C overnight. lOmls of L-Broth were inoculated with a single colony
and grown overnight, shaking in a 37°C incubator. The overnight culture was then
used to inoculate a further 500mls of L-Broth and left to shake in the 37°C incubator
until they reached log phase (OD59o=0.7).
Cells were pelleted by spinning at 5000rpm for 5 minutes, and washed with 250mls
of cold 0.1M MgCL and pelleted again. They were re-suspended in 250mls of cold
0.1M CaCl2 and incubated on ice for 20 minutes. Cells were harvested and re-
suspended in 42.5mls 0.1M CaCl2 and 7.5mls sterile glycerol. Aliquots were frozen
in liquid nitrogen and stored at -70°C.
2.1.5 Transformation of Competent Cells
Competent cells were thawed on ice for 15 minutes. lOfils of a plasmid were mixed
with lOOpls of cells and incubated on ice for 30 minutes. Cells were heat shocked at
37°C for 2 minutes and then incubated on ice for a further 15 minutes. The
transformation mixture was then plated on pre-warmed L-Agar plates containing the
appropriate selection.
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2.1.6 Small Scale Preparation of Plasmid DNA
Manual Minipreping
When large numbers of transformed colonies had to be screened for recombinant
plasmids, the alkaline lysis method of plasmid preparations was used according to
Molecular Cloning: A Laboratory Manual.
2mls of L-Broth containing the appropriate antibiotic was inoculated with a single
bacterial colony and grown overnight at 37°C with vigorous shaking. Cells were
spun down in a microfuge and the growth medium was removed, leaving the
bacterial pellet as dry as possible.
The bacterial pellet was then re-suspended in lOOpls of solution I (50mM glucose,
25mM 2-amino-2(hydromethyl)-l,3-propanediol (Tris).Cl (pH 8.0), lOmM
ethylenediaminetetra-acetic acid disodium salt (EDTA) (pH 8.0)) followed by 200(1
Is of solution II (0.2M NaOH, 1% sodium dodecyl sulphate (SDS)) and the tube
inverted several times to mix the contents. The tubes were stored on ice for 5
minutes. 150pls of solution III (3M acetate, 5M potassium ions) was added and the
tubes mixed to disperse the lysate through solution III. Tubes were stored on ice for 5
minutes and then spun at 12,000g for 5 minutes. A phenol:chloroform extraction
was carried out on the supernatant to remove any salts, proteins and solvents from
the DNA. The double-stranded DNA was precipitated with 2 volumes of ethanol,
and the DNA pellet was then washed with 1ml 70% ethanol, and the pellet allowed
to air-dry. The DNA pellet was then dissolved in 50pls of lOmM Tris.Cl (pH8.0),
ImM EDTA (pH 8.0) (TE) containing DNase -free RNase (20|ig/ml).
Qiaprep Spin Plasmid Kit
For increased purity of the DNA required for sequencing, a Qiagen kit was used
according to the manufacturer's instructions.
2.1.7 Large Scale Preparation of Plasmid DNA
For large pure quantities of DNA, Qiagen maxiprep (500 Tips) kits were used,
according to the manufacturer's instructions.
2.2 Yeast Two Hybrid Work
2.2.1 Strain Used
The strain of yeast used for the yeast two hybrid (Y2H) system was Y190, whose
genotype is: MATa, gal4, gal80, his3, trpl-901, ade2-101, ura3-52, leu2-3, -112
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URA3::GAL-lacZ, LYS2::GAL(UAS)-HIS3,cyh.r. This strain therefore has lacZ and
the yeast biosynthetic gene HIS3 as the reporter genes under the control of Gal4-
upstream activator sequence (UAS).
2.2.2 Vectors
The vectors used in the Y2H were the Gal4p DNA-binding domain vector pASl-
CYH2 (gift from Dr. Elledge, Texas) and the Gal4p activation domain vector
pGADIO (Clontech). The genes of interest had to be subcloned in frame to produce
fusion proteins with either the DNA-binding domain or the activation domain
2.2.3 cDNA Libraries
The cDNA library used in the screen was the Clontech human foetal kidney library,
made up as a Gal4p transcription activation domain fusion library. A cDNA library
from the mesonephric cell line, Ml5, was made in house together with Dr. Michael
Ladomery by following the HybriZAP Two-Hybrid cDNA Gigapack Cloning Kit
from Stratagene.
2.2.4 Yeast Transformations
A preculture of Y190 was made by inoculating 1 Omls of YPD (1 Og yeast extract,
20g peptone, 20g D-glucose per litre, autoclave) supplemented with 200fils of
adenine (2mg/ml) with a single colony of the yeast. The culture was placed at 30°C
overnight.
lOOpls of the preculture was then inoculated into lOOmls YPD supplemented with
lml of adenine (2mg/ml). It was allowed to grow at 30°C until it reached an OD60o
of 0.7. The yeast was then spun down at 2000rpm for 5 minutes and washed in
20mls sterile water. This was repeated again and after the second wash the yeast
were re-suspended in lml LiAcTE (lOOmM LiOAc, lOmM Tris pH 8, ImM EDTA.
Autoclave) and transferred to an eppendorf. They were then spun for 20s and re-
suspend in lml LiAcTE, so as to make yeast competent to take up the vectors to be
transformed. This step was then repeated. The yeast were re-suspended to a final
volume of 1ml in LiAcTE and kept on ice.
Meanwhile the transformation material was prepared by adding 0.5pg of the plasmid
DNA with 5pg of library DNA, together with 50p.g of salmon sperm DNA. 50pls of
the prepared yeast was added to each transformation tube as well as 300pls 40%
polyethylene glycol (PEG, MW 3350, dissolved in 1 x LiAcTE) and the mixture was
vortexed. The tubes were incubated at 30°C for 30 minutes followed by heat shock
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at 42°C for 20 minutes. The tubes were then spun again and the PEG removed,
leaving no trace of it. The yeast were re-suspend in 1 ml of YPD and incubated at 30°
C for 1-2 hours. The yeast were then plated out onto AH and 50mM AT plates (see
below) and incubated at 30°C for up to a week.
Yeast plates are made as follows:
20g/l glucose, 6.7g/l yeast nitrogen base without amino acids, 20g/l bacteriological
agar (Oxoid), 800mg adenine. Amino acids and additives were added as required
(see below) and the media was then autoclaved.
AH plates: Add histidine at 20mg/l. These plates select for yeast that have both
vectors transformed and thus can synthesise their own leucine and tryptophan.
50mM 3-AT: Add 3-amino-l,2,4-triazole (3-AT, Sigma). Yeast that have been
transfected will express the two proteins encoded by the cDNA cloned into the
vectors described in section 2.2.2. If the two proteins interact, they will reconstitute
the Gal4 transcription factor which will active transcription of the His3 gene, and
therefore will grown on plates that have not been supplemented with histidine. To
ensure there is no background level of histidine 3-AT is added to the plates
otherwise yeast which do not have the two interacting proteins would grow. 3-AT
removes basal levels of histidine and so allows for the selection of yeast carrying two
interacting proteins.
2.2.5 (3-Galactosidase Yeast Filter Lifts Assay
The yeast strain used carries a (3-galactosidase gene as a second reporter and this
reporter can therefore be used to determine whether an interaction between two
proteins of interest is occurring. It was therefore used as a way of eliminating false
positives during a library screen as well as trying to determine whether deletion
constructs of one particular protein can still bind to its partner protein in the same
way that the wild type protein could. The clones of interest, including positive and
negative controls were taken from AH plates and streaked onto fresh AH plates.
Once the colonies had grown a fdter lift was carried out by transferring the colonies
onto a filter paper (Whatmann qualitative grade 1). The filter paper was then dipped
into liquid nitrogen to permeabilise the yeast, and the filter was allowed to thaw. It
was then placed, yeast side up, on top of another filter paper which was soaked in
0.18ml lOx buffer Z (0.6M Na2HP04, 0.4M NaH2P04, 0.1M KC1, 0.01M MgS04,
0.5M (3-mercaptoethanol) and 30pls X-gal (20mg/ml in DMF). The filters were
incubated at 30°C until a blue colour developed.
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2.2.6 Liquid (3»GaIactosidase Assay
This assay can be used to compare the different strengths of the interactions between
proteins (Estojak et al., 1995). The yeast transformed with the plasmids of interest
were grown in lOmls of AH media and grown to OD60o of 0.7. The yeast were then
spun down at 2000rpm for 5 minutes and re-suspended in 1ml of sterile water. The
yeast were spun down again and re-suspended in 250pls Tris pH 7.5/0.05% Triton
X-100 and frozen in liquid nitrogen and stored at -70°C until required for further
use. 200pls of this yeast extract was then added to 0.8mls of lx buffer Z (see section
2.2.5) and 0.2ml of ONPG (4mg/ml). They were incubated at 30°C until a yellow
colour developed, with the time of reaction being noted. The reaction was then
terminated by adding 0.3ml of 1M Na2C03, and it was placed on ice. The debris
were spun down and the OD42owas measured. In the meantime a protein
concentration reading from 5jils of the yeast extract was taken using the BioRad
protein assay (see section 2.6.4). The [3-galactosidase activity could then be
calculated using the following formula:
Activity = (1000 x OD420)/ (volume of yeast used/ml x time for colour to
develop/minutes x protein concentration/mg/ml)
2.2.7 Recovery Of Plasmids From Yeast Into E. coli
The plasmid of interest could be recovered and re-tested against other bait plasmids
used as negative controls, or it could be sequenced. To recover the plasmid, the
yeast had to be streaked onto AHT plates (AH plates containing tryptophan at
20mg/l, which was added after autoclaving). As the vector containing the
tryptophan selectable marker is no longer required the yeast start to lose the vector at
a low frequency when grown at 30°C. A single colony that had grown on these
plates was then grown on AHT-cyclohexamide plates (2.5pg/ml of cyclohexamide
dissolved in water and filter sterilised). The Y190 strain is resistant to
cyclohexamide due to a mutation in the CYH2 gene, but the pASl-CYH2 plasmid
contains a wild type CYH2 gene thus causing the yeast to be sensitive. Thus when
the yeast are grown on this medium, only yeast which have lost the pASl-CYH2
plasmid can survive. To ensure that this plasmid has been lost, a [3-galactosidase
yeast filter lift can be done, and there should be no blue colour developing.
The remaining pGADIO plasmid was then extracted from the yeast by adding a loop
of yeast from the streaked yeast on the AHT-cyclohexamide into an eppendorf
containing plasmid release buffer (2% Triton X-100, 1% SDS, 0,1M NaCl, 0.01M
Tris pH 8, 0.001M EDTA), 300p.ls glass beads (Sigma), lOOpls phenol and lOOpls
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chloroform. The yeast were vortex well for 2 minutes and spun for 5 minutes. A
chloroform extraction was then carried out on the supernatant. The DNA was then
precipitated (see section 2.3.8) and the plasmid could then be transformed into
bacteria (see section 2.1.5).
2.3 DNA Manipulations
2.3.1 Restriction Endonuclease Digestion of DNA
DNA was digested with the appropriate endonuclease using the specified buffer,
according to the manufacturers. The enzyme volume never exceeded 10% of the
final reaction volume as the glycerol in the enzyme solution can inhibit the
endonuclease. The digests were typically carried out for 2 hours at 37°C, except
were specified by the manufacturers. If a double digest was to be carried out, then
only if both enzymes required the same buffer and temperature where they used
simultaneously. Otherwise, the enzyme requiring the lowest salt concentration was
used for the digestion first, and after a couple of hours the second buffer and enzyme
were added and allowed to digest for another two hours.
2.3.2 DNA Gel Electrophoresis
DNA molecules can be separated according to size using agarose gel electrophoresis.
In general a 1 % gel was run, but if smaller fragments were to be resolved, then a
higher percentage gel was used. The gels were made in TBE buffer (20 X TBE: 1M
Tris.Cl, pH 8.0; 20mM EDTA; 1M boric acid, pH 8.3) unless the fragments were to
be purified from the gel in which case a low melting point agarose (Flowgen) was
used and this was made using TAE buffer (20 X TAE: 0.8M Tris.Cl pH 8.0; 20mM
EDTA; 0.4M acetic acid). The DNA to be run on the gel was first mixed with lOx
loading buffer (20% ficoll; lOOmM EDTA; Orange G (Sigma)) to one tenth of the
final volume. A DNA ladder (A DNA digest with Hind III together with (J)X174
digested with Hae III) was also run on the gel for size markers. After electrophoresis
the DNA fragments could be visualised on a UV transilluminator as the gel had been
stained with ethidium bromide (0.5|ig/pl).
2.3.3 Dephosphorylation of Linear Plasmid DNA
If subcloning is carried out with an enzyme that leaves compatible ends on the cut
plasmid, the cut plasmid DNA has to be dephosphorylated to prevent the ends from
re-annealing. Thus after the digest, lpl of calf intestinal alkaline phosphatase (CIP)
and its corresponding buffer were added and placed at 37°C for an hour. To
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inactivate the CIP, the reaction was shifted to 75°C for 10 minutes. Before ligation,
the plasmid had to be cleaned up to remove all the enzymes, and this was done by
using a Geneclean Kit (Biol01).
2.3.4 Genecleaning
The Geneclean II Kit (Bio 101) is used to remove and purify DNA from virtually any
type or grade of agarose and to eliminate impurities such as RNA, proteins and also
primers from PCR reactions. This procedure was carried out as instructed by the
manufacturers.
2.3.5 Ligation of DNA Molecules
To construct recombinant plasmids with cohesive termini, the plasmid which had
been digested, dephosphorylated and genecleaned (see sections 2.3.1, 2.3.3 and
2.3.4) was mixed with the DNA to be subcloned at equal molar ratios. If blunt end
ligation was to be carried out, then the plasmid and DNA were mixed such that there
was always an excess of the insert, lfil of T4 DNA ligase was added to the plasmid
and insert mix, together with I pi of lOx ligase buffer. The reaction volume was
made up tolOpls with H20 and placed in a 16°C incubator overnight,
2.3.6 PhenoEChloroform Extraction
This is used to purify DNA or RNA from salts, protein or solvents. Before use the
phenol needs to be equilibrated with lOOmM Tris pH 7.5 to ensure that when the
DNA is purified it goes into the aqueous phase instead of into the phenol. The
chloroform needs to be mixed in a 24:1 ratio with isoamyl alcohol to stop the
chloroform from frothing. The phenol and chloroform can then be mixed in a 1:1
ratio and kept in the dark. To purify the DNA or RNA, an equal volume of
phenolxhloroform was added, mixed by vortexing and centrifuged at 12,000rpm for
2 minutes. The aqueous supernatant was then transferred to a fresh tube for the
nucleic acid to be precipitated.
2.3.7 Ethanol Precipitation
To concentrate DNA or RNA a tenth of the volume of 3M NaOAc was added to a
DNA or RNA solution followed by 2-2.5 volumes of 100% EtOH (or alternatively
0.7 volumes of isopropanol can be used). The tubes were left at least 20 minutes on
ice (or -70°C to increase yields) and then centrifuged at 12,000rpm for 40 minutes
at 4°C. The pellet was washed in 70% EtOH and then spun again. The supernatant
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was then removed and the nucleic acid pellet allowed to dry before re-suspending it
in the desired volume of dH20.
2.3.8 Southern Blotting
Preparation of the Filters:
lpg of DNA was digested with the appropriate enzyme to release the insert from the
vector, and the fragments were separated by agarose gel electrophoresis. The DNA
was depurinated by soaking the gel in 0.25M HC1 for 10 minutes (or until the
bromophenol turns yellow). The DNA was then denatured by soaking the gel twice
for 15 minutes in 0.5M NaOH, 1.5M NaCl, after which time the gel was blotted by
capillarity onto Hybond N+ membrane. After the transfer, the DNA was crosslinked
onto the membrane by UV crosslinking.
Radioactively Labelling a DNA Probe
The random prime DNA labelling kit (Boehringer Mannheim) was used to make the
probe. The insert which was to be used as the probe was purified by Genecleaning.
25-50ng of DNA was made up to 9pls with water, and the DNA denatured by
heating to 100°C for 5 minutes and then cooled on ice.
2pls of reaction mixture (containing the random hexanucleotide primers and the
reaction buffer) was added to the DNA followed by lpl of each dATP, dGTP, dTTP;
lpl Klenow polymerase and 5pls of [or 2P] dCTP. The reaction was incubated at 37°
C for 30 minutes. The probe was then purified from the reaction components by
running the mixture through a Sephadex G-50 column (Pharmacia).
Hybridisation
The Hybond membrane was prehybridised in 5mls of 0.5M NaPPi, 1% SDS, ImM
EDTA, 0. lmg/ml heat denatured salmon sperm DNA and 5pg heat denatured vector
(competitor) for at least an hour at 65°C.
The probe was denatured by heating to 100°C for 5 minutes and then cooled on ice.
250pls of prehybridisation solution was added to the probe and lOOpls of this was
then added to each hybridisation bottle containing the membranes. Hybridisation
was carried out overnight at 65°C. The filters were then washed three times in 2 x
SSC (20xSSC: 175g sodium chloride, 88.2g of sodium citrate per litre of water, pH
7.0), 0.2% NaPPi, 0.4% SDS at 65°C. They were then checked for background
activity and if hot, washed once more before being placed inside plastic wallets,
assuring there were no trapped air bubbles that would distort the signal, and then put
down for autoradiography.
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Stripping and Reusing the Filters
If the filter was to be re-probed, the filters could be re-used so long as they had not
dried out. The filters were first stripped by soaking them in 0.4M NaOH at 50°C for
2 x 30 minutes. The stripping could then be checked by placing the filter down on
the phosphoimager,
2.3.9 Screening a Mouse cDNA Library
A mouse 11-day embryo 5' stretch plus cDNA library form Clontech was screened
using [ P]-NAL probe as described in section 2.3.8. Approximately 1x10 clones
from the library were screened with the probe. Hybridisation of the filters was
carried out at 65°C in 4x SSC, 0.4%SDS,0.2%NaPPi, lOOpg/ml salmon sperm DNA
and 2x denhardts. Washes were carried out at 65°C in 2xSSC, 0.4%SDS and 0.2%
NaPPi. Positive clones were subjected to secondary and tertiary screening. The
vectors containing the Nal inserts were then recovered by using a Qiagen lambda
prep kit, and finally the inserts were subcloned into Bluescript vector and sequenced.
2.3.10 Primer Production
Primers were ordered for synthesis by Genosys,
2.3.11 Polymerase Chain Reaction (PCR)
PCRs were carried out in 500pls eppendorf tubes in a total volume of 50pls.
If the PCR product was to be cloned and used further, then the proof reading DNA
polymerase Deep Vent (New England Biolabs) was used. If the PCR was used to
only detect the presence of a stretch of DNA then the cheaper polymerase,
AmpliTaq, was used instead. PCR reactions were set up to get a final concentration
of the following: a 1 x concentration of the polymerase buffer, 2mM MgS04, 200pM
of each dNTP, lpM each of a forward and reverse primer, 25-100ng of DNA
template and 1 unit of the polymerase. The PCR reactions were carried out in a
Hybaid Omnigene machine using the appropriate conditions for each PCR reaction.
2.3.12 ABI Sequencing
All sequencing reactions were carried with the automated sequencer and the Dye
Terminator Sequencing Kit (Perkin Elmer, Applied Biosystems).
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The reactions were set up as follows:
Terminator Ready Reaction Mix - 8pls
Pure DNA Template (Qiagen prepared)- 1 pg
Primer - 3.2pls/pM or 3.2pmols
H20 - up to 20pls
Overlay with mineral oil to avoid evaporation.
The PCRs were set up in a Hybaid Omnigene, under the following conditions:
94°C for 30 seconds
50°C for 15 seconds
60°C for 4 minutes
The reaction was allowed to proceed for 25 cycles.
The DNA was then precipitated by adding the PCR mixture to 2pls 3M NaOAc (pH
7.2) and 50pls EtOH. It was left on ice for 15 minutes and spun for 20 minutes
before the precipitate was washed with 250pls of 70% EtOH. The pellet was air
dried. At this point the pellet was handed over to the technical assistant for loading
on to the gel, and formatting the output. It is to be noted that the later sequences
were obtained by using rhodamine instead of the terminator ready reaction mix, as
the system was upgraded.
2.4 RNA Manipulations
2.4.1 Northern Blotting
RNA Preparation From Tissue
The organs required for RNA extraction were dissected out of an adult mouse and
stored on ice. 3mls of 3M LiCl/ 6M Urea were added to the tissue which were
immediately homogenised. The LiCl causes RNA precipitation whilst the urea
denatures proteins to minimise RNase activity. The samples were then sonicated for
1 minute at the power setting of 22 to shear the genomic DNA, and the RNA was
then left to precipitate overnight at 4°C. The RNA was then pellet by spinning at
12,000rpm at 4°C for 20 minutes and all traces of the LiCl/Urea removed. The
pellet was re-suspended in 0.3mls 10mMTris/0.5%SDS, and a phenol/ chloroform
extraction followed by chloroform extraction was carried out to purify the RNA. The
RNA was then precipitated by adding 30pls NaOAc and 1ml 100% EtOH and left at
-70°C overnight to increase yields. The RNA was washed with 70% EtOH and
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precipitated again, and finally was re-suspended in 50-100pls DEPC-H20, according
to the size of the pellet.
Gel Electrophoresis ofRNA Samples
When running RNA out on a gel, care must be taken to ensure that RNases do not
degrade the RNA. The gel tank was therefore treated overnight with DEPC-H20 to
remove all traces of RNase. The gel itself contains formaldehyde to inactivate any
RNase, and was made by dissolving lg agarose in 72mls dH20 and lOmls lOx
electrophoresis buffer (20mM 3- [N-morpholino]propanesulfonic acid (MOPS),
5mM NaOAc pH7,0, ImM EDTA). When the solution had cooled to 60°C, 18mls
formaldehyde and 50|ig ethidium bromide were added and the gel cast. 15(ig of
RNA were added to 15|ils sample buffer (50%formamide, 2.2M formaldehyde, fx
electrophoresis buffer) and then heated to 55°C for 5 minutes. 5(ils loading dye
were added to the samples before they were loaded onto the gel. The gel was then
run overnight, to give better resolution of the bands, at 10V.
RNA Transfer
The RNA was transferred to a nitrocellulose fdter so as to be able to do the
hybridisation step. Transfer was done by capillarity by placing a piece of Whatmann
3MM paper on a glass plate, soaked in and dipping into transfer buffer (16xSSC,
2.2M formaldehyde) with any air bubbles removed using a glass rod. The gel was
then placed over this, followed by a Hybond N+ filter, cut to the size of gel, soaked
in transfer buffer. 2 more pieces of Whatmann paper, cut to size and soaked in
transfer buffer were then placed on top of the filter, followed by several paper
towels, ensuring there was no short circuiting of fluid. A weight was then placed
over the stack of paper towels and transfer was allowed to proceed overnight.
Prehybridisation of the Filter
After transfer was complete, the filter was briefly washed in 2xSSC to remove
residual formaldehyde, and then baked at 80°C for an hour, The filter was then
prehybridised (50% formamide, 5xSSPE ( 3m NaCl, 0.3M NaOAc,2mM EDTA) 1 %
SDS, 5x denhardt (50xdenhardts: 5g ficoll, 5g polyvinyl pyrolidine, 5g BSA, Make
up to 500mls with dH20 and filter sterilise), 100pg/pi ssDNA) for at least 30
minutes, prior to the probe being added and allowed to hybridise at 42°C overnight.
Washing the Filter
The filter was then washed to remove any unbound probe, with 2x SSC/0,1% SDS
for 2x 10 minutes, followed by 3x10 minutes of 0.2x SSC/ 0.1 %SDS at 60°C. The
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filter was then wrapped in Clingfilm and placed in a phosphoimage cassette
overnight, before it was developed.
2.4.2 Reverse Transcriptase PCR (RT-PCR)
To detect the presence of certain RNA's in tissues, an RT-PCR can be carried out.
RNA was first extracted from the tissue (see section 2.4.1 - RNA preparation from
tissue) and 5pg of the RNA in a total of 5pls of water was denatured by heating to
90°C. After cooling on ice the following was added to the tube: lOpls of 5x RT-
buffer, 5pis lOmM dNTPs, lpl RNase inhibitor, lpl of random hexamers, 27pls
DEPC-H20, lpl of reverse transcriptase. This was then placed at 37°C for an hour to
allow for the cDNA to be synthesised. A standard PCR reaction (see section 2.3.11)
can then be carried out using the RT-product as a template.
2.4.3 DIG Labelling An RNA Probe
RNA probes can be labelled with digoxigenin (DIG) and detected after homologous
binding to endogenous RNA by enzyme-linked immunoassays using an anti-
digoxigenin alkaline phosphatase conjugate (anti-DIG-AP). A subsequent enzyme-
catalysed colour reaction with 5-bromo-4-chloro-3-indolyl-phosphate (BCIP) and
nitroblue tetrazolium salt (NBT) produces an insoluble blue precipitate, thus
detecting the hybrid molecules.
The DNA to be transcribed was cloned into bluescript vector such that it had T3 and
T7 promoters adjacent to the polylinker. The DNA template was linearised so that
the RNA polymerase produced "run-off' transcripts, which were then purified using
a gel extraction kit (Qiagen). The DIG-labelled probe was then synthesised
according to the DIG RNA Labelling Kit from Boehringer Mannheim, where DIG-
UTP is used as one of the nucleotides which is incorporated into the transcript,
together with CTP, ATP, and GTP. Typically lOpg of DIG-RNA was produced
from lpg DNA. The newly labelled RNA was then precipitated and run on a 1%
agarose gel to check the integrity.
2.5 In Situ Hybridisations
2.5.1 Whole Mount In Situs
This protocol taken from Hammond et al., 1998 was used to determine the gene
expression pattern during embryonic development in mice. Embryos of the desired
age were dissected in DEPC-treated PBS (dPBS) and they were then fixed
immediately in 4% paraformaldehyde (PFA, Sigma) overnight and then dehydrated
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by placing in 100% methanol. The embryos could then be stored in methanol at -20°
C.
Pre-Hybridisation
The embryos were first re-hydrated after being stored in methanol as follows:
75%methanol: 25%dPBS: 0.1%Triton X-100 - 5 minutes on ice
50%methanol: 50%dPBS: 0.1% Triton X-100 - 5 minutes on ice
25%methanol: 75%dPBS: 0.1% Triton X-100 - 5 minutes on ice
The solution was then replaced with dPBS/0.1% Triton X-100 for 3 x 15 minutes to
permeabilise the cells.
Embryos were then treated with proteinase K (10pg/pl; Boehringer Mannheim) in
dPBS/0.1% Triton X-100 to remove the proteins allowing the probe to penetrate.
Treatment varied from 15-25 minutes according to the age of the embryos. The
embryos then had to be fixed by treating with 4% PFA for 45 minutes on ice.
The fix was then replaced with prehybridisation solution (25mls de-ionised
formamide (Sigma); 12.5mls 20xSSC; lg blocking powder (Boehringer Mannheim);
500|ils 10% Triton X-100; 50 pg/pls heparin (Sigma); Img/ml yeast-RNA (Sigma);
0.5mls 0.5M EDTA; 2.5mls 10% 3-[(3-Cholamidopropyl)dimethylammonio]-l-
propane-sulfonate (CHAPS, Sigma) for 2x5 minutes at room temperature. The
embryos were prehybridised for 1 hour at 65°C, and the solution was then replaced
with fresh prehybridisation solution and left for a further 2-4 hours at 65°C, after
which time the probe (see section 2.4.3), which had first been denatured at 80°C,
was added and left to hybridise overnight at 65°C.
Post-Hybridisation
The next day the unbound probe was washed off as follows:
100% post-hybridisation solution for 5 minutes;
75% post-hybridisation; 25% 2xSSC for 10 minutes at room temperature;
50% post-hybridisation; 50% 2xSSC for 20 minutes at room temperature;
25% post-hybridisation;75% 2xSSC for 30 minutes at room temperature.
Post-hybridisation solution: 50% formamide, 5xSSC,0.1% Triton X-100, 0.5%
CHAPS.
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Further washes were carried out at 55°C for 2x30 minutes with
2xSSC/0.1%CHAPS, followed by one quick wash and then 2x30 minutes washes at
55°C with 0.2xSSC/0.1 %CHAPS.
TNT (0.1% Triton X-100; 50mM Tris pH7.5; 150mMNaCl) was then added for 2x5
minutes at room temperature.
Signal Detection
The embryos then had to be blocked (0.1% Triton X-100; 50mM Tris pH 7.5;
150mMNaCl; lg BSA; 15% sheep serum) for 3-4 hours at 4°C so that there was no
background binding of the antibody. This solution was then replaced with fresh
block containing the anti-DIG antibody (1/2000 dilution) and incubated at 4°C
overnight.
The following day, the excess unbound antibody had to be removed by several
washes: TNT/0.1%BSA for 4x1 hour followed by 2x30 minutes with TNT.
The embryos were then placed in AP buffer (0.1M Tris pH 9.5; 0.05M MgCl2;
0.1M NaCl) for 3x10 minutes, to ensure they were at the correct pH for the
phosphatase to act. The colour reaction was carried out by adding 45(ils NBT
(dissolve 0.5g NBT in lOmls of 70% DMF, store at 4°C) and 35|ils BCIP (dissolve
0.5g of BCIP in lOmls of 100% DMF, store at 4°C) to fresh AP buffer and this was
added to the embryos and incubated in the dark for 1-3 hours to allow for the colour
reaction to occur. Once the signal had appeared, the embryos were fixed in 4% PFA
overnight at 4°C after which time the PFA is replaced by PBS.
2.5.2 In Situ Hybridisation For Sections
DIG-labelled in situs can also be carried out on sections through mouse embryos for
a more precise internal examination of where a gene is expressed.
Section Preparation
Dissected embryos of the required age were fixed in fish fix (4% PFA in fish fix
buffer: 4% sucrose in non-DEPC treated PBS) at 4°C overnight. The embryos were
then washed for 3x5 minutes in fish fix buffer. They were embedded in 1.5%
agarose, 5% sucrose in PBS. Care was taken to ensure the embedding mixture was
not too hot or starting to set already. After the blocks containing the embryos had
hardened they were trimmed to size and transferred to 30% sucrose in PBS and kept
at 4°C until the blocks had sunk- usually overnight. The blocks were then frozen in
dry ice by placing on top of a piece of aluminium foil which in turn was on top of a
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metal rack which was covered by dry ice At this stage the blocks could be kept at -
70°C for up to a year.
For sectioning the blocks, a cryostat machine was used. The embryo blocks were
fixed onto the chuck using OCT. The chamber temperature was set to -24°C and
sections cut to 10-16pm thick. As sections were cut they are transferred onto 3-
aminopropyl-triethoxy silane (TESPA) slides see below. The sections were allowed
to air dry for up to 2 hours and then placed in a box with silica gel and were stored at
-20°C until required.
TESPA slides
To avoid sections from floating off slides, the slides can be TESPA coated as
follows:
Slides were dipped in 10% HC1 in 70% EtOH for 20 seconds; followed by distilled
H20 for 20 seconds and finally 100% acetone for 20 seconds. The slides were then
allowed to air dry. For the second stage of coating, the slides were dipped into 2%
TESPA in acetone for 20 seconds followed by 100% acetone for 20 seconds and
then into fresh acetone for another 20 seconds. The slides were allowed to air dry
again before use.
Hybridisation
Cut sections had to be defrosted for an hour. The DIG-labelled probe (see section
2.4.3) was diluted 1 in 200 in hybridisation buffer (Hyb buffer: lx salt (lOx salt:
114g NaCl, 14.04g Tris HC1, 1.34g Tris base, 7.8g NaH2P04.H20, 7. lg Na2HP04,
100ml 0.5M EDTA in a total of lOOOmls H20. pH 7.5; autoclave) 50% de-ionised
formamide, 10% dextran sulphate, Img/ml yeast RNA, Ix denhardts). The mix was
denatured at 70°C for 5 minutes before lOOpls of the probe mix was added to each
slide. A cover slip was added and the hybridisation allowed to proceed overnight in a
Hybaid slide machine at 65°C,
Post Hybridisation Washes
Slides were transferred to a coplin jar and washed in solution A (IxSSC, 50%
formamide, 0.1% Triton X-100) at 65°C for 15 minutes. Coverslips were removed
and the slides were washed for 2x30 minutes at 65°C in buffer A. They were then
rinsed at room temperature for 2x30 minutes in Tris buffered saline with Tween 20
(TBST).
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Blocking and Antibody Staining
Slides were blocked in 10% heat inactivated sheep serum in lxTBST for 1 hour at
RT. The slides were then dried around the edges before applying lOOpls of 1 in
2000 dilution anti-DIG AP Fab fragments in 10% heat inactivated sheep serum in
lxTBST. They were incubated overnight at 4°C.
Post Antibody Washes And Staining Reaction
5x20 minutes washes in TBST at RT, removing the coverslips after the first wash.
2x10 minutes washes in lxNTMT (lOOmM NaCl, lOOmM Tris HC1 pH 9.5, 50mM
MgCl2 and 0.1% Triton X-100. The solution should be made fresh on the day from
stock solutions). The slides were then stained in the dark with 4.5pls NBT and 3.5|4
Is BCIP diluted in 1ml NTMT. A total of 30mls staining solution was needed per 10
slides. The staining was checked after a few hours.
Post Staining and Mounting
The staining reaction was stopped by washing twice in water. The stain was then
fixed in 4% PFA/0.1% glutaraldehyde for 20 minutes. Sections were then
dehydrated through an alcohol series. The slides were counterstained with 0.1%
eosin in 95% EtOH for 20 seconds, and rinsed twice in 95% EtOH. They were
transferred to histoclear for 2x5 minutes and then mounted in DPX.
2.6 Protein Work
2.6.1 In Vitro Transcription and Translation of Proteins
The Promega TNT coupled reticulocyte lysate system was used to make in vitro
protein starting from a DNA template. By using [35S]-methionine in the reaction the
protein could be radioactively labelled for detection (see below, section 2.6.8). The
protocol was followed according to the manufacturers' instructions.
2.6.2 Expressing pET6H-WTl Proteins in Bacteria
Proteins can be expressed with 6 histidine molecules attached to them by using the
pET6H vector. The 6 histidines then allow the protein to be purified using a nickel
column.
A preculture of BL21 bacterial cells transformed with the pET6H-WTl vector were
grown overnight in LB containing ampicillin. The next day a 500mls culture was
grown from the preculture and left until they reached an OD60o=0.7 (at this stage 1ml
of the culture was removed for analysis). The rest of the culture was induced at 30°
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C with lOOmM isopropyl [3-D- thiogalactoside (IPTG). Samples were then removed
again after 30 minutes; 1 hour; 2. hours and 3 hours. To test whether the induction
had worked, the 1ml bacterial samples were re-suspended in cracking buffer (lOmM
NaPPi pH 7.2, 1% SDS, 8M Urea, 0,1% Triton X-100, 1% (3-mercaptoethanol,
0.15% bromophenol blue) and run on an SDS PAGE (see section 2.6.7) to see if
there was a strongly induced protein, corresponding to 6H-WT1.
Once the optimum expression time had been found from the time course experiment
done, the solubility of the protein could be tested. The bacteria, which had been
transformed with pET6H-WTl, were grown until they reached an OD60o=0.7. They
were then induced with IPTG for 2-3 hours, after which time the bacteria were spun
down. The pellet was then re-suspended in lOOmls buffer A (lOmM imidazole,
50mM NaCl, lOmM Tris.Cl pH7.9, 10% glycerol, 0.1% Triton X100, and one tablet
complete protease inhibitors per 50mls (Boehringer Mannheim)). The bacteria were
freeze thawed and then sonicated using a Lucas Soniphore sonicator, power 5
ensuring the sample was kept on ice. The solution was then left rotating at 4°C for
30 minutes before being centrifuged. The supernatant, or soluble fraction, was
mixed with 2x sample buffer and the pellet was re-suspended in cracking buffer
before being run on an SDS-PAGE gel to see in which fraction the protein is found
in.
2,6.3 Expressing GST-Fusion Proteins in Bacteria
A protein of interest can be overexpressed in bacteria and then purified from the rest
of the bacterial extract by using a glutathione S-transferase (GST) tag on the protein
The pGEX vector (Pharmacia Biotech) is an inducible expression vector which
fuses the GST to your protein of interest, and this allows for easy purification of the
protein because the GST tag can bind to a glutathione sepharose 4B affinity matrix
(Pharmacia Biotech), whilst the rest of the bacterial extract gets washed through it
The vector was transformed into BL21-pLysS bacteria (the pLysS expresses a
lysozyme which aids in breaking down the bacterial cell wall, and this vector
contains the CA resistance gene, see section 2.1.2). One colony was then grown
overnight in 20mls LB/Amp/CA to select for both the pLysS and pGEX vectors.
The next day, 400mls LB/Amp/CA were inoculated with 20mls of the preculture and
allowed to grow at 30°C to reach an OD590 of 0.7 (at this stage 1ml of the culture
was removed for analysis). The rest of the culture was induced at 25°C with lOOmM
isopropyl (3-D- thiogalactoside (IPTG) for 2-3 hours (after which time 1ml was
removed for analysis). To test whether the induction had worked, the 1ml bacterial
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samples were re-suspended in cracking buffer (lOmM NaPPi pH 7.2, 1% SDS, 8M
Urea, 0.1% Triton X-100, 1% p-mercaptoethanol, 0.15% bromophenol blue) and run
on an SDS-PAGE to see if there was a strongly induced protein, corresponding to the
GST-fusion protein of interest.
2.6.4 Purification of the GST-Fusion Protein
The induced bacterial culture was pelleted by centrifuging at 6000rpm for 10
minutes, and the bacterial pellet re-suspended in 40mls of GST-binding buffer
(50mM Tris pH 7.5, lOOmM NaCl, 10% glycerol, 1% Triton X-100, 1 tablet of
complete protein inhibitors per 50mls (Boehringer Mannheim)). The bacteria were
freeze thawed and then sonicated using a Lucas Soniphore sonicator, power 5
ensuring the sample was kept on ice. The solution was then left to rotate at 4°C for
30 minutes to allow the proteins to solubilise, after which time they were centrifuged
at 12,000rpm for 30 minutes to pellet insoluble cellular material. The supernatant,
which contained the soluble proteins, was collected. The pellet was re-suspended in
cracking buffer and compared to the soluble fraction on an SDS-PAGE to establish
whether the protein of interest was soluble. Solubility of the protein could be
optimised by altering the inducing conditions, such as the IPTG concentration, the
inducing temperature or the length of time of induction. The GST-fusion protein was
then purified from the rest of the fraction by using the prepared affinity matrix. The
affinity matrix was prepared as follows: for the required bed volume of 200pls of
glutathione sepharose 4B, 266ftls were used as the matrix was supplied as a 75%
slurry. The slurry was sedimented and washed in PBS to remove the EtOH. The
slurry was then re-suspended in 200(ils PBS to form a 50% slurry. This slurry was
then mixed with the soluble bacterial sample and left to spin for 30 minutes at 4°C.
The mixture was then placed into a column, where any protein not bound to the
slurry run through. The slurry was then washed 3 times with GST-binding buffer to
remove any non-specific binding proteins. The GST-fusion protein could then be
eluted with 200(ils of glutathione elution buffer, and a sample run on an SDS-PAGE
to see how pure the protein of interest was.
2.6.5 BioRad Protein Assay
Protein concentrations can be estimated by using the BioRad protein assay. An
aliquot of protein was diluted in 800pls water and 200|ils of the BioRad solution
was added and the solution mixed. It was allowed to stand for 10 minutes at RT for
the colour to develop and an OD595 taken. To calculate the concentration of the
protein, a standard curve had to be produced using known concentrations of BSA.
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The graph produced could then be used to read off the concentration of the protein
using its OD value.
2.6.6 In Vitro Binding Assays
In vitro binding assays can be carried out to see if two proteins interact. 5jng of the
GST-fusion protein of interest (see section 2.6.4) was mixed with in vitro translated
(IVT) (see section 2.6.1) protein together with 200pls of low salt association buffer
(LSAB) (lOOmM NaCl, lOOmM Tris.Cl pH 8, 0.1% NP40). For more specific
binding the salt concentration could be increased to 250mM and was then called
medium salt association buffer, or the salt concentration could be increased to
500mM, in which case it was called high salt association buffer. The mixture was
left on a rotor at 4°C for 2hours. Then prepared glutathione sepharose 4B (see
section 2.6.4) was added and left to rotate for another 30 minutes. The slurry was
then precipitated and washed 6 times with the association buffer, to remove any
protein not binding to the GST-fusion protein. After the final wash, 30jils of 2 x
sample buffer (SB: 62.5mM Tris.Cl pH 6.8, 2% SDS, 2% [3-mercaptoethanol, 10%
glycerol, 0.1% bromophenol blue) was added to the slurry and after boiling the
proteins were run on an SDS -PAGE followed by fluorography to detect the presence
of the radioactive protein (see sections 2.6.7 and 2.6.8).
2.6.7 SDS-PAGE Electrophoresis
SDS-polyacrylamide gel electrophoresis (PAGE) was used to resolve proteins
according to their molecular weight. The resolving gels were cast as shown in table
2.1.
The gel was assembled and the samples which had been mixed with 2 x SB were
boiled for 5 minutes and loaded into the wells. Running buffer (25mM Tris, 250mM
glycine pH 8.3 and 0.1% SDS) was added and the gel run at 150V.
The gel was then stained with Coomasie dye (0.1% Coomasie blue dye, 50%
methanol, 10% acetic acid) for an hour before being placed into destain solution








30% acrylamide mix 3.3 6.7
1.5M Tris (pH 8.8) 2.5 5.0
10% SDS 0.1 0.2
10% ammonium persulfate 0.1 0.2
TEMED 0.004 0.008
Solution components
tor a 5% stacking gel
Component volumes per 4ml and
8ml gel moulds (ml)
4ml 8ml
h20 2.7 5.5
30% acrylamide mix 0.67 1.3
1.0M Tris (pH 6.8) 0.5 1.0
10% SDS 0.04 0.08
10% ammonium persulfate 0.04 0.08
TEMED 0.004 0.008
Table 2.1: Solutions for preparing resolving (upper table) and stacking
(lower table) gels for Tris-glycine SDS PAGE.
2.6.8 Detecting A Radioactive Protein
This is used when a radioactive ^S-methionine protein needs to be detected. After
the protein sample had been run on an SDS-PAGE, the gel needed to be fixed (50%
EtOH, 10% acetic acid) for 2x30 minutes. The gel then had to be placed in Amplify
(Amersham Science) for 15 minutes. This is an organic scintillant which converts
the emitted energy of the isotope to visible light which can then be detected on X-ray
film. The gel was then dried and placed overnight in a photographic cassette together
with X-ray film.
2.6.9 Western Blotting
Transfer ofProteins Onto Hybond Filter
Western blotting is used to transfer proteins run on an SDS-PAGE, onto a Hybond
filter. A semi-dry blotter was used which provided the anode and cathode plates.
Ch 2 Materials and Methods
The system was set up on the anode plate as follows: 2 Whatmann filters cut to the
size of the gel were soaked in anode 1 (0.3M Tris, 10% methanol, pH 10.4),
followed by another 2 pieces soaked in anode 2 (25mM Tris, 10% methanol,
pH10.4). The Hybond filter, also cut to size, was equilibrated in anode 2 and placed
on top of the Whatmann papers. The gel which had been soaked in anode 2 was
then laid over the filter. 3 pieces of Whatmann soaked in cathode buffer (40mM
glycine, 25mM Tris and 20% methanol, pH 9.4) were placed over the gel. The
cathode plate was then put in place and the transfer carried out at 10V, 240mA for
30 minutes.
Detecting The Protein of Interest
Once the Western blot had been carried out the protein of interest could be identified
using the appropriate antibody. First the nitro-cellulose membrane had to be
blocked in blotto (5% fat-free milk in TBST) for 1 hour at room temperature and
then incubated with the primary antibody overnight at 4°C. The unbound antibody
was then washed off by carrying out three 15 minute washes in blotto. Secondary
antibody, which recognises the primary antibody and is conjugated with horseradish
peroxidase (HRP), was then added for an hour at room temperature, after which
another three washes were carried out. Finally the filter was quickly washed in
TBST and the antibodies detected using the ECL-Plus (Amersham), as described by
the manufacturer.
Stripping The Filters For Re-Probing
If the filter had to be re-used so as to detect another protein, the filter first had to be
stripped of the initial antibodies used. This was carried out by submerging the filters
in stripping buffer (lOOmM (3-mercaptoethanol, 2% SDS, 62.5mM Tris .HC1 pH
6.7) and incubated at 50°C for 30 minutes. The filter was then washed in TBST for
2x10 minutes at RT. The filter was blocked with blotto and the immunodetection of
the new protein of interest was then carried out as before.
2.7 Antibody Work
2.7,1 Antibody Production
A polyclonal antibody was to be raised against NAL in rabbits. A GST-NAL fusion
protein was overexpressed in bacteria and purified (see section 2.6.3 and 2.6.4). A
final concentration of lOOjig of antigen was injected for each injection and
subsequent boosts. Two rabbits were inoculated so as to increase the chances of
obtaining a good antibody, and each rabbit was injected once followed by 3 booster
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injections. The handling of the rabbits and the production of the sera was all carried
out at the Scottish Antibody Production Unit (SAPU), Law Hospital, Carluke,
Lanarkshire ML8 5ES, Scotland, co-ordinated by Dr. Maggie Chambers.
2.7.2 Affinity Purification of NAL Antisera
A 10% SDS-PAGE (see section 2.6.7) was cast, using a preparative comb to run
purified GST-NAL. A Western blot (section 2.6.9) was carried out and the filter was
then stained with Ponceau red so that the strip of pure GST-NAL could be seen and
cut out. This strip was then blocked in blotto, before being cut up into tiny
fragments using a razor. 800|ils TBS were then added to the fragments together with
200[ils of the NAL antisera, and the tube were left to spin on a wheel for 2-3 hours at
room temperature. The filter was then rinsed 3 times in TBST before washing 3
times with 1 ml TBST for 30 minutes on the wheel. The filter was incubated with
200pls of 200mM glycine pH 2.5 containing 0.1% BSA for 30 minutes to elute the
bound antibody. The supernatant was then collected and another 50pls of the
glycine/BSA solution was added for another 10 minutes before that was collected
and this was done twice over. The supernatant was then neutralised by adding 30fi
Is 1M Tris (non-pHed). The purified antibody was finally dialysed using a 0.025pm
filter for 10 minutes against TBS. The filters could be reused by washing them in
TBST and then stored in TBS containing sodium azide.
2.7.3 Antibodies Used
Several antibodies have been used for Western blots and immunofluorescence. The
antibodies used, together with some information about them are listed in the table
below.
Antibody Type of antibody Supplier
Anti- IGC, 3C5 IgM Monoclonal Bryan Turner
Anti-NAL, 474 Rabbit Polyclonal Natalie Little
Anti-HA, 12CA5 Mouse Monoclonal Boehringer-Mannheim
Anti-WTl, C19 Rabbit Polyclonal Santa Cruz Biotechnology
Anti-WTl, H2 Mouse Monoclonal DAKO
Mouse IgG Mouse Monoclonal Sigma
Table 2.2: List of antibodies used for Western blots and immunofluorescence.
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2.8 Tissue Culture
2.8.1 Cell Lines
The cell lines used were the mesonephric cell line, M15 (Larsson et al., 1995), COS
7 and HeLa (European Collection of Cell Cultures, ECACC). They were grown at
37°C in a humidified, 5% C02 environment
2.8.2 Medium
The medium used for all these cell lines was Dulbecco Modified Eagle Medium
(DMEM, Gibco BRL), 500mls, supplemented with 5mls sodium pyruvate, 5mls
penicillin and streptavidin antibiotic mix, 5mls glutamine and 50mls of heat
inactivated foetal calf serum (FCS).
2.8.3 Splitting Cells
All cell lines used grew in an adherent manner and thus trypsin was used to remove
cells from plates so that they could be used either in making nuclear extracts, to re-
plate them at different densities or to freeze down as stocks. First the medium was
aspirated off and cells rinsed twice with PBS. 1ml of trypsin was added to the cells
and they were incubated at 37°C for 1 minute, after which time the cells started to
come off the plate. The trypsin was then inhibited by adding the components of the
FCS in the medium, and the cell suspension could then be used accordingly.
2.8.4 Freezing Cell Lines Down
The cell line to be frozen down for stock were washed with PBS and then trypsinised
to remove the cells from the plate. 5 mis of medium were added to stop the
trypsinisation after the cells had come free from the plate, and the cells were
collected and spun down at lOOOrpm for 5 minutes. The medium was aspirated
away and the cells re-suspended in 3mls of cold medium containing 10% DMSO.
The cells were then aliquoted into vials and placed in a polystyrene box and placed
at -70°C so that they froze down slowly after which time the vials were transferred to
a liquid nitrogen tank for storage.
2.8.5 Growing Cell Lines Up From Frozen Stocks
A frozen down vial of cells was quickly thawed at 37°C. 5mis of medium was
added and the cells were pelleted by centrifuging at lOOOrpm for 5 minutes. The
medium was then aspirated off to remove all traces of DMSO. The cells were then
re-suspended in 5mls of medium and transferred to a flask and incubated at 37°C.
/Q
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2.8.6 Transient Transfections
The cell line to be transiently transfected was grown on an appropriate sized plate
and allowed to reach 50-80% confluency. To enable the DNA to be transfected, the
plasmid had to be mixed with LipofectAmine (Gibco BRL) and the quantities vary










35 100 2-25 1-2 0.8
60 300 6-75 3-6 2.4
100 800 16-200 8-16 6.4
Table 2.3: Reagent quantities for transfection of DNA onto different sized culture plates.
The diluted DNA and lipid solutions were then gently mixed together and incubated
at room temperature for 30 minutes to allow DNA-liposome complexes to form.
Whilst these complexes form, the cells were washed in serum free medium, or
optimem (Gibco BRL). The appropriate transfection medium volume, according to
the table, was then added to the complexes and gently mixed, before overlaying on
the cells. The cells were incubated at 37°C for 24 hours, after which time the
transfection medium was replaced with complete medium, and cells were incubated
for a further 24 hours. The cells could then be assayed for activity of the transfected
gene.
2.8.7 P-Galactosidase Assay
As a positive control for transient transfections and to give an idea of the
transfection efficiency, a (3- galactosidase gene under the control of a CMV promoter
was also transfected into the M15 cells. The transfection was carried out as for the
other plasmids and 24 hours after transfection, the cells were rinsed in PBS and then
fixed for 5 minutes at 4°C in 2% formaldehyde, 0.2% glutaraldehyde in PBS. The
cells were then rinsed with PBS and then 1ml of X-gal reaction mixture (5mM
potassium ferrocyanide, 5mM potassium ferricyanide, 2mM magnesium chloride
and a final concentration lmg/ml of X-gal in PBS, filter sterilised) was added to the
chamber slides. The chamber slides were then incubated at 37°C for 1-18 hours to
allow the blue colour to develop.
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2„8«8 Co-Immunoprecipitations
Cross-Linking ofAntibodies to Protein A Sepharose Beads
The antibody which was going to be used to immunoprecipitate a particular protein
first had to be crosslinked to protein A sepharose beads, lpg of the antibody was
incubated with 50|ils of a 20% bead slurry per immunoprecipitation to be carried
out. The mix was then made up to 1 ml with IPB 100 (lOOmM sodium chloride,
lOmM Tris and ImM EDTA, made to pH 8) and left incubating at 4°C overnight.
The beads were then spun down and washed twice in 0.2M sodium borate and then
incubated for 30 minutes at room temperature in 0.2M sodium borate containing
20mM dimethylipimelidate pH >8.3. The beads were washed in 0.2M ethanolamine
pH 8 and then incubated for 2 hours at room temperature in the same solution. The
cross-linked beads were then washed twice in PBS, followed by two washes in
lOOmM glycine, pH 3 and then another further two washes in PBS. Finally the
beads were re-suspended in 50|ils PBS.
Preparation ofNuclear Extracts
3 large plates of M15 cells were grown until confluent, Cells were then trypsinised
(see section 2.8.3) and the cells pelleted by centrifuging for 5 minutes at 1200rpm,
washed with PBS and re-pelleted. The cells were then re-suspended in 500pls PBS
and spun at 2000rpm for 3 minutes. The pellet was re-suspended in 5 times the
packed cell volume of buffer A (10 X buffer A: 0.1M Hepes pH 7, 15mM MgCl2,
0.1M KC1) containing 0.5fil/ml of 1M DTT and protein inhibitors. The solution was
incubated on ice for 10 minutes and then spun at 2500rpm for 5 minutes. The
supernatant was removed and the pellet was re-suspended in 2 times the packed cell
volume of buffer A. The cell suspension was then homogenised on ice with a tight
pestle for 10 strokes. The solution was spun for 10 minutes at 2500rpm, and the
supernatant removed. The pellet was re-centrifuged at 13000rpm for 10 minutes to
remove all the supernatant and the pellet that was left were the cell nuclei. These
were then re-suspended in 1 ml of fresh buffer T (50mM Tris pH 8, 250mM NaCl,
1% Triton X-100, 0.2mM sodium vanadate, 5mM (3-glycerophosphate and protein
inhibitors). The nuclei were then spun at 13000rpm for 10 minutes and the
supernatant was transferred to a fresh tube.
Carrying Out The Co-Immunoprecipitations
To carry out immunoprecipitations the cross-linked antibody was mixed with the
nuclear extracts made, which had been previously pre-incubated with pre- blocking
beads for one hour at 4°C to remove any proteins binding directly to the beads. The
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mixture was incubated overnight at 4°C, after which time the beads were washed 6
times with IPB 100 containing 0.5% NP-40. The beads were finally re-suspended in
30pls of 2xSB, boiled and then run on 8% SDS-PAGE (see section 2.6.7) followed




M15 cells were grown on chamber slides (Nunc) until they had reached 80%
confluency, after which time immunocytochemistry was carried out. The cells were
rinsed twice in PBS and then fixed for 10 minutes at room temperature in an
acetone: methanol (1:1) mix. The cells were blocked to reduce background in
blocking solution (2% BSA, 0.2% Tween 20, 6.7% glycerol, 0.02% sodium azide, in
PBS) for 1 hour at room temperature. The primary antibody was then added at the
required concentration in blocking solution. 200(ils of the primary antibody mix
was used per 1 well chamber slide and overlaid with parafilm so as to minimise
antibody usage. The cells were then rinsed 3 times in TBST for 5 minutes. The
secondary antibody, which should recognise the heavy chain of the primary antibody
and is tagged with a fluorescent label, was then added at a dilution of 1 in 100.
Again 200pls were used per chamber slide which now had to be kept in the dark so
that the fluorescence did not fade. The cells were incubated with the secondary
antibody for 45 minutes after which time another 3 washes were carried out with
TBST. The slides were then mounted with Vectashield containing 4',6 diamidino-2-
phenylindole (DAPI, Vectra) to preserve the fluorescence and stain the nucleus. The
fluorescence was then looked at under an Axioplan fluorescent microscope. Images
were captured using a Digital Scientific Smartcapture software.
2.9.2 Immunohistochemistry
Immunohistochemistry was carried out on E=17.5d kidneys and testes. The organs
were dissected out and immediately fixed in 4% PFA for 1-1.5 hours. They were
then washed twice for 20 minutes in PBS, before placed overnight in a 30% sucrose
solution made in PBS. The next day the organs were embedded in OCT and frozen
in liquid nitrogen, and stored at -70°C. Sections, 10pm thick, were then cut onto
TESPA slides using the cryostat (see section 2.5.2). The slides were left to dry at
room temperature for 1 hour before the immunohistochemistry was carried out.
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The sections on the slide were circled with wax, using a PAP pen, so as to use less
quantities of antibodies. All subsequent steps were then carried out in a humidifying
chamber to avoid the sections drying out. The sections were then blocked for an
hour in blocking solution as was used in section 2.9.1. If the primary antibody to be
used was monoclonal, then the sections had to be incubated with goat IgG Fab arms
(1 in 25 dilution) for an hour to remove any background as the sections originated
from mice. The sections were then washed 3x5 minutes in TBST, The primary
antibody was then added, diluted accordingly to a total volume of 150(J.ls in block.
This was left for an hour before 3x5 minute washes with TBST were carried out.
The secondary antibody, coupled to either FITC or Texas Red, was then added for 45
minutes and the slides were then kept in the dark from now on. The slides were then
washed 3x5 minutes in TBST before being mounted with Vectashield containing
4',6 diamidino-2-phenylindole (DAPI, Vectra) to preserve the fluorescence and stain
the nucleus. The fluorescence was then looked at under an Axioplan fluorescent
microscope. Images were captured using a Digital Scientific SrnartCapture software.
2.9.3 Fluorescent In Situ Hybridisation (FISH)
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Chapter 3: Yeast Two Hybrid System
In an attempt to identify proteins that interact with WT1, the yeast two hybrid (Y2H)
system was to be used. The identification of proteins that interact with WT1 should
help to elucidate its function and shed light on how WT1 works at the molecular
level. Thus it is hoped that using this technique we will further our understanding of
the role of WT1 in both development and tumourigenesis.
3.1 Introduction to the yeast two hybrid system
The Y2H system is a very powerful and sensitive tool used in the identification of
protein-protein interactions. It is based on a yeast genetic assay in which the
interaction of two proteins is measured by the functional restoration of a
transcriptional activator (Fields and Song, 1989). There are a couple of variations
on the system which use different strains of yeast, reporter genes and vectors - such
as the system that uses the Saccharomyces cerevisiae Gal4p DNA binding and
activation domains; or the one that uses the Escherichia coli LexA protein as the
DNA-binding domain and the herpes virus VP 16 protein as the activation domain;
or even the one that uses the E. coli LexA protein as the DNA-binding domain and
the E. coli B42 sequence as its activation domain. The system that was used, and
therefore will be discussed here, is the one that uses the Saccharomyces cerevisiae
Gal4p DNA binding and activation domains together with the HIS3 and lacZ
reporter genes.
The Gal4 transcription factor has two domains: a DNA-binding domain as well as a
transcriptional activator domain, and the transcription factor is only active when
both domains come together. The DNA-binding domain binds to an upstream
activation sequence (UAS),which targets this domain to a promoter of a reporter
gene, and the activator domain, once in a complex with the DNA-binding domain of
Gal4, initiates transcription of the gene in question. The two Gal4 domains do not
have to be in direct contact with each other and thus can be reconstituted through
non-covalent interactions of two independent hybrid proteins which are fused to
either domain. For the system to work, the hybrid proteins on their own should not
activate transcription of the gene. Thus transcription is only brought about when the
two hybrid proteins genuinely come together thus restoring the Gal4 transcription
factor and causing expression of the gene. In order to know whether the two hybrid
proteins interact, the genes transcribed are the reporter genes lacZ and HIS3 (Durfee
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et al., 1993), figure 3.1. Any positive interactions can then be identified because the
yeast carrying the two interacting proteins will grow on plates that lack histidine,
and these yeast will also turn blue when a (3-galactosidase assay is carried out.
A: No Expression Of Reporter Genes
The WT1-Gal4 DNA-Binding Domain (BD) binds to the upstream
activator sequence (UAS), but because protein X does not bind to WT1 the
Gal4 Activator Domain (AD) cannot localise to the Gal4 BD and so the
Gal4 transcription factor is not reconstituted. The reporter genes are not
expressed as the Gal4 AD cannot localise to the UAS on its own.
B: Expression Of Reporter Genes
If protein Y binds to WT1, the GaI4 BD and the Gal4 AD will be brought
together, thus reconstituting the Gal4 transcription factor The Gal4 BD will
localise to the UAS and together with the Gal4 AD, they will express the
reporter genes, lacZ and His3.
Figure 3.1: Schematic illustrating the basis of the yeast two hybrid system.
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The first steps that need to be carried out when performing a yeast two hybrid
screen, is the construction of the hybrid proteins. Usually the gene encoding the
protein of interest, in this case WT1, is cloned into a vector that contains the DNA
binding domain of Gal4 and this is done so as to form a fusion protein when the
vector is expressed in yeast. This vector is referred to as the bait and it carries
tryptophan as the selectable marker. The other vector, containing the Gal4 activator
domain, is called the prey and carries leucine as the selectable marker. As the
objective of using the Y2H was to identify proteins that interact with WT1, a cDNA
library was cloned into the prey vector so that a large number of potential binding
proteins could be tested in the system.
The bait and prey vectors are co-transformed into yeast using the lithium acetate
method of transformation and then plated onto two different types of media. The
first type is the AH medium, which contains added adenine and histidine (see
materials and methods). This is because the yeast has a phenotype such that it
auxotrophic for adenine, tryptophan, leucine and histidine (see material and methods
for the yeast Y190 genotype), and thus because the two vectors only provide leucine
and tryptophan, the adenine and histidine have to be provided if the yeast are to
grow. If transformed yeast grow on these AH plates then they must have taken up
and expressed both vectors. The second type of medium is the 50mM 3-
aminotriazole (AT), which contains adenine and 50mM AT (see materials and
methods) (Durfee et al., 1993). 3-aminotriazole is added to the plates to dampen
down any background levels of histidine which may be present due to the mutation
in the HIS3 gene in Y190 being leaky. When plated onto the 50mM AT medium,
yeast can only survive if they have both vectors transformed into them, providing the
leucine and tryptophan as before, but this time the two hybrid proteins have to
interact. It is only with the two hybrid proteins interacting that the Gal4
transcription factor is reconstituted and the HIS3 gene expressed, synthesising the
required histidine for growth. Therefore any yeast colonies that grow on the 3'AT
plates in theory have the two hybrid proteins interacting and this can be further
tested by carrying out a (3-galactosidase assay. Only those colonies arising from 'real'
interactions, as opposed to HIS3 revertants, will turn blue as they will express the
lacZ gene.
This second assay therefore removes any potential false positives. The beauty of the
yeast two hybrid system, when it is used to identify new binding partners, is that
once such a real interaction is found the gene of interest can quickly be cloned and
sequenced, as the cDNA fused to the Gal4 activation domain in the prey vector can
easily be recovered.
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The yeast two hybrid system has been used successfully to find protein partners
(Bender et al., 1996; Durfee et al., 1993; Lesage et al., 1994), and even used to build
networks of protein-protein connections through exhaustive searches (Fromont-
Racine et al., 1997). It has also been used before to identify proteins that bind to
WT1 (Johnstone et al., 1996; Johnstone et al., 1998; Wang et al., 1996). It is
therefore hoped that the system can be used to identify other WT1-interacting
proteins.
3.2 Testing the activity of WT1, as well as control proteins, in the Y2H system
Before a library screen can be carried out, the activity of WT1 in the Y2H system
has to be tested. The reason for this is that some bait proteins can activate the
expression of the reporter genes of the system on their own accord, without the need
to bind to a prey. This could happen if the protein of interest, which is fused to the
Gal4 DNA-binding domain, has an activation domain which could cause initiation
of transcription. It was especially important to carry out this test on WT1 because
WT1 has been shown to be able to activate transcription in vitro (see section 1.6.1).
If WT1 does activate transcription of the system on its own, then it will not be able
to be used as a bait to screen a library and instead it would have to be fused to the
Gal4 activation domain and re-tested in the hope that it would no longer activate
transcription on its own.
Whenever a transformation is carried out to see if there is an interaction occurring,
there have to be controls added to ensure the system is working correctly. These
controls have to be designed such that there is a positive and negative interaction so
that growth on the plates can be checked accordingly. The controls to be tested as a
positive interaction were WT1 +/+ used as both the bait and the prey, as it was
know that this protein dimerises (Englert et al., 1995b). Another positive control to
be tested in the system was the interaction between SNF1 (sucrose non fermenting
gene) and SNF4, as these two proteins are known to interact (Celenza et al., 1989).
The negative interaction to be tested was set up as WT1+/+ as the bait and SNF4 as
the prey.
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Bait Prey
Number of colonies on plates
AH 50mM AT
WTl +/+ None 0 0
WT1 +/+ SNF4 40 0
WTl +/+ WTl +/+ 80 38
SNF1 SNF4 200 100
SNF1 WTl +/+ 200 0
Table 3.1: Testing the activity of WT1 and control proteins in the Y2H
system. The control proteins produced the expected activities, and WT1 on its
own does not activate the reporter genes, and so can be used as a bait for library
screens to identify interacting proteins.
The activity of WT1 and the control proteins was tested in the yeast two hybrid
system using the bait and prey vectors which had been constructed by Dr. Davies.
The results produced are summarised in table 3.1. From the experiment carried out,
it is shown that WT1 on its own cannot activate transcription of the reporter genes.
When WT1 is used as the bait, but no prey vector is added, the yeast cannot even
grow on the AH plates and this is because they lack leucine, which is normally
provided by the prey vector. This therefore shows that even on AH plates there are
no background colonies. The WT1 bait interacting with SNF4 prey shows that if the
prey vector is now added the yeast can grow on AH plates as they now express
leucine, but cannot grow on the 50mM AT plates as WT1 and SNF4 do not interact.
This interaction not only acts as a negative control, but shows that WT1 cannot
activate the reporter genes if there is no interacting prey protein present. The
interaction between WT1+/+ used as both the bait and the prey can be used as a
positive control as it is seen that yeast colonies transformed with these two proteins
do grow on 50mM AT plates because the dimerisation of WT1 causes the two Gal4
domains to come together and express HIS3. The SNF1 and SNF4 proteins which
interact with each other, also show a positive interaction in the system. From this test
experiment, it can be seen that the system can be used to screen a cDNA library
using WT1 +/+ as the bait.
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3.3 Screening an M15 library
To try to identify proteins that interact with WT1 a cDNA library was to be
screened. A flow diagram is illustrated to show the steps taken when screening a
library (see figure 3.2) In preference to using a commercial kidney library, where
WT1 only represents a small subset of the proteins present (see WT1 expression in
the kidney, section 1.7.1), an M15 cDNA library was to be constructed and used.
The Ml5 cell line expresses endogenous WT1 and it was thus hoped that by using
this cell line, WT1 - and the proteins it interacts with - would be more highly
represented in such a cDNA library compared to a whole kidney library, thus
increasing the chances of isolating them.
3.3.1 Generating an M15 cDNA library
An M15 cDNA library fused to the prey expression vector is not commercially
available and therefore it had to be made, with the help of Dr. Ladomery. PolyA
mRNA was isolated from Ml5 cells and cDNA was made using oligo (dT) primers.
The cDNA was then cloned into the prey expression vector using the HybriZAP two-
hybrid cDNA gigapack cloning kit from Stratagene, as directed by the
manufacturers. The cDNA library had an average insert size of 400bp, with the
largest being about Ikb
3.3.2 Identifying WT1-interacting clones
The M15 cDNA library was screened in the yeast two hybrid system to see if any
proteins encoded by it interacted with WT1+/+. 270,000 colonies were transformed,
as calculated by plating out a small proportion of the library onto AH plates, and out
of these 20 colonies grew on 50mM AT plates. However the colonies that grew were
very small and did not have the appearance of a convincing positive clone, as
compared to the positive controls used. Nonetheless, the colonies were re-streaked
onto fresh 50mM AT plates and a (3-galactosidase yeast fdter lift assay was carried
out, to ensure that the clones were 'real'. Only 4 colonies, out of the 20, turned blue,
and thus this confirmed the initial suspicion that the small colonies that had grown
were false positives,
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Construction ofbait and prey vectors
jgEaamBtw
Co-transform yeast with WT1 (bait) and cDNA
library (prey) vectors and plate onto 50mM AT
Select HIS3+ colonies and perform an X-gal filter
lift assay to select for (3 galactosidase activity
Blue colonies are plated onto cyclohexamide
plates to select for bss of the bait plasmid
Recover prey plasmid. Specificity tests done to
; ensure prey still binds to WT1 but not to
unrelated proteins non-specifically
Domain binding studies as well as other 2ndry
assays are carried out with WTl-binding proteins
Figure 3.2: Flow chart showing the steps taken when
using the yeast two hybrid system to screen a library
for WT1-interacting proteins.
As the screen produced such few colonies, the plates were incubated for a few more
days, in the hope that more colonies would grow, perhaps due to a weaker
interaction. Another 60 colonies did grow, and out of these, 15 of them turned blue
when assayed for lacZ expression.
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3.3.3 Ensuring that the prey protein on its own does not activate the Y2H
system
The next stage was to isolate the prey proteins which at this stage seem to bind to
WT1, and check that they cannot activate the Y2H system on their own accord,
without having to bind to WT1. To isolate the prey protein, the positive colonies are
first streaked onto AHT plates (AH plates containing added tryptophan) and then
plated onto cyclohexamide plates as described in section 2.2.7. By plating the
colonies onto these plates, the yeast should lose the bait plasmid, because now that
the yeast have tryptophan in the medium, they no longer require the bait plasmid to
provide them with that amino acid. In addition the bait plasmid contains a
cyclohexamide sensitive gene, which makes the originally cyclohexamide-resistant
yeast sensitive to the drug when they are plated onto cyclohexamide plates. For
these reasons the yeast lose the bait vector, retaining only the prey vector, which
provides them with the required leucine. A (3-galactosidase yeast filter lift assay can
then be carried out on these colonies, and since these colonies no longer have the
bait protein, they should not turn blue as they cannot express lacZ. If the colony
does turn blue, it suggests that the prey protein can activate the system without
having to bind to the bait, and is therefore a false positive. One of these colonies
tested did turn blue and was therefore discarded as being a false positive. The
isolation of the prey plasmid from the remaining 18 colonies was achieved as
described in section 2.2.7. A digest of the prey clones isolated was carried out to
determine the size of the cDNA cloned. Unfortunately out of the 18 potential clones,
8 seemed not to have an insert. This was rather surprising as it is known that WT1
must have interacted with a prey protein to be able to grow on 50mM AT plates.
3.3.4 Testing the specificity for WT1 interaction
The 10 remaining clones which did contain inserts were still candidates for binding
to WTl and so had to be re-tested in the yeast two hybrid screen against WT1 to
ensure that the interaction was real, and against a negative control, such as SNF1, to
ensure that the prey protein did not bind weakly to other unrelated proteins. This
last control was added because it had been noted that some proteins promote
transcription in concert with a number of different hybrid partners. This could be
because the protein may have a surface that has low affinities for many different
proteins, such as a large hydrophobic surface (Allen et al, 1995). Thus the potential
WTl-binding proteins were tested to see if they bound to another unrelated protein,
to ensure that this was not the case.
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Unfortunately out of the 10 clones that were re-tested in the Y2H, none seemed to
interact with WT1 again, and must have been false positives. Thus although the
selection procedure is a dual one, so as to cut back on the number of false positives,
several clones which were false positives did come through the screen. However
from the start of the screen the colonies had looked doubtful as they were very
weedy when they initially grew on the plates. Nevertheless some of the clones were
sequenced to see if they encoded any known protein which could be of interest, and
they could then be tested for their interaction with WT1 in an alternative way.
However, the clones only matched to ESTs thus giving no clue as to what their
possible role could be.
3.3.5 Summary of M15 screen
The screening of the M15 cDNA library did not isolate any WT1 -binding proteins.
The screening had not been carried out to saturation and if this had been done, then
perhaps WT1-interacting clones could have been isolated. However it was decided
that the library was not to be screened further as it did not appear to be an adequate
library because the largest insert isolated was only lkb, the average size being 400
bases. It is likely therefore that only small domains of proteins are present in the
prey and thus the regions of the proteins required for WT1 binding may not be
present. Also because the cDNA had been made using only oligo (dT) as primers, it
is possible that many of the clones would only have contained the 3TJTR, again not
providing the domain required to bind to WT1. It was decided that a commercially
available cDNA library was to be screened instead.
3.4 Screening a commercial kidney cDNA library
3.4.1 Choice of library
The commercial library chosen to search for WT1-interacting proteins was a
Clontech human foetal kidney MATCHMAKER cDNA library. This particular
library was chosen because the mRNA source was from normal, whole kidneys of
aborted Caucasian foetus' at 19-23 weeks of gestation. The age of the kidneys used
to make the library coincides with the temporal pattern of expression seen for WT1
(Pritchard Jones et al., 1990) and it was thus hoped that in this library there would
be high expression of WT1-interacting proteins which could be picked out in the
screen. The library was made by oligo (dT) and by random priming so that as many
cDNAs could be represented and so that the clones extended beyond the 3' end. The
cDNA was fused to the pGADIO vector containing the Gal4 transcriptional
activation domain.
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3.4.2 Identifying WTl-interacting clones
The library was screened with WT1 as the bait, and control proteins were also used
as was done for the M15 library screen. The bait and prey vectors were transformed
using the lithium acetate method and the yeast were plated onto AH and 50mM AT
plates. This library screen produced 31 colonies that grew on the 50mM AT plates,
out of 1.2 million clones screened. These positive clones were all picked and
streaked out onto a fresh 50mM AT plate and left to grow at 30°C before a (3-
galactosidase yeast filter lift assay was carried out. As is shown in figure 3.3, the
filter lift assay indicated that 21 out of the 31 colonies turned blue. It was therefore
assumed that the clones that did not turn blue were false positive, and this may
sometimes occur if there is a mutation occurring in the yeast which overcomes the
nutritional problem. The clones that did turn blue were therefore potentially real




Figure 3.3: B galactosidase yeast filter lift assay. The 31
clones from the Clontech screen that grew on the plates that
lacked histidine were streaked onto fresh 50mM AT plates.
This 6 galactosidase assay yeast filter lift shows that 21 of
these were potential WT1 interacting proteins.
3.4.3 Ensuring the clones are specific for WT1 interaction
At this stage it was very encouraging to obtain such a large number of clones which
seemed to interact with WT1 The next stage was therefore to recover the prey
plasmid so that the interaction could be re-tested in the yeast two hybrid screen
against WT1 to ensure that the interaction was real, and against a negative control,
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to ensure that the prey protein did not bind weakly to other unrelated proteins, as is
described in section 3.3.4. The prey plasmids were recovered as described in section
2.2.7 and unfortunately when a digest was made from these plasmids, it was seen
that 8 of the clones appeared to have no insert. The remaining clones had inserts
varying from 700bp to 2.4kb. None of the clones turned blue when a (3-
galactosidase yeast fdter lift assay was carried out after the colonies had been
streaked onto AHT and cyclohexamide plates, showing that none of the colonies
could activate the reporter genes on their own without having to bind to WT1.
The clones with inserts were re-tested in the two hybrid screen with WT1 and with
SNF1. From the first batch of 5 clones tested one clone, clone E, showed no
interaction with WT1 as shown in figure 3.4. Again, as for the M15 screen, this was
a surprise finding as the clone was initially isolated due to its ability to interact with
WT1. The other 4 clones tested did interact with WT1 but this time they all









Figure 3.4: fi galactosidase assay for the specificity test.
Clone E is an example of a clone that could not bind to WT1
when re-tested, despite having originally been isolated due to
its interaction with WT1. Clone A is an example of a clone
that could interact with WT1 when the specificity test was
done, but it could also bind to SNF1. It could not, however,
bind to mtsl. The controls were added to ensure the assay
was working correctly.
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This was also disconcerting as it was not expected that so many proteins would bind
non-specifically. To try to address this finding, the protein sequence of SNF1 was
compared to that of WT1 to ensure that there was no common motif between the two
proteins which may explain the reason for both binding to the same proteins. There
apparently was no common motif between the two proteins, so it may be that either
the 3-dimensional structure produced a similar fold in both proteins which would
form a binding motif, or the clones were binding to both proteins non-specifically.
The validity of SNF1 acting as a negative control was now under doubt. Therefore
to double check that these clones, as well as the clones not yet tested, were really not
specific for WT1 it was decided that from then on they would all be tested against a
range of different proteins and not just SNF1. These proteins were p53, msxl and
mtsl, and these were chosen as they were already cloned into the bait vector and
were readily available in the laboratory. From the 13 remaining clones - which were
the ones that had grown on the plates lacking histidine, turned blue during the filter
lift assay, and had an insert in the vector isolated - 8 no longer interacted with WT1
when re-tested and the other 5 did. Only one clone bound to WT1 and none of the
other control proteins, and the 4 other clones all interacted with WT1 and SNF1
again, but not with the other 3 control proteins.
These results show that there is at least one clone, clone D, which is probably a real
WT1-interacting protein as it specifically bound to WT1 but not any of the other
control proteins. The other 4 clones (clones A, B, C and F) which did bind to WT1
and SNF1 but not to msxl, mtsl or p53 may be real interacting proteins but further
tests would have to be carried out to see if the binding to SNF1 was non-specific.
3,4.4 Domain binding studies with the possible WT1-specific clones
Domain binding studies
Once a protein-protein interaction has been found, the yeast two hybrid system can
also be used for domain binding studies, which maps the site of interaction. These
studies test the binding of the candidate prey protein, isolated in a screen, to new
bait proteins which now only contain domains of WT1 instead of the full length
protein. Those domains of WT1 which are tested and continue to show a positive
interaction with the candidate prey, are therefore involved in the binding interaction.
Domain binding studies were carried out on clones A and C, as random
representatives of the four clones A, B, C, and F, to be able to determine whether
these clones were binding to WT1 non-specifically or whether they were binding to
both WT1 and SNF1 due to the presence of a common 3 dimensional motif. Thus if
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clone A and C bound to the same domain of WT1, it would suggest that there was a
3 dimensional motif on WT1 that was being recognised by clones A, B, C and F
which was also present on SNF1 thus accounting for these clones not being as
specific as clone D when biding to WT1. Clone D was also used in these domain
binding studies to see whether all 4 isoforms of WT1 could bind to it, and to
determine which domain of WT1 was responsible for binding.
Cloning the bait plasmids for domain studies
The domain studies are carried out in the yeast two hybrid screen using deletion
constructs of WT1 as well as all four isoforms of WT1 as baits. The cloning of all
these baits was carried out by Dr. Davies. The following are the deletions constructs
of WT1 that were used, and they are also depicted on figure 3.5a :
Nco5'\ this is a deletion construct containing the first 182 amino acids of WT1 (or
exon 1 and most of exon 2). This was cloned by digesting the WT1+/+ bait with
Ncol. The smaller of the 2 fragments was purified and ligated into pASl-CYH2 bait
vector, which had been digested with Ncol.
Nco3'+KTS : This clone contains the remaining segment of WT1+/+ not covered by
Nco5\ The larger of the two fragments produced when WT1+/+ was digested with
Ncol was cloned into the bait vector as for Nco5\
Nco3'-KTS : This deletion construct is the same as Nco3'+KTS but it has the -KTS
splice variant, and so was cloned in the same way too but originating from WT1+/-.
Nard3: This deletion construct consists of WT1+/+ that has had amino acids 38-159
removed. It is constructed by carrying out a Narl digest on WT1+/+ and re-ligating
the large fragment into the bait vector.
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Figure 3.5: WT1 domain binding studies with Clone D. Panel (a) is a
schematic showing the WT1 deletion constructs used in the assay. Panel (b) is
a graph showing the binding of Clone D. and the control SNF'4, to the different
WT1 isoforms and deletion constructs as well as to non-related proteins.
Domain binding studies using the yeast two hybrid system
The clones A, C and D where tested for this domain binding study, by co-
transforming each clone with all of the WT1 isoforms or deletion constructs in turn.
The bait plasmids that continued to bind to the candidate clones would contain the
region of WT1 required for interaction. The results are summarised in table 3.2.
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No. of colonies growing on plates
Bait










WTl +/+ 200 10 400 100 750 67
WT1 +/- 100 12 210 25 500 350
WTl -/+ 200 30 400 50 783 250
WTl -/- 280 16 400 100 700 420
Nard3 140 14 240 5 145 128
Nco3'-KTS 350 50 600 0 738 500
Nco3'+KTS 110 14 200 0 930 350
Nco5' 210 0 240 58 1000 0
p53 400 0 600 0 400 0
mtsl 320 0 400 0 270 0
Table 3.2: WT1 domain binding studies. Clones A and C were tested in these studies to see
whether they bind to the same WT1 domain, to assess whether their interaction with WT1 is
specific. Clone D was used in this domain binding study to see if it could bind to all 4 WT1
isoforms, and to identify the WT1 domain required for binding.
These binding studies show that clones A and C do not bind to the same region of
WT1, as clone A binds to the C-terminal domain of WT1 while clone C binds to the
N-terminus of WT1. The difference in the number of colonies growing for clone A
compared to clone C suggests that clone A may be slightly toxic to the yeast. These
results suggest that the interaction between clones A, and C, with WT1 are likely to
be non-specific as they do not bind to the same 3D motif which would otherwise
account for the binding of these clones to SNF1.
The domain binding studies carried out on clone D show that it can indeed bind to
all 4 isoforms of WT1 and it seems to not be able to bind Nco5', thus indicating that
exons 1 and 2 are not involved in the interaction. To give a better idea of the
strength of interactions between clone D and the different isoforms as well as the
deletion constructs, a liquid (3-galactosidase assay was carried out as described in
section 2.2.6 (Estojak et al., 1995).
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The graph shown in figure 3.5b shows the results obtained when the liquid [3-
galactosidase assay was carried out. The data in the graph represents an average of 2
independent experiments, each itself an average of the results obtained from 3
separate colonies. The graph shows that clone D does bind to all four isoforms
above background levels, where background is taken as the equivalent of the bait
protein binding to SNF4. However, the graph clearly shows that the interactions
between clone D and the -KTS isoforms of WT1 are a lot stronger than the
interactions with the +KTS isoforms.
The deletion constructs then show that exons 1 and 2 are not required for binding as
Nco5' does not show an interaction with clone D. The deletion construct Nco3'-KTS
showed the strongest interaction with clone D, and when compared to the binding
with Nco3'+KTS, it shows that the +KTS results in a reduced affinity for the
interaction. The reason why the interaction between clone D and the Nco3 -KTS is
stronger than for the wild type -KTS isoforms may be due to the fact that the
deletion construct removes the repression domain of WT1. This domain may
interfere slightly with the transcription of the reporter genes by Gal4, The removal
of the repressor domain in the Nco3'+KTS may also explain why this deletion
construct has a slightly higher binding affinity to clone D compared to the wild type
WT1 +KTS isoforms. However the reason why Nard3, which also has +KTS, has a
higher affinity for clone D compared to the other +KTS clones is not yet understood.
It would be of interest to see if the -KTS version of Nard3 would have an even
higher affinity. These results suggest that clone D binds to the C-terminus of WT1,
maybe via the leucine zipper domain, but more likely to the zinc finger region
because the insertion of +KTS seems to reduce binding.
3.4.5 Sequencing the clones
Although at this stage it seemed that clones A, B and C were non specific for WT1
binding, they were still sequenced together with clone D. This was done in case
there was any of these clones encoded a protein which may be of interest. Clone A,
which was 2.4kb, appeared to match fibrillin, but the cDNA clone was out of frame
so that instead of encoding for fibrillin, a non-sense protein was made. This non¬
sense protein may now possibly fold in such a way that it could interact with WTl
but because it is likely to be non-specific binding, this clone was now abandoned as
a possible WTl-interacting clone.
Clone B, whose sequence matched a human EST, AA 083180, from a Stratagene
endothelial cell line and clone C which had no match in the database were also
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discarded as possible WT1-interacting proteins because their binding to WT1
seemed to be non-specific and their sequence did not highlight any motifs which
could be of interest.
Clone D, which was the only specific WTl-binding clone and was 1.2kb in length,
matched the human EST D14661. This EST had no motifs that appeared in the
database and so it yielded no clues as to its possible function, nor why it was binding
to WT1. However, because this protein did seem to bind to WT1 in the yeast two
hybrid system, it could still produce some useful information if characterised further.
Further test therefore had to be carried out on clone D which from now on was to be
called NAL (novel associating ligand), as it was a novel WTl-binding protein.
3.5 NAL, a candidate WT1 binding protein
As NAL was now a candidate WT1 protein, other tests using the yeast two hybrid
screen were carried out to provide more evidence about the specificity of its
interaction with WT1.
3.5.1 NAL can bind to WT1 when expressed as the bait or the prey protein
NAL was isolated from the Clontech library screen when WT1+/+ was used as the
bait. As a indication of whether the association between the two proteins is 'real', a
domain swap experiment can be done. In these experiments, the selection procedure
is swapped around such that the cDNA encoding for NAL now becomes fused to the
DNA-binding domain of Gal4, instead of to the activation domain. Now NAL acted
as the bait, and WT1+/+ was the prey. The WT1-/- isoform was also tested to see if
this too could bind to the NAL when it acted as a bait.
Table 3.3 shows the results of the yeast two hybrid screen carried out with NAL as
the bait and WT1 as the prey, together with controls. This experiment shows that the
interaction between NAL and WT1 is very likely to be real as the association
between the two proteins can be found whether NAL is acting as the bait or the prey.
The failure to see an association between NAL, as the bait, and WT1-/-, as the prey,
does not mean that the interaction is not real with this isoform, as when WT1-/- is
used as the bait then there is an association seen. The reason behind not seeing an
association when the prey and the bait have been swapped could be because the
conformation of the two proteins in their new environment may have altered slightly
such that the binding region of the protein becomes masked. This experiment can
therefore only have a positive interpretation in that if an interaction occurs then it
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provides more support for the association. The Y2H data produced for NAL, points
towards the interaction between WT1 being real and specific.
Bait Prey
No. of colonies on plate
AH 50mM AT
NAL WT1+/+ 800 120
NAL WT1-/- 1200 0
NAL SNF4 325 0
WT1+/+ NAL 1200 400
WTl-/- NAL 1000 400
SNF1 NAL 1000 0
SNF1 WT1+/+ 900 0
SNF1 WT1-/- 1200 0
SNF1 SNF4 275 130
WT1+/+ SNF4 250 0
WT1-/- SNF4 300 0
Table 3.3: NAL can bind to WT1+/+ when acting both as
the prey and the bait.
3.5.2 NAL hinds to the -KTS, zinc finger region of WT1
Section 3.4.4 shows that NAL bound to WT1 with a higher affinity for the -KTS
isoforms, and it appeared that NAL was binding to the zinc fingers and not to the
leucine zipper motif because the +KTS disrupted binding. A quick Y2H screen
with the zinc fingers, both +KTS and -KTS, of WT1 was carried out, to see if NAL
could bind to them without the rest of the WT1 protein being present. The results
obtained are in table 3.4.
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Bait Prey
No. of colonies on plate
AH 50mM AT
ZF +KTS NAL 1200 0
ZF-KTS NAL 800 700
WT1+/+ NAL 1000 50
SNF1 NAL 1000 0
ZF +KTS SNF4 1000 0
ZF-KTS SNF4 500 0
WT1+/+ WT1+/+ 1600 300
WT1+/+ SNF4 1200 0
SNF1 SNF4 1600 800
Table 3.4: NAL can bind to the zinc fingers (ZF) of WT1 but
only if they are -KTS.
This experiment indicates that NAL can bind to just the zinc fingers of WT1 so long
as it lacks the 3 amino acids, KTS. The insertion of the +KTS must alter the
conformation of the zinc fingers such that NAL can no longer bind to them.
However the fact that NAL can bind to WT1 +KTS isoforms, although weaker than
the -KTS isoforms, suggests that the remainder of the WT1 protein stabilises the
interaction between NAL and the +KTS zinc finger motif, thus allowing for some
binding. These results suggest that NAL preferentially binds to the -KTS zinc
fingers of WTL By binding to the zinc fingers of WT1, NAL may be interfering
with the DNA and/or RNA properties of WTL
3.6 Conclusions
The aim of using the yeast two hybrid system to screen cDNA libraries was to
identify WT1-interacting proteins. If known proteins were identified, then through
virtue of knowing their function, the consequences of them interacting with WT1
could be addressed and this might increase the understanding of the function of
WT1 at the molecular level.
The first library screen performed on the M15 cDNA library constructed, did not
identify any WT1-interacting clones. This was unfortunate, but may have been due
to the library containing very short cDNAs, which because the library was made
from oligo (dT) primers, might not have included much more than the 3TJTR of
-76-
Ch 3 Yeast Two Hybrid System
clones. The Clontech library screen did isolate some WT1 -binding proteins. In the
end it seems that out of 5 potential WT1 -binding proteins, only one clone ended up
being specific for WT1, as the rest all bound to an unrelated negative control, SNF1.
This problem with specificity has been reported before (Fromont-Racine et al., 1997)
and they suggest that perhaps it is due to the presence of the HA epitope tag which is
present in the bait protein. The one protein that did bind to WT1 specifically was
NAL, which is a novel protein. It was a shame that no known proteins were isolated
in the screens, especially proteins which have already been documented to bind to
WT1, such as WT1 itself. There are several possible reasons as to why no known
proteins were isolated, and indeed why such few clones were isolated from the
screens, as outlined below.
One reason, as already mentioned for the M15 library, was that the cDNAs in the
library are not full length. Although the Clontech library used both oligo (dT) as
well as random priming to synthesise the cDNA, and thus have more than just the
3TJTR, the clones may still be lacking the domains needed for binding to WT1. For
example, for WT1 to dimerise the N-terminus is required, and if this motif is not
present in the cDNA made from the WT1 transcript, then the Y2H screen will not
isolate the WT1 transcript in the library.
A problem encountered when carrying out the screen was that clones that originally
had been isolated because they interacted with WT1, no longer did so when the
clone was isolated and re-tested. One possibility for this occurrence is that when the
yeast are transformed, some may pick up more than the one prey plasmid. It is likely
that out of the transformed prey plasmids, only one will bind to WT1 and thus when
the vector is isolated, it is possible that the other prey present in the yeast is
captured. Therefore when this clone is re-tested it will no longer be able to activate
transcription as it was not the original prey that was binding to WT1. This
hypothesis can also explain why clones that seemed to activate the system had empty
vectors i.e. the yeast had been transformed with two preys, one of which had an
WT1 binding insert - thus causing transcription of the reporter genes - and the other
one which was empty, but happened to be isolated in preference to the WT I-binding
clone. This hypothesis could have been tested by carrying out mating type assays,
where the prey plasmid does not have to be isolated as the colony is directly streaked
to a fresh plate and mated with a strain of the opposite mating type. In these mating
type assays, the clones should still be able to interact with WT1.
Another problem with the system was that the screen may not have reached
saturation and this was certainly true for the M15 library screen where only a quarter
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of a million clones were screened. Over 2 million clones had been screened in total
for the Clontech library. Although in theory this would have screened the 2 million
clones present in the library, it is highly unlikely that all clones would have been
screened. It is also possible that when the library was being amplified, some clones
may have been selected for and therefore enriched, whilst others may have been
selected against, especially those that could be harmful towards the bacteria. For
this reason a lot of potential candidate WT1-interacting proteins may not have been
represented in the libraries. Also some of the cDNAs which are represented in the
library may be out of frame, as was seen for clone A, which was a fibrillin clone out
of frame. Only one sixth of the cDNAs will be in the correct frame for translation,
and so a lot of nonsense proteins will be present in the library.
Another possibility as to why so few clones were isolated is highlighted by section
3.5.1. In this experiment, it was found that NAL could bind to WT1 +/+ whether
NAL was used as the prey or the bait. However, NAL could only bind to WT1-/- if
NAL was the prey but this did not mean that the interaction was weaker because the
quantitative [3-galactosidase assay shows that in fact the WT1-/- isoform interacted
better with NAL that the +/+ isoform. Thus the conformation of WT1 may be altered
slightly depending on whether it is fused to the Gal4 DNA-binding domain or to the
Gal4 activation domain, and this may be sufficient to prevent some interactions from
occurring. Therefore if the screen had been performed with WT1 as the prey instead
of the bait, then other proteins which can only bind to WT1 in this orientation may
have been isolated. This has in fact been shown by Davies et al. as U2AF65, which
has been identified as a WT1-interacting protein (Davies et al., 1998), can only bind
to WT1 if the latter is used as the prey.
All these reasons can explain why the screens did not identify other WT 1 -interacting
proteins. It would be possible, in an attempt to identify other WT1-interacting
proteins, to continue screening the libraries, to ensure that the screens were carried
out to saturation, or to screen other available libraries. It would also be feasible to
carry out the screens using WT1 as the prey, but this would mean having to redone
the libraries into the DNA binding domain vectors. Alternatively a different
approach to identify WT1-interacting proteins could be carried out, such as
screening lambda expression libraries. However, all these possibilities were not
carried out, because it was decided that the Y2H screening had already identified a
potential WT1-interacting protein - NAL. NAL is a good candidate because it binds
to WT1 specifically, without binding to unrelated proteins and it binds to WT1 +/+
whether it is expressed as the bait or the prey, thus providing more support to
suggest that the interaction is 'real'. NAL seems to be isoform dependent, binding
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more strongly to the -KTS isoforms. The WT1 zinc fingers seem to be the motif
NAL binds to, and this suggests that perhaps NAL may interfere with the DNA
and/or RNA functions of WT1. Thus although NAL is a novel protein and so does
not provide any immediate clues as to why it binds to WT1, it is still of interest and
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Chapter 4: Identification of a novel protein
As detailed in chapter 3, NAL was identified as being a potential WT1-binding
protein. It was of interest to characterise this protein further to gain as much
information about it as possible, and so the clone was fully sequenced and mapped.
4.1 Sequencing NAL
The sequencing of NAL that had been described in chapter 3 had only covered the
first 300 bases of the clone and so now it was sequenced fully to see if there were
any motifs within the sequence which could point to a possible function. The clone
was sequenced in the forward and reverse orientation to ensure the fidelity of the
sequence produced. Each section of sequencing run was also carried out in
duplicate. Figure 4.1 shows the sequence obtained together with the primers used
(the primers are also detailed in the appendix).
4.2 Database matches for NAL
4.2.1 NAL partially matches EST D14661
The sequence obtained for NAL was run through the GenBank database to see if it
matched any known sequences. The EST D14661 produced a 60% identity match.
However, it was noted that for the first 445 bases of NAL, the match was 100%
identical, after which there seemed to be a breakpoint where there was no longer any
real homology - see figure 4.2. This was highly suggestive of one of the two
sequences originating from a chimaeric clone, formed by the fusion of two non-
related cDNAs. This possibility had to be clarified to determine which of the two
was from a chimaeric clone.
4.2.2 Do either NAL or the EST originate from a chimaeric clone?
To address the question of whether NAL, or the EST, originated from a chimaeric
clone, RT-PCR was carried out on RNA from Ml5, COS and HeLa cells (see
appendix for primer sequences). For both the EST and NAL, the PCR was carried
out across the breakpoint (primers M729 and M730 for the EST, and primers M729
and M731 for NAL) and across most of the whole length of the clone (primers M717
and M728 for the EST and M717 and M718 for NAL). A PCR was also carried out
for the region that was perfectly matched between the two, called the N-terminus
(primers M717 and M715), as a positive control as well as for the C-terminus of
NAL (primers M716 and M718) to ensure that this sequence was also an expressed
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sequence. Figure 4.3a illustrates which primers were used to amplify the different
segments of the clones.
H792
CGAAGAACCT CTTCCCAAGA AGGTTCGATT GAGTGAAACA GACTTCAAAG
51 TTATGGCAAG AGATGAGTTA ATTCTAAGAT GGAAACAATA TGAAGCATAT
101 GTACAAGCTT TGGAGGGCAA GTACACAGAT CTTAACTCTA ATGATGTAAC
151 TGGCCTAAGA GAGTCTGAAG AAAAACTAAA GCAACAACAG CAGGAGTCTG
201 CACGCAGGGA AAACATCCTT GTAATGCGAC TAGCAACCAA GGAACAAGAG
LS6 ^
251 ATGCAAGAGT GTACTACTCA AATCCAGTAC CTCAAGCAAGTCCAGCAGCC
301 GAGCGTTGCC CAACTGAGAT CAACAATGGT AGACCCAGCG ATCAACTTGT
351 TTTTCCTAAA AATGAAAGGT GA ACT GGAA C A GA CTAAA GA CAAACTGGAA
L342
401 CAAGCCCAAA ATGAA^HMBBKGGAAG TTT4^GCCTG ATAGCCAAAC
451 AGGGAAAAAG TTAATGGCGA AGTGTCGAAT GCTTATCCAG GAGAATCAAG
501 AGCTTGGAAG GCAGCTGTCC CAGGGACGTA TTGCACAACT TGAAGCAGAG
551 TTGGCTTTAC AGAAGAAATA CAGTGAGGAG CTTAAAAGCA GT CA GGAT GA
601 ACTGAATGAC TTCATCAT CC A GCTTGAT GA AGAAGTAGAG GGTATGCAGA
t ( IJ43
651 GTACCATTCT AGTTCTGCAG CAGCAGCTGA AGGAGACACG CCAGCAGTTG
701 GCTCAGTACC AGCAGCAGCA GTCTCAGGCC TCTGCCCCAA GTACCAGCAG
751 GACTACAGCT TCTGAACCTGTAGAACAGTC AGAGGCCACA AGTAAAGACT
801 GCAGTCGTCT GACAAACGGA CCAAGTAATG GTAGCTCCTC CCGCCAGAGG
851 ACGTCTGGTT CTGGATTTCA CAGGGAGGGC AACACAACCG AAGATGACTT
L55
901 TCCTTCTTCT CCAGGGAATG STAATAAGTC CTCCAACAGC TCAGAGGAGA
Q147
951 GAACTGGCAG AGGAGGTAGT GGTTACGTAA ATCAACTCAGTGCGGGGTAT
1001 ^HHh-AG ACTCTCCCACGGGCAGTGAA AACTCTCTCA CACACCAATC
1051 AAATGACACA GACTCCAGTC ATGACCCTCA AGAGGAGAAA GCA GTGA GT G
1101 GGAAAGGTAA TCGAACTGTG GGTTCCCGCC ACGTTCAGAA TGGCTTGGAC
H793
1151 TCAAGTGTAA ATGTACA
Figure 4.1: NAL sequence showing primers used to sequence it. Primers
H792 and H793 originate in the pGADIO vector. The NAL clone is not full
length as it does not have a start or a stop codon.
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1 CGAAGAACCTCTTCCCAA
IMIIIII MINI I III
101 GCTTCTGCCTGGAGAGGATTCAAGi^ft.CCAACGAAGAACCTCTTCCCAA
19 GAAGGTTCGATTGAGTGAAACAGACTTCAAAGTTATGGCAAGAGATGAGT 68
M M 1111111 M II M 11111 M 11111 M 11111111111 M 11 M 11
151 GAAGGTTCGATTGAGTGAAACAGACTTCAAAGTTATGGCAAGAGATGAGT 200
69 TAATTCTAAGATGGAAACAATATGAAGCATATGTACAAGCTTTGGAGGGC 118
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I
201 taattctaagatggaaacaatatgaagcatatgtacaagctttggagggc 250
119 aagtacacagatcttaactctaatgatgtaactggcctaagagagtctga 168
I I I I I I I I I I I I II I I I I II I I I I II I I I I I I I I I I I I I I I I I II I I I I I
251 AAGTACACAGATCTTAACTCTAATGATGTAACTGGCCTAAGAGAGTCTGA 300
169 AGAAAAACTAAAGCAACAACAGCAGGAGTCTGCACGCAGGGAAAACATCC 218
I I I I I I I I II I I I I I I I I I I I I I I I I II I I I I I I I I I II I I I I I I I I I I I
301 agaaaaactaaagcaacaacagcaggagtctgcacgcagggaaaacatcc 350
219 ttgtaatgcgactagcaaccaaggaacaagagatgcaagagtgtactact 268
I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I
351 TTGTAATGCGACTAGCAACCAAGGAACAAGAGATGCAAGAGTGTACTACT 400
269 CAAATCCAGTACCTCAAGCAAGTCCAGCAGCCGAGCGTTGCCCAACTGAG 318
I I I II I I II I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
401 caaatccagtacctcaagcaagtccagcagccgagcgttgcccaactgag 450
319 atcaacaatggtagacccagcgatcaacttgtttttcctaaaaatgaaag 368
I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I
451 ATCAACAATGGTAGACCCAGCGATCAACTTGTTTTTCCTAAAAATGAAAG 500
369 GTGAACTGGAACAGACTAAAGACAAACTGGAACAAGCCCAAAATGAACTG 418








I II I III I I III I I I III
601 aagacttccctgacagtcccactacgagaaagctgtggtgggacag.... 646
519 cccagggacgtattgcacaacttgaagcagagttggctttacagaagaaa 568
II II II Mil I II Mil II II II III
647 ccaagtactcgtttccacaccaagactcagactttttgagccaaaaaaaa 696
569 ..tacagtgaggagcttaaaagcagtcaggatgaactgaatgacttcatc 616
III I II III I I II I Mil
697 GCCACATTCTTACACTGTCCAGCTTGTAATGGTTAATGTAAAACTTACCA 746
Figure 4.2: Sequence comparison between NAL and the EST, D14661.
It can be seen that the sequence is 100% identical until base 445 of
NAL, after which there is a breakpoint where there is no real homology.
At the breakpoint the EST has a 5'splice site consensus sequence,
followed by a stop codon. The EST sequence continues on (not shown)
and at the end it has a poly-adenylation site (AATAAA).
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Point Length Terminus Terminus
Key:
1 = COS Cells
2 = HeLa Cells
3 = M15 Cells
4 = Water
(B)
Figure 4.3: RT-PCR experiment to determine whether NAL and D14661
are transcribed in cells. Panel A shows the primers used to amplify the various
segments of the EST and NAL clones. Panel B shows the products of the RT-
PCR run on a 1% agarose gel. For NAL, products can be seen for every
combination of primers, although the whole length product is very faint. For the
EST on the other hand, no products can be amplified for any of the cell lines
used.
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Figure 4.3b shows that for the EST, neither the breakpoint nor the whole sequence
could be amplified. On the other hand, all regions tested for NAL could be
amplified, although only a faint band was produced for the whole length product,
possibly because the conditions had not been optimised. This experiment thus
showed that NAL was in fact the mRNA that is found normally in these cells
because the PCR can occur across the breakpoint, and the whole clone. The
experiment also pointed towards the EST originating from a chimaeric clone because
neither the breakpoint nor the length of the clone could be amplified. Although it
could be argued that the PCR had not worked for the primer combinations used for
D14661, it seems unlikely to be the case as all the other combinations for the rest of
the reactions worked well.
4.2.3 The ESTs matching NAL may originate from unspliced RNA, or they
could be alternative transcripts
The initial thoughts that the EST, D14661, originated from a chimaeric clone could
have been misleading as when the sequence across the breakpoint was analysed
more closely, it seemed to resemble an exon-intron boundary (see figure 4.2). This
boundary is characterised by the sequence (A/C)AG at the end of the exon and
GTAAGT at the beginning of the intron. This sequence is the perfect complement of
bases 4-12 from the 5' end of the U1 snRNA component of the spliceosome: 5'
ACUUACCUG 3', which guides selection of the 5' cleavage site. The EST has the
following sequence at the breakpoint: TAG at the end of the presumed exon and
GTAAAC at the beginning of the proposed intron. The initial base of the exon
consensus is not conserved as the G at position 12 of U1 RNA is thought not to be
critical for splice site selection. Bases 5 and 6 of the EST intron are not exactly like
the consensus sequence either, but some bases are not 100% conserved - the only
ones that are, are the first two bases of the intron -GT (Jackson, 1991). Thus 6 out
of the 9 nucleotides for the splice site consensus are conserved, including the two
critical residues, -GT. Therefore perhaps this D14661 EST is not derived from a
chimaeric clone after all but is instead an unspliced RNA. Further reason to believe
that the EST has not arisen from a chimaeric clone is that when the EST D14661 is
run through the database, it matches other EST clones which have exactly the same
sequence, even after the breakpoint, and it is extremely unlikely that they all
originate from chimaeric clones.
To see if the C-terminus of the NAL clone, which did not match the D14661 EST,
was homologous to any other clones, it too was put through the database.
Intriguingly it matched an EST (H90530), amongst others, but again there seemed to
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be a breakpoint in H90530 where there is a sudden loss in homology after a good
match. This time the initial sequence of H90530 doesn't match NAL, and then after
a breakpoint does so perfectly as illustrated in figure 4.4. If this breakpoint is
examined, it shows that it is an intron-exon boundary. This has the consensus
(Y)10NYAG for the sequence of the intron and a G for the start of the exon, (where
Y= T or C). The breakpoint of where the clone H90530 begins to match NAL is
CTCTTTCCTTTGCAG at the end of the intron and a C at the start of the exon. This
therefore matches 100% for the end of the intron sequence. The start of the exon
sequence does not match but again there is not 100% conservation for all bases,
except for the AG at the very end of the intron (Jackson, 1991), which is what we
have. Thus again there seems to be an unspliced RNA in the database.
Unfortunately the 5' sequence of the H90530 intron does not extend far enough to
see if it reads into the 3'end of the D14661 intron.
The picture that is emerging is therefore that NAL is a bone fide cDNA, which is
made up of several exons - the first few being the same as the exons in D14661 and
others being the same as the exons in H90530. The introns of the primary RNA
transcript of NAL would therefore consist of the introns in D14661 together with
those of H90530. The picture can however be more complicated than that.
Although it is not uncommon for the database to have ESTs originating from
unspliced RNA, it seems unlikely that so many clones in the database which are like
D14661, but shorter, are unspliced. Therefore if the sequence of D14661 is looked
at further, it shows that in fact it could encode an open reading frame (ORF) that
goes beyond the exon-intron boundary until it reaches a stop codon which is found
straight after the breakpoint. The rest of the sequence would then be 3UTR, at the
end of which there is a poly-adenylation site (AATAAA). It now appears that the 5'
splice site of this primary RNA transcript could either be used, and so by removing
the intron and joining on the next exon - followed by a 3TJTR - it would produce
NAL, or it could be read through and so produce a smaller ORF, with its own
3LJTR, such as that just described for D14661 (see figure 4.5). This phenomenon of
having alternative 3 UTR and polyA sites within a transcript has been described for
other genes (Edwalds-Gilbert et al., 1997; Lee and Maihle, 1998).
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h90530.gb_est4 x NAL.seq ..
1 TTTGAGATGAAAATAGATGGATTTCAGAATTGATTATTGATGT 43 H90530
III I! I I I I! I I
151 TGGCCTAAGAGAGTCTGAAGAAAAACTAAAGCAACAACAGCAGGAGTCTG 200 NAL
44 AATAGANACAAGGTGTAGCTGTTTGGGCACTTTTTGTTTAGGGTNTATTT 93
I h II I III I III III : I
201 CACGCAGGGAAAACATCCTTGTAATGCGACTAGCAACCAAGGAACAAGAG 250
94 TTGCTGCTGTGT..TGGCAAAATACTGAAATGCAGAAGATGGATGTGTCC 141
III Mil I Mil I I I II I III
251 ATGCAAGAGTGTACTACTCAAATCCAGTACCTCAAGCAAGTCCAGCAGCC 300
142 CAGAAAAGAAGATGGTAATTATGGGGAAGCATCTGCTGTGATATAGTTAT 191
II II II II I I III I II I
301 GAGCGTTGCCCAACTGAGATCAACAATGGTAGACCCAGCGATCAACTTGT 350
192 GTTTGTATGTGTTACATCTATCACTGTAATAATTGTAAGCAAAGACAGAG 241
III I I Mil II I III II II
351 TTTTCCTAAAAATGAAAGGTGAACTGGAACAGACTAAAGACAAACTGGAA 400
242 AGTTGTCTTCATTTTGTGATGGATGG...CTCTTTCCTTTGCAGCCAAAC 288
I II III I I I I II lllllll!
401 CAAGCCCAAAATGAACTGAGTGCCTGGAAGTTTACGCCTGATAGCCAAAC 450
289 AGGGAAAANGTTAATGGCCGAAGTGTCGAATGCTTATCCAGGAGAATCAA 338
I 111111 h 11111111 1111111111II11111 1111 1111II11111
451 AGGGAAAAAGTTAATGG.CGAAGTGTCGAATGCTTATCCAGGAGAATCAA 499
33 9 GAGNCTTGGGAAGGCAGCTGTCCC 3 62
III: I I I I II I II II II I I I I
500 GAGC..TTGGAAGGCAGCTGTCCCAGGGACGTATTGCACAACTTGAAGCA 547
Figure 4.4: Sequence comparison between the EST. h90530, and NAL. The two
sequences only match from base 445 of NAL. It is likely that the h90530 clone is
unspliced, because as highlighted by the green box, there is an intron/exon consensus
sequence.
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EST in database: Exon 1 3'UTR Poly A
Stop
Figure 4.5: Schematic showing the model proposed for the formation of
two alternative transcripts. From the pre-mRNA 2 alternative transcripts can
be produced to form the EST and NAL. As the genomic sequence is not
known, for simplicity's sake, the group of exons in NAL which match the EST
will collectively be called exon 1, and the group of exons which do not match
the EST will collectively be called exon 2. In the proposed model then, the
intron could be spliced out, and exon 1 and 2 joined to form NAL, which has
its 3'UTR and polyadenylation site. Alternatively the splice site at the junction
between exon 1 and the intron could be read through, such that the intron
becomes a terminal exon, which has its own 3'UTR and polyadenylation site
which are different to those of NAL.
Initially it would appear that the RT-PCR experiment carried out would not back this
hypothesis up, because if there were to be read through to produce D14661, then
there should have been a product formed. As the 5' splice site consensus sequence is
well conserved, it likely to be spliced in preference to being read through, but all this
will depend on levels of poly-adenylation factors, splicing factors and termination
factors within a particular cell. Therefore the transcripts may be cell type specific
and as only three cell lines were tested for the RT-PCR experiment, it cannot be
excluded that D14661 might not be amplified in other cell lines. Another possibility
is that D14661 is present in the cell lines tested but the mRNA may not be very
stable, and so cannot be amplified. Although not carried out, the best way to have
tested this hypothesis would have been to carry out the PCR on genomic DNA. If
D14661 does have this exon-intron boundary, through which splicing may or may
not occur, then this sequence should be the equivalent to the genomic DNA, and so
if the PCR is carried out across the breakpoint then a small product should be seen.
For NAL, on the other hand, the breakpoint PCR product produced from genomic
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DNA should be a lot larger than that produced in the RT-PCR experiment as there
would now be an intron separating the two primer pairs. Northern blots could also
be carried out to see whether there are different size transcripts present which would
represent the alternative products. The RT-PCR experiment could also have been
carried out using RNA originating from the cell line from which the EST was
initially isolated.
4.3 NAL is a novel protein
The database search showed that NAL partially matched the human EST D14661 in
the database. There was also one clone arising from a mouse and one from rat cell
line but from no other species. There were no matches seen at all in the invertebrate
nor the fungi databases, suggesting that only vertebrates have this NAL clone. The
Swissprot database was searched to see if there were any homologous proteins but
none were found. The motif database also showed that the only motifs known in
NAL were those of phosphorylation sites; amidation and glycosylation sites but apart
from these there were no motifs which could be associated with any particular
function. The only recognisable motif present in NAL is that of glutamine rich
stretches, which are often associated with transcription factors. These database
searches conclude that NAL is a novel protein which has not been characterised
before.
4.4 Isolating a mouse cDNA homologue of NAL
The mouse clone found in the database that matched the human EST, D14661,
started at the position equivalent to base 672 in the human D14661 clone. This
mouse clone therefore matches the EST after the breakpoint, and so is either part of
the 3TJTR of the EST, or if the human EST did arise from a chimaeric clone then it
is from the cDNA that does not match NAL. Either way the mouse clone in the
database did not match the NAL transcript, and thus a library screen was to be
carried out to isolate the mouse homologue of NAL.
4.4.1 Screening a mouse cDNA library
The library screen was to be performed on a mouse cDNA library to obtain the
mouse homologue of NAL. Initially an RT-PCR was carried out on whole mouse
mRNA, E=11,5d, to ensure that there was a mouse homologue of NAL present at
this age, before carrying out the screen. The primers to be used were those that
would amplify the breakpoint, the length of the whole clone as well as the N- and C-
terminus of NAL, as these were the primers that were used for section 4.2 As
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shown in figure 4.6 products were amplified for each of the primer pairs used, but
again the whole length product was very faint due to the conditions used. This RT-
PCR experiment suggests that there could be a mouse homologue of NAL in the
E=11.5d library. This experiment also suggests that the mouse and human NAL










terminusfC A Whole A Break Aterminus length point
H-,0 H,0 H,0 H-,0
Figure 4.6: RT-PCR on whole mouse RNA (E=11.5d).
Primers against the N-terminus; C-terminus; whole length; and
across the breakpoint of NAL were used, as depicted in figure
4.3a. The products of each amplification can be seen, except for
the whole length where only a faint band was produced due to the
PCR conditions used. This experiment suggests there could be a
mouse homologue of NAL in the library to be screened.
The Clontech mouse 11-day embryo 5'-STRETCH PLUS cDNA library was
screened with the NAL probe which consisted of the full length clone. The probe
was made by PCR of the NAL clone using primers M717 and M718, starting at base
13 and finishing at base 1143. The probe was then labelled with [32P]dCTP as
described in section 2.3.8. The primary screen produced 9 positive clones from a
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total of a million screened. The inserts of three clones were then subcloned into the







4 Average Mismatch: -2.003
1825 Length: 614
4.704 Gaps: 0
97.059 Percent Identity: 96.524
Match display thresholds for the alignment(s):
I = IDENTITY : =
. = NAL.pep x Nal.pep ..
1 EEPLPKKVRLSETDFKVMARDELILRWKQYEAYVQALEGKYTDLNSNDVT 50 Human NAL
Mouse Nal
I I 11 1II ! I! I I I I 11 I 111II111IIIII 111 11
1 FKVMARDELILRWKQYEAYVQALEGKYTDLNSNDVT 3 6
51 GLRESEEKLKQQQQESARRENILVMRLATKEQEMQECTTQIQYLKQVQQP 100
I I I I I I I I I I II I I I I I I I I I I I I I I I II I I I I I I II I I I I I I I I I II I I
37 GLRESEEKLKQQQQESARRENILVMRLATKEQEMQECTTQIQYLKQVQQP 86
101 SVAQLRSTMVDPAINLFFLKMKGELEQTKDKLEQAQNELSAWKFTPDSQT 150
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
87 SVAQLRSTMVDPAINLFFLKMKGELEQTKDKLEQAQNELSAWKFTPDSQT 136
151 GKKLMAKCRMLIQENQELGRQLSQGRIAQLEAELALQKKYSEELKSSQDE 200
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I
137 GKKLMAKCRMLIQENQELGRQLSQGRIAQLEAELALQKKYSEELKSSQDE 186
201 LNDFIIQLDEEVEGMQSTILVLQQQLKETRQQLAQYQQQQSQASAPSTSR 250
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Figure 4.7 Comparison of the peptide sequence of the human NAL and
mouse Nal clones. The two clones are 967c identical at the amino acid
level and the amino acids that differ are highlighted. The divergence
occurs within a cluster and thus this region is probably not involved directly
with the function of the protein. As can be seen, 6 amino acids after the end
of the available human NAL sequence, the mouse NAL sequence has a stop
codon. suggesting that the human NAL clone is not far off from a
termination site.
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4.4.2 The mouse and human clones of NAL are 94% identical
One of the mouse clones was sequenced fully and it was found that this mouse clone
isolated matched NAL. At the DNA level the human and mouse NAL clones are
94% identical and at the protein level are 96% identical, as shown in figure 4.7.
This shows that the mouse and human NAL are very highly conserved, and it
suggests that the structure of the protein must be important for function as there is
hardly any divergence. The fact that the mouse sequence is 94% identical to the
human sequence also shows that NAL could not have originated from a chimaeric
clone, as was thought at one stage (see section 4.2). Also a more recent search
through the database showed that there was now a mouse EST clone which matched
the one isolated, from position 744 to 1124. This shows that the library I had
screened was not contaminated with human clones, as could be thought in light of
the two clones being so similar, because the mouse clone in the database came from
an independent source.
W26318.gb_est4 x nal.seq ..
1 ttnnnnntncncggncagtgaaaactctctcacacaccaat 41
::::: : I = I I I = I I I I I I II I I I I I I I I I I I I I I I I I I
1000 tgaaagtgtagactctcccacgggcagtgaaaactctctcacacaccaat 1049
42 caaatgacacagactccagtcatgaccctcaagaggagaaagcagtgagt 91
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
1050 caaatgacacagactccagtcatgaccctcaagaggagaaagcagtgagt 1099
92 gggaaaggtaatcgaactgtgggttcccgccacgttcagaatggcttgga 141





Figure 4.8: Sequence comparison between the end of the NAL
clone and a human clone from the database. This sequence
comparison shows that the ESTw26318, which originated froma
human retina cDNA library, matches NAL, and the clone shows that
there is a stop codon 5 amino acids after the end of the N AL. clone.
4.5 The Human NAL clone is not quite full length
The human NAL clone which was isolated from the yeast two hybrid screen is not
quite a full length clone. The clone does not have a start site, but by comparing its
sequence to the human EST, D14661, it can be seen that it is only 3 amino acids
away from the ATG site of the EST (see figure 4.2). The sequence around the ATG
site has the conserved A three nucleotides upstream of the ATG, but the rest of the
sequence is not a good Kozak consensus site (Kozak, 1984), so it is not definite that
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this ATG is the start site. However, as discussed later in chapter 5, an antibody
raised against NAL shows that the molecular weight of the endogenous protein is
very similar to that of the NAL protein made in vitro from the NAL clone. The NAL
clone also does not have a termination site, but there is a human clone in the
database, originating from a retina library which matches NAL at position 1025, and
goes through to a stop codon, as shown in figure 4.8. Also by comparing human
NAL to mouse Nal, it can be seen that 6 amino acids after the end of the human
clone sequence, the mouse clone has a termination site, followed by 3UTR and a
poly-adenylation site. Since the mouse and human clone are 96% identical at the
amino acid level, it is likely that the human clone will be similar in length and so
have a stop codon around the same place. The 3TJTR would, however, probably
differ. If a full length NAL clone were to be needed, the rapid amplification of
cDNA ends (RACE) technique could be used.
4.6 Mapping NAL
The EST D14661 had been isolated and placed in the database by a Japanese group
that was trying to accumulate information on the structure of unidentified human
genes by carrying out a big sequencing project of full-length cDNA clones. They
therefore also mapped the EST to chromosome 6 (Nagase et al., 1995). However,
the primers they used for mapping the EST were not documented and so it is not
known if they were directed to the part of the sequence that did not match NAL, and
because it is not yet totally clear whether this EST originated from a chimaeric
clone, it was decided to map NAL independently, both in the human and mouse, by
fluorescence in situ hybridisation (FISH) and also for the mouse by using the
European collaborative interspecific backcross (EUCIB). By using these methods,
the chromosomal location of NAL would also be more refined and it may provide
some interesting findings if it maps to any disease locus.
4.6.1 Fluorescent in situ hybridisation
Mapping of the human NAL
Human NAL was mapped using FISH. For this purpose the full length NAL clone
was digested out of the pGADIO vector, and purified. FISH was carried out on
human chromosome spreads and this was carried out by Muriel Lee. The FISH
results (figure 4.9) showed that the human NAL gene mapped to chromosome 6,
towards the telomere possibly between 6q25-27. This was encouraging because the
EST also mapped to chromosome 6 (Nagase et al., 1995), increasing the likelihood
that the EST is not from a chimaeric clone but is either an isoform of NAL or
originates from unspliced RNA.
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Figure 4.9: FISH analysis on human chromosome
spreads using human NAL cDNA as the probe.
The results show the signal appearing on chromosome
6, very close to the telomere. Some backgound signal
can be seen, but this is because only a small cDNA
probe was used. The FISH anaylsis was carried out
by Muriel Lee.
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Figure 4.10: FISH analysis on mouse chromosome spreads
using mouse Nal cDNA as the probe. The results show the
signal appearing on chromosome 17, very close to the
centromere. Some backgound signal can be seen, but this is
because only a small cDNA probe was used. The FISH
anaylsis was carried out by Muriel Lee.
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Mapping of the mouse Nal clone
The mouse Nal gene was also to be mapped using FISH. The mouse insert was
digested out of bluescript and purified. Again Muriel Lee carried out the FISH, this
time on mouse chromosomal spreads. The results (figure 4.10) show that the mouse
Nal gene maps to chromosome 17, near the centromere. This was also very
encouraging as from linkage maps the mouse chromosome 17 and the human
chromosome 6 show conserved synteny in the regions where the two genes map.
4.6.2 European collaborative interspecific mouse backcross
The EUCIB panel of mice provides a resource for genetically mapping a mouse gene
at high resolution. It consists of 1,000 animal backcross progeny produced from a
backcross between two mouse species, Mus spretus and C57BL/6 which was
generated jointly between the UK HGMP centre and the French Institute Pasteur. F1
females are then backcrossed either to C57BL/6 or Mus spretus. The backcross
progeny mouse are then scored for 3-4 markers per chromosome to produce an
anchor map of 70 loci across the mouse genome (The European Backcross
Collaborative Group, 1994). A new marker to be mapped first has to be linked to a
chromosomal region and then analysed through a panel of mice identified as
carrying recombinants within that chromosomal region. The new clone is then
mapped to the closest marker that carries the same sequence of recombination events
for each mouse tested.
Firstly, to detect whether a recombination event has occurred, a sequence variation
within the clone of interest has to occur between the two species of mouse.
Normally the sequence looked at is the 3TJTR, as this region of a gene is not so well
conserved and therefore is more likely to have sequence variations. The 3TJTR of
Nal was amplified in both strains of mice. However because in the laboratory there
was no available DNA from Mus spretus, DNA from Ts/BL was amplified instead.
The Ts/BL mice are a mixture of spretus and C57BL/6 mice, and thus the PCR
should produce 2 bands: one corresponding to the C57BL/6 chromosome and one
for the spretus chromosome. The PCR 5' primer started at position 1194 and the 3'
primer started at position 1743 of the Nal clone, and this primer pair would amplify
the 3TJTR. It was hoped that the 3UTR would differ in length between the two sets
of mice. Unfortunately no size difference could be resolved using PCR and so
restriction digests were performed to find sequence polymorphisms between the two
strains. It was found that one enzyme, Ddel, did show a difference between the two
mouse strains. One band was produced for the C57BL/6 DNA digest and two bands
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were produced for the Ts/BL DNA (one higher band representing the C57BL/6 DNA
and the other representing spretus DNA), as shown in figure 4.11.
oo CM _ r- 1
V/-> m vO 1—1
O o O o o o O CQ
CQ CQ CQ CQ CQ CQ CQ C/3







Figure 4.11: Ddel digests on test mice. The amplified PCR products
for the 3'UTR of Nal from 7 test mice,were digested with Ddel and run
on a 1.5% agarose gel. Test mice were chosen so that they had either
both chromatids like the parental type or one chromatid of the parental
type and the other chromatid from the other strain of mouse. In this
way if the Ddel digest produced the expected number of bands, it could
be used unambiguously as a diagnostic digest on the panel of mice used
to map Nal. DNA from CB57BL/6 mice and from Ts/BL (a mixture of
spretus and C57BL/6) were run as internal controls.
To ensure that this PCR followed by a Ddel digest was a good way to distinguish
between DNA from the two different mice strains, C57BL/6 and Mus spretus, the
experiment was first tried on test mice. 7 mice were chosen in such a way that they
had either both chromosomes as the parental type e.g. both C57BL/6, or had one
chromosome from the parent and the other chromosome from the other mouse strain
e.g. one from C57BL/6 and the other from spretus. The digests should then produce
either one or two bands respectively. In this way the number of bands expected are
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known, and thus it should be clear whether the diagnostic digest works without there
being any ambiguity. Table 4.1 shows the backcross progeny used, together with
the number of bands expected to be produced after a Ddel digest. The letters within
the progeny name represent the strain of mouse to which the F1 generation were
backcrossed to, as follows: LB= London Black 6; PB= Paris Black 6; LS= London
spretus; PS= Paris spretus. Thus if an F1 is backcrossed to an LB and one band is
produced, it suggests that for that locus, both chromosomes originated from
C57BL/6 DNA. If the same backcross produces 2 bands, then one chromosome is
like the parental C57BL/6 DNA whereas the other chromosome originates from
spretus DNA.
Figure 4.11 shows the number of bands that were produced for each progeny after
the Ddel digest, and these results are summarised in table 4.1. The results obtained
show that the digests did produce the expected bands, and so the Ddel digest is a















Control C57BL/6 1 1
Control Ts/BL 2 2
Table 4.1: Ddel digest of the 3'UTR of Nal of test mice. The table shows the
mouse progeny used to test whether the Ddel diagnostic digest produces the
expected results. This experiment showed that the Ddel digest can distinguish
between the DNA originating from C57BL/6 mice and the DNA originating from
spretus mice.
The diagnostic digests could now be carried out on a larger panel of mice so as to be
able to map Nal. The first stage of the mapping procedure - linking Nal to a
chromosomal region - had effectively already been done by using FISH. Therefore
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rather than having to take a random panel of mice to achieve this chromosomal
linkage, mice where chosen according to whether they would be informative. This
meant choosing mice that had as many markers mapped to the candidate Nal region.
These mice were also chosen according to whether their markers had been ordered
on the chromosome via one recombination event only. This is because usually only
one recombination event occurs and so if markers are mapped onto a chromosomal
region by the formation of 2-3 recombination events, it suggests that perhaps a
typing error had occurred. The informative mice were those that had markers on
chromosome 17 from the centromere up to marker D17Mit9. This region was the
selected region because from the mouse FISH data, Nal is known to map to
chromosome 17 near the centromere. The human FISH data shows that NAL maps
to chromosome 6q near the telomere. When a linkage map of chromosome 17 is
looked at, it can be seen that the region between the centromere and marker
D17Mit9 shows conserved synteny with the telomeric end of human chromosome 6,
and so it is likely that Nal maps in that region.
The MBx database, which supports the backcross, was used to find the panel of mice
that had markers within the chosen region of chromosome 17. From this panel, 45
mice were chosen for the mapping so as to make the experiment statistically
significant. The 3UTR of Nal was amplified from these mice. Only 38 tubes of
DNA from the backcross progeny amplified the product and this was because a lot
of the tubes were old and so contained no DNA. The backcross progeny used and the
haplotype for each marker, as determined by EUCIB, are shown in table 4.2. The
PCR products that had been amplified were then digested with Ddel and the number
of bands produced were recorded, as shown in table 4.3. The number of bands
produced for each mouse helps to pinpoint the Nal locus, as the markers in that
region which are linked to Nal will have the same number of bands, as shown in
table 4.2. By using a large number of mice, the markers which are closely linked to
Nal will become apparent. Table 4.2 highlights in grey those markers which are
linked to Nal for each backcross progeny.
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Ch 4 Identification of a Novel Protein
These results map Nal at least as far up as marker D17Mit25, because 35 out of 38
recombinants are concordant with this anchor marker. In other words, each
backcross progeny used to map Nal, has produced a series of 1 or 2 bands, and all 35
of them correspond to the number of bands which have been produced for the
marker D17Mit25. This suggests that Nal is very closely linked to this anchor
marker because the probability of getting the same output of ones and twos for a
marker that Nal does not map close to is minimal. There is a possibility that Nal
maps even closer to the centromere than marker D17Mit25, because one of the mice
which was not concordant with the anchor marker was mouse PB050. The linkage
seen for this mouse would place Nal up as far as marker D17Mit97, and the limited
data available for this marker still agrees with the output produced for Nal. The
other two markers which were not concordant with the anchor marker D17Mit25,
were mice LS583 and LS-F780. However, because both of these mice have no data
for markers just above D17Mit25 (table 4.2, highlighted in dark grey), it could be
that another recombination event could have occurred in these mice and this would
place Nal just above D17Mit25.
According to the linkage map produced for chromosome 17 on the Jackson
Laboratory mouse genome informatics web page, marker D17Mit25 is 4cM from the
centromere, and therefore Nal maps centromeric to the Brachyury (T) and within the
T-locus of the mouse.
- 102-
Ch 4 Identification of a Novel Protein
Backcross Progeny No. of Bands After Ddel
Digest
Site Mapped To
(refer to table 4.2)
LB202 1 Above Mit43
LS285 2 Above Mitl02
LS215 2 Above Mitl74
PB044 2 Above Mitl08
LS554 2 Above Mitl05
PS044 1 Above Mitl97
LS318 2 Above Mitl05
PB050 1 Above Mit97
LS226 2 Above Mit5l
LS276 2 Above Mit55
LS-F772 1 Above Mit225
PB202 1 Above Mit62
LS-F786 1 Above Mit51
LS-F787 1 Above Mitll
LS556 1 Above Mit216
LB 162 2 Above Mit80
LB-F411 1 Above Mit25
PS028 1 Above Mit68
PB191 1 Above Mitl08
PB186 1 Above Mitl08
PS031 1 Above Mit68
LS181 2 Above Mitl06
LS586 1 Above Mit225
PB041 2 Above Mit51
LS700 1 Above Mit225
LB237 2 Above Mit51
LS695 2 Above Mit85
LS690 1 Above Mit25
LB252 1 Above Mitl02
LB354 2 Above Mit46
LB356 1 Above Mit22
LSI 74 1 Above Mit68
LB201 2 Above Mitl25
LS-F771 2 Above Mitl67
LS583 2 Below Mit21
LS-F777 1 Above Mit21
LS-F780 1 Below Mit60
PS049 2 Above Mit51
Control CB57BL/6 1 -
Control Ts/BL 2 -
Table 4.3: Mapping results for Nal using EUCIB mice.
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4.7 Conclusions
NAL which binds to WT1 in the yeast two hybrid system, has been shown to be a
novel protein which has not been characterised before. The database searches
showed that NAL matched an EST, D14661, but only across the first 445 bases,
after which there was a breakpoint where all homology was lost. This was intriguing
and suggested that maybe one of the two originated from a chimaeric clone. It was
important to determine whether NAL was expressed in vivo by carrying out RT-PCR
experiments. The results showed that NAL was not chimaeric and pointed towards
the EST in the database being composed of two non-related cDNAs. However
further analysis suggests that perhaps the EST is an alternative transcript, although
Northern blots would have to be carried out to confirm this. The Northern blots
would also help determine whether the transcripts are tissue specific.
A mouse homologue of NAL was isolated from a library screen and shown to be
94% identical at the DNA level, and 96% identical at the protein level, to human
NAL. This sequence conservation suggests that the structure of the protein must be
very important for function as there is very little variation. No other homologues
have been identified in the database, not even the fungi or invertebrate database,
suggesting that NAL is only found in vertebrates. The only known motif that is
present in the protein is a stretch of polyglutamines. This motif is often associated
with transcription factors, and so further work could be done to assess whether NAL
plays a role in transcription.
Mapping studies using FISH on mouse chromosomes as well as segregation analysis
in the EUCTB resource, have mapped mouse Nal to chromosome 17, around 4cM
from the centromere. This region of chromosome 17 is home to the T-locus (Bennett,
1975). The T-locus in the mouse is a region of chromosome identified by sets of
dominant and recessive mutations, some of which have profound effects on
embryonal development, sperm production and function and genetic recombination
in a large region of their chromosome. The origin of the T-locus region began with
the detection of the dominant mutation, Brachyury (T), which produces short tails in
heterozygous mice but is lethal in homozygotes. Recessive mutations produce
normal tailed heterozygotes, and they interact with dominant T-alleles to form a
tailless phenotype. Recessive t-alleles of independent origin can complement each
other as they represent different mutations. Different t-alleles produce different
embryonic abnormalities when they are homozygous, and examples include fused
which influences tail length; quaking which is a neurological disorder; and tfwhich
causes hair loss. This suggests that this region of chromosome 17 has several genes
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which are essential for normal development. It is not really known how much of
chromosome 17 the T-locus occupies, but it probably spreads for about 16cM. No t-
alleles have been isolated so close to the centromere where Nal maps and so it is not
known therefore whether Nal is part of this T-locus and whether it is one of the
genes essential for development.
The human NAL gene has been mapped to chromosome 6q26-27 by FISH on human
chromosomes. This region of the human chromosome 6 shows conserved synteny
with the centromeric region of the mouse chromosome 17. Interestingly 6q26-27,
has been associated with several malignancies and therefore it is thought that a
tumour suppressor gene may lie in the region. These malignancies include renal cell
carcinoma (Morita et al., 1991); ovarian cancer (Cooke et ah, 1996); and acute
lymphoblastic leukaemia (Menasce et ah, 1994). It is interesting to note that
mutations in WT1 have been found associated with some of these diseases too, as
explained in section 1.8. It could be envisaged that if WT1 and NAL do interact,
then mutations in both genes could lead to multistep carcinogenesis. However, it
has not been shown that NAL is the gene in 6q which predisposes to any of these
malignancies. It would be of interest to get some tumour tissue to see if the structure





Ch 5 Binding Studies
Chapter 5: Binding Studies
The yeast two hybrid system identified NAL, a novel protein, as potentially binding
to WT1, as discussed in chapter 3. Although within the Y2H system the interaction
between the two proteins appeared real and specific, other binding assays had to be
carried out to confirm that the interaction is physiologically relevant. This is
because, despite the yeast two hybrid system being a powerful tool used to identify
protein-protein interactions, both proteins are overexpressed in the yeast and
therefore there is a possibility that they will be forced to interact, where under
normal circumstances they might not.
5.1 In Vitro Binding Assays
In vitro binding assays are a good way to determine whether two proteins interact.
Although these assays use excess protein and therefore, like the yeast two hybrid
system, do not provide evidence that the two proteins will interact at their
endogenous levels, they do provide an alternative system to test the interaction.
Thus if the interaction between NAL and WT1 still occurs in these in vitro assays,
then it will indicate that the two proteins can bind to each other in systems other
than the Y2H.
5.1.1 Problems Using Bacterially Expressed pET6HWTl
To test whether NAL can bind to WT1 in vitro, bacterially expressed WT1 and in
vitro translated NAL were to be used. The idea was to clone WT1 into the pET6H
expression vector, which would fuse 6 histidine residues to the N-terminus of WT1.
The 6 histidine residues would allow the bacterially expressed 6H-WT1 protein to
be purified over a nickel-chelate affinity resin. An in vitro transcription/translation
kit (Promega, section 2.6.1) would be used to express [3:>S]NAL. This labelled
protein would then be mixed with 6H-WT1 before running over the nickel column.
The 6H-WT1 would be purified from the mixture, and if NAL binds to WT1 it
should be co-purified, and not be removed during the washing steps. The presence
of any bound [ S]NAL would then be detected using fluorography (see section
2.6.8).
To express 6H-WT1, the WT1 was cloned into the pET6H vector (this had
previously been carried out by Dr. Davies) which contains the 6 histidine residues
just after the translation initiation site. The vector can then be transformed into
bacteria and the expression of 6H-WT1 induced by the addition of IPTG, as
discussed in section 2.6.2.
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Time Course Studies
To express the 6H-WT1 protein in bacteria, the expression vector had to be induced
with IPTG. The time of induction had to be optimised for the best expression levels
of the protein. For this time course experiment, the vector was transformed into
bacteria which were left to grow at 30°C to an OD60o of 0.7. Then before ImM
IPTG was added, a sample of bacteria was taken, and this was to be time point 0.
The bacteria were then induced and samples taken at time points corresponding to
30 minutes; 1 hour; 2 hours; and 3 hours (see materials and methods). The bacterial
samples at the different time points were then resolved on a 10% SDS -PAGE to see
if there was any expression of 6H-WT1 - see figure 5.1.
Figure 5.1: Induction time course for pET6H-WTl.
The 10% SDS PAGE shows that high levels of 6H-
WT1 are induced after 2-3 hours.
The gel showed that expression of WT1 had occurred after induction with IPTG, as
compared to the pre-induced sample. Higher levels of expression were seen 2 and 3
hours after the start of induction. The 1 hour sample did express 6H-WT1 but to a
lower level. Thus for the rest of the experiments, the induction time ranged between
2-3 hours.
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6H-WT1 is insoluble in bacteria
The 6H-WT1 protein expressed in bacteria had to be soluble so that it could be
purified and used in the in vitro studies. Thus after the induction, the bacterial
cultures were lysed as discussed in section 2.6.2 and soluble proteins separated from
insoluble ones by centrifugation. Samples at each stage of the procedure were
resolved on 10% SDS PAGE. All four isoforms of WT1 had been expressed in







Markers 0 Hr 3 Hrs Soluble Pellet 0 Hr 3 Hrs Soluble Pellet
V
Y v '
6H-WT1 +/+ 6H-WT1 +/-
Figure 5.2: 6H-WT1 is insoluble. The 10% SDS-PAGE was run from
samples taken for 6H-WT1 +/+ and +/- expressed in bacteria. The 0 hr
and 3 hrs samples represent the time points after induction with IPTG,
and are whole bacterial lysates. After 3 hours of induction the bacteria
were lysed and both the soluble and insoluble fractions were run on the
gel. As can be seen for both 6H-WT1+/+ and +/- the protein was
expressed after 3 hours, but was found in the pellet fraction as it was
insoluble.
The gel in figure 5.2, which only presents the data for WT1+/+ and +/- isoforms,
shows that unfortunately the 6H-WT1 is predominantly insoluble as most of the
protein is found in the pellet fraction and not into the soluble fraction. Rauscher et
al. had also had problems when they tried to use 6H-zinc fingers of WT1, as they
- 110-
Ch 5 Binding Studies
were not soluble and so had to be re-suspended in 6M guanidine-HCl (Rauscher et
al., 1990). Although potentially the 6H-WT1 protein could be solubilized in this
way, it was decided against as the binding properties may be altered following the
denaturation/renaturation procedure. Instead, in an attempt to solubilise the protein,
the induction temperature was lowered to 25°C, as the different conditions can
sometimes help with solubility. Unfortunately at this temperature the protein was
not expressed. It was therefore decided to use the glutathione S-transferase (GST)
expression system in the hope that in this way WT1 may be more soluble.
5.1.2 Problems Using Bacterially Expressed GST-WT1 Zinc Fingers
The pGEX glutathione S-transferase (GST) fusion protein system can be used to
express and purify high levels of fusion proteins from bacteria. The 26kDa GST
enzyme binds reversibly and with high affinity to glutathione-containing affinity
matrices. Thus the soluble fraction of bacterial lysates, containing the GST fusion
protein, can be incubated with glutathione agarose beads and the fusion protein
purified away from other bacterial proteins. The fusion protein can then be eluted
from the beads by using glutathione elution buffer.
As seen from the previous experiment, 6H-WT1 is fairly insoluble. Therefore rather
than use full length WT1, only the zinc fingers were to be used as these had been
soluble in the past (Bickmore et al., 1992). It was also known that NAL bound to
the zinc finger of WT1 (section 3.5.2) and so the in vitro binding studies could be
performed with just the zinc fingers of WT1.
Section 2.6.3 describes the expression of the GST-WT1 zinc fingers in bacteria. An
induction time course was performed, as was done for 6H-WT1, but this time the
induction was carried out at 25°C, and it was found that again a good induction
period ranged between 2-3 hours. After a 3 hour induction, the bacterial cultures
were lysed as described in section 2.6.4. Both the soluble and pellet fractions were
run on a 10% SDS PAGE to analyse whether the protein was soluble.
The gel in figure 5.3 shows that unfortunately GST-WT1 zinc fingers were insoluble,
as the protein was found in the pellet fraction. There may have been a small amount
of the protein in the soluble fraction, which had less sample loaded onto the gel
compared to the other samples, but in comparison to the amount of protein required
for the binding assays, it was not nearly enough. The induction time and
temperature were altered to try and get more soluble GST-zinc fingers but the fusion
protein remained insoluble. Different host bacterial strains were also used, but the
protein was still insoluble. At this stage it was decided that rather than persevere
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with trying to solubilise WT1, it was best to switch the experiment round so that









Markers 0 Hr 3 Hrs Soluble Pellet
Figure 5.3: Bacterial expression of GST- WT1 Zinc Fingers.
The 10% SDS-PAGE shows that the GST-WT1 zinc fingers
(-KTS) were expressed after 3 hours of induction. However,
unfortunately the fusion protein is predominantly insoluble as it
is found in the pellet fraction.
5.1.3 Using Bacterially Expressed GST-NAL
NAL first had to be cloned into the pGEX-5X-l vector. To do this NAL was
digested out from the pGadlO-NAL vector, which had been used in the Y2H system,
as an EcoRI fragment and cloned straight into the pGEX vector.
The GEX-NAL vector was then transformed into bacteria, expression induced and
bacterial cultures lysed as for the GST-zinc fingers. An SDS-PAGE was run to see if
GST-NAL was soluble. This time it could be seen that there was a large amount of
GST-NAL protein which was soluble despite some of the protein still being present
in the pellet fraction, as is shown in figure 5.4. Nevertheless there was sufficient
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Figure 5.4: GST-NAL is partially soluble. The 10% SDS-PAGE
shows that the GST-NAL fusion protein was induced after 3 hours. The
soluble fraction does contain GST-NAL, even though it is not all soluble
as the pellet fraction still contains some of the fusion protein. However
the soluble fraction contains enough of the protein and, as the last lane of
the gel shows, the GST-NAL fusion protein could be purified.
Binding Assays Under Low Salt Conditions
The GST-NAL could now be used in the in vitro binding assays together with in
vitro translated WT1. In these binding assays, GST-NAL and in vitro translated
[35S]WT1 are allowed to mix under low stringency conditions, by using a low salt
concentration of lOOmM. The mixture is then run through glutathione agarose
beads, from which GST-NAL is purified. If WT1 binds to NAL then it should be co-
purified, rather than being removed during the washing steps. To detect the
presence of WT1, the purified complex is run on an SDS PAGE to resolve the two
proteins, and WT1 can then be detected by fluorography as it is radioactively
labelled. For these binding assays, a control has to be run to ensure that WT1 is
binding to NAL and not to the GST moiety or the beads. Therefore a parallel
experiment is carried in exactly the same manner, except that this time instead of
using GST-NAL, the GST protein on its own is mixed with [35S]WT1. In this
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negative control, no WT1 should be detected on the fluorograph unless WT1 is being
purified non-specifically.
[3r,S] WT1 was prepared as described in section 2.6.1 and it was allowed to mix
either with GST-NAL or GST on its own, both of which had previously been bound
to glutathione beads, under low stringency conditions as described in section 2.6.6.
After several washing steps, the GST and GST-NAL were eluted from the beads. The
eluates were then run on an SDS PAGE and the presence of WT1 detected by
fluorography.
The fluorograph produced (figure 5.5) shows that both in vitro translated WT1+/+
and WT1-/- could bind to GST-NAL but not to GST alone. This demonstrates that
in vitro NAL and WT1 can bind together, albeit under low stringency conditions.
This result therefore shows that NAL and WT1 can associate in a system other than
the Y2H, providing further evidence that the interaction is likely to be real.
Binding Assays Under Higher Salt Concentration
To show that the interaction between NAL and WT1 can occur under higher
stringency conditions, the salt concentration was increased from lOOmM to 250mM.
These higher stringency experiments would also include all four WT1 isoforms and
deletion constructs described in section 3.4.4 to test the specificity of the interaction
between NAL and the C-terminus of WT1 and to test whether NAL could bind to all
four isoforms of WT1. As the fluorographs show, all four isoforms of WT1 can bind
to NAL under these higher salt concentrations (figure 5.6, panels A and B),
suggesting that the interaction between WT1 and NAL is reasonably strong.
However these assays proved insufficiently sensitive to detect any subtle differences
in NAL binding affinity between the WT1 isoforms, even when the salt
concentration was increased to 500mM (data not shown).
This in vitro assay was able to show that NAL can bind to the deletion constructs
Nco3'+KTS and -KTS but cannot bind to the deletion construct Nco5'as shown in
figure 5.6, panels C and D. The interaction between WT1 and NAL is shown to be
specific as NAL hardly binds to EGR1, another zinc finger protein (figure 5.6, panel
D).
The results obtained in these in vitro assays were very encouraging as they provide
further evidence that NAL is a WT1-binding protein. The Y2H data and the in vitro
data both agree that NAL binds to the C-terminus of WT1, although no isoform
specific differences were apparent in the in vitro experiments.
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Figure 5.5: In vitro binding studies between WT1 and NAL.
The fluorograph in panel (A) shows in lane 1 an in vitro translation
(IVT) check to show that [35S]WT1 was made. The band in the last
lane, labelled GST-NAL/WT1+/+, represents WT1+/+ which was
co-purified with the GST-NAL, indicating that WT1+/+ can bind to
NAL in vitro under low salt conditions. The middle lane, labelled
GSTAVT1+/+, indicates that there is very little residual binding of
WT1 to GST alone. Panel (B) is exactly the same as panel (A) but
this time WT1-/- was used.
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Figure 5.6: Higher stringency in vitro binding studies. The four panels
represent the results produced for the binding studies carried out under
higher salt conditions (250mM salt) between GST-NAL, as well as the
GST controls, and in vitro translated WTL Each panel represents two
experiments, each comprising of an in vitro translation check (IVT), the
binding seen with GST on its own, and the binding seen with NAL.
The WTl isoform or deletion construct used is shown under the bracket.
Panel (A) shows that WTl +/+ and WTl +/- can bind to NAL but not to
GST only, which only shows slight background bands. Panel (B) shows
that WT1-/+ and WTl-/- can also bind to NAL. Panel (C) shows that
Nco3'+KTS and Nco3'-KTS can bind to NAL, although the background
levels for GST interacting with Nco3'-KTS are also rather high. Panel
(D) shows that the Nco5' deletion construct cannot bind to NAL, as was
also shown in the yeast two hybrid system. A very slight band can be
seen for the interaction with EGR1, suggesting that perhaps NAL can
bind to EGR1, but the interaction does not seem to be as strong as that
seen for WTL
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5.2 In Vivo Assays Using HA Epitope-Tagged NAL
The in vitro data, like the yeast two hybrid data, shows that NAL can bind to WT1.
However, these assays overexpress both proteins and are not carried out under
endogenous conditions and so may not represent the in vivo situation. Therefore to
ensure that the interaction was physiologically relevant, in vivo binding assays were
carried out.
Ideally these in vivo assays would be carried out on cells that endogenously express
both proteins. However, these in vivo assays require both proteins to be detected by
antibodies, and as NAL is a novel protein there are no antibodies available against it.
To overcome this problem, NAL could be epitope tagged, transfected into WT1
expressing M15 cells, and detected by using an antibody against the epitope. Co-
immunoprecipitation experiments can then be carried out as detailed in section
2.8.8. Essentially nuclear extracts from these transfected cells are made, and WT1 is
immunoprecipitated from these extracts by incubating them with a WT1 antibody,
which itself has been crosslinked to protein A sepharose beads. WT1 is then
purified from the lysate, together with any proteins that bind to it. The WT1
complex can then be resolved on a SDS-PAGE, and an immunoblot carried out as
described in section 2.6.9. Thus to determine whether NAL binds to WT1, the
immunoblot is probed with an antibody raised against the epitope with which NAL
has been tagged. In this way it should be possible to establish whether NAL and
WT1 form a complex in vivo.
5.2.1 Epitope Tagging NAL
The epitope tag to be used was a haemagglutinin (HA) motif which the monoclonal
antibody 12CA5 can detect. A pCI-neo vector (Promega), which had three N-
terminal HA motifs engineered into it (gift from Matteo Ruggiu), was used to
epitope tag NAL. NAL was cloned into this vector as a Xbal/Sall fragment, these
sites having been added to the NAL clone by PCR using primers N842 and N845
(see appendix).
5.2.2 Testing Expression Of The HA-NAL Clone
Before the binding assay could be done, the HA-NAL clone had to be transiently
transfected into the Ml5 cell line, and preliminary studies carried out to ensure the
tagged construct could be easily transfected, expressed and detected in these cells.
HA-NAL was thus transiently transfected into the M15 cell line, as detailed in
section 2.8.6. As a control, the M15 cells were also transfected with a CMV vector
- 117 -
Ch 5 Binding Studies
which did not have the HA tag or NAL cloned into it. The cells were lysed 24 or 48
hours after transfection and equal amounts of each lysate run on an SDS PAGE. An
immunoblot was carried with the HA antibody, 12CA5, to detect the HA-NAL
clone. Figure 5.7 shows that the HA-NAL protein was detected by the 12CA5
antibody, and therefore was properly transfected, expressed and detected. The better
expression levels of the HA-NAL protein were seen 48 hours after transfection. The
HA antibody did not detect anything in the negative controls which had the CMV
vector transfected in the cells.
200 kDa








Figure 5.7: Expression studies for transiently transfected HA-NAL.
The immunoblot shows the detection of HA-NAL in transiently transfected
M15 cells. The expression levels is greater after 48 hours compared to the
expression level seen 24 hours after transfection. The negative controls,
where a CMV vector containing no HA-NAL was transfected in M15 cells,
show no detection of the HA-NAL protein.
5.2.3 Binding Assays With HA-NAL
Now that the conditions for transfecting and detecting HA-NAL were set up, the co-
immunoprecipitation assays could be carried out. The cells were transfected with
HA-NAL as before and left for 48 hours to get high levels of HA-NAL expression.
Using a (3-galactosidase vector as a control for the efficiency of the transfection (see
section 2.8.7) it was shown that the transient transfection had worked. After this
time, the cells were harvested, and nuclear extracts made, as detailed in section
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2.8.8. The nuclear extracts were then split into three, and mixed with either a WT1
antibody, H2, to carry out the binding assay; the HA antibody, 12CA5, as a positive
control; or mouse IgG, as a negative control. The immunoprecipitations were
performed, as is detailed in section 2.8.8, and resolved on an 8% SDS PAGE . An
immunoblot was then carried out with the 12CA5 antibody to detect the presence of
HA-NAL in any of the immunoprecipitates.
Figure 5.8 shows the results obtained for the binding assay. The whole cell extract
(WCE) lane had been run as a control, to demonstrate that the cells that had been
transfected with HA-NAL were indeed expressing it. This lane was also run as a
positive control to ensure the detection step of the experiment was working. The
positive control lane that contained the immunoprecipitate from the 12CA5 also
showed a band as expected. This positive control used the 12CA5 antibody to
immunoprecipitate HA-NAL from the cells, and so shows that the experimental
conditions were right for the immunoprecipitation. The lane which contained the
WT1 immunoprecipitate, and was the lane which was to show whether NAL and
WT1 interact, also had a band. Unfortunately this band probably does not represent
HA-NAL, but instead the heavy chain of some WT1 antibody which had not been
completely crosslinked to the sepharose beads prior to the start of the experiment.
The heavy chain of the antibody is of a very similar size to the HA-NAL protein and
unless it is covalently crosslinked to the sepharose beads it would run at a similar
position to HA-NAL on an SDS-PAGE. If there is any antibody which remains un-
crosslinked, then it would be recognised by the secondary antibody during the
immunoblot procedure thus producing a band which does not represent HA-NAL.
Normally any antibody which is not crosslinked is removed by the washing steps
carried out with glycine after the crosslinking procedure. However, in this particular
experiment is seems that the washes with glycine were not thorough enough as there
was still some residual antibody which had not been crosslinked.
Although the heavy chain of the antibody and HA-NAL run very close together they
could be distinguished on this 8% SDS PAGE. If the HA-NAL band produced in
the WCE lane is compared to the one in the WT1 lane, it can be seen to resolve at a
different molecular weight. The 12CA5 lane shows this difference more clearly
because it has both bands present. It has the higher band, running at the same level
as the band in the WCE and representing HA-NAL, and it has the lower band
running at the same level as that in the WT1 track and representing the heavy chain
of the antibody. The negative control IgG also has slight band, and again this would
represent the heavy chain of the antibody and not HA-NAL, and this runs at the
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same level as the WT1 immunoprecipitate band. Thus this experiment did not show
that WT1 and HA-NAL interacted.
The experiment was repeated, but again there was no HA-NAL band seen in the
WT1 immunoprecipitate. However, it may not be too surprising that the experiment
cannot detect WT1 immunoprecipitating HA-NAL. Apart from the fact that perhaps
the interaction between NAL and WT1 could be transitory, this experiment was
carried out following transient transfections. Therefore not all cells would have the
HA-NAL protein, and for those cells that do, perhaps not all of the HA-NAL would
be involved in binding to WT1, and so the levels of HA-NAL protein to be detected
in the WT1 immunoprecipitate could be fairly low.





Figure 5.8: Co-immunoprecipitations of transiently
transfected HA-NAL. The immunoblot was blotted with
12CA5, an antibody which would recognise HA-NAL which
had been transiently transfected into Ml5 cells. The whole
cell extract (WCE) lane shows the expression of HA-NAL in
the transfected M15 cells. The 12CA5 lane shows that the
immunoprecipitation conditions were correct as this antibody
did immunoprecipitate NAL. The H2 lane shows the
immunoprecipitation carried with the H2 antibody directed
against WT1. If NAL and WT1 interacted, there should be a
band representing NAL, as NAL would have been part of the
WT1-complex. Although there is a band present in the lane,
it is likely to be a non-specific band due to the detection of
the heavy chain of uncrosslinked antibody. This band can be
seen in the negative control, IgG, and also it is the lower band
in the 12CA5 track. (M=markers)
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As it was hard to detect an interaction between the two proteins in these transient
transfection experiments, it seemed logical to try to detect the association in cells
that endogenously express both proteins. An antibody to NAL would therefore have
to be made, which in the long run would prove beneficial as it could not only be
used for these in vivo experiments, but would also provide a resource for future
experiments.
5.3 Producing A Polyclonal Antibody Against NAL
5.3.1 Production Of Antibody
An antibody against NAL was required, and it was decided to raise polyclonal
antisera in rabbits. The rabbits were to be injected with the NAL protein such that
the immune response would produce antibodies which recognise NAL. Originally
NAL was to be made by bacterially expressing the GST-NAL clone as described in
section 5.1.3. Then the GST-NAL fusion protein was to be cleaved to remove the
GST portion, and this was to be done by taking advantage of the thrombin cleavage
site found after the GST moiety. However, only a low yield of NAL was recovered
after thrombin cleavage (data not shown) and so it was decided to inject GST-NAL
into the rabbits instead. The immunisation of rabbits and the isolation of the serum
was carried out by the Scottish Antibody Production Unit (SAPU) as detailed in
section 2.7.1. The rabbit antiserum was then affinity purified to get a good quality
antibody to NAL as described in section 2.7.2.
5.3.2 Testing The NAL Antibody
The affinity purified NAL antibody, called 474, had to be tested to ensure it
recognised NAL, and to determine the concentration it should be used at for
subsequent experiments. Ml5 cells were again transiently transfected with HA-NAL
and after 48 hours of expression, the cell lysate was run on an 8% SDS PAGE. Cell
lysates from untransfected M15 cells were also run, as they express endogenous
NAL.
Three immunoblots, each containing cell extracts of both transfected and
untransfected M15 cells, were probed with different dilutions of the 474 antibody
against NAL. As shown in figure 5.9, the 474 antibody can recognise NAL in both
its endogenous form and as HA-NAL. The band produced for untransfected M15
cells is very clean with no other background. This probably reflects the purity of
GST-NAL initially injected into the rabbits, leading to a very specific immune
response The transfected M15 cells produced a slightly larger sized band than for
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untransfected cells because the transfected cells had the HA epitope tagged onto
NAL. The other bands appearing in the track are probably breakdown products of
the excess HA-NAL. As seen from the dilution assays done, the best concentration
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(1): M15 cells transfected with HA-NAL
(2): Non-transfected M15 cells
Figure 5.9: Immunoblot showing that the NAL antibody can
detect both endogenous and transfected NAL in M15 cells. 3
immunoblots, each containing whole cell extracts from either M15
cells transfected with HA-NAL, lane (1), or non-transfected M15
cells, lane (2), were probed with the NAL antibody 474 used at
different dilutions. All 3 blots could detect the endogenous and the
transfected NAL but the best dilution to use the antibody for
detection on immunoblots is between 1/500 to 1/200.
The 474 antibody recognises endogenous NAL which is resolved at a molecular
weight of about 55kDa, as shown in figure 5.9. This molecular weight is the same
as that produced when the protein is made in vitro from the NAL clone that was
isolated from the yeast two hybrid. This can be seen in figure 5.9, where the HA-
NAL fusion protein, which is only just larger than the NAL clone due to the HA tag,
runs slightly higher than the endogenous NAL protein in M15 cells. This therefore
indicates that the NAL clone isolated is very nearly full length, as discussed in
section 4.5.
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5.4 In Vivo Binding Assays using Endogenously Expressed NAL
Now that there was an antibody that recognised endogenous NAL, the in vivo
experiments that would assess whether NAL binds to WT1 under physiologically
relevant conditions, and not just in yeast or in vitro, could be done. Co-
immunoprecipitations were carried out on M15 cells essentially as detailed in
section 5.2.3. This time no transient transfections were carried out, and the
antibodies used to carry out the immunoprecipitations were 474 to test whether this
antibody could immunoprecipitate NAL, and if it could it would act as a positive
control; IgG as a negative control; and WT1 to assess whether binding between NAL
and WT1 was occurring.
WCE M 474 IgG H2
69 kDa
46 kDa
Figure 5.10: WT1 co-immunoprecipitates NAL. The
immunoblot was probed with the NAL antibody 474. The whole
cell extract (WCE) lane shows that the expression of NAL can be
detected by 474. The 474 track represents an immunoprecipitation
carried out with 474, and the band seen is the immunoprecipitated
NAL. Thus the positive control showed that the
immunoprecipitation reactions were working. The IgG track
represents an immunoprecipitation carried out with the non
specific mouse IgG antibody which served as a negative control.
Finally the H2 track represents an immunoprecipitation carried out
with the anti-WTl antibody H2. The band present in this track is
NAL, which means that it was co-precipitated with WT1 and so the
two proteins must interact.
Figure 5.10 shows that now an association between NAL and WT1 could be
detected. The immunoblot was carried out with 474 antibody, to detect NAL. The
lane containing the whole cell extract (WCE) shows that the endogenous NAL could
be detected. The immunoprecipitation carried out with 474 also shows a band for
NAL, which demonstrates that the antibody can not only be used for immunoblots,
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but also for immunoprecipitations. The immunoprecipitation with 474 also acts as a
positive control showing that the conditions for the immunoprecipitations were
good. The track which immunoprecipitated WT1 with the H2 antibody also shows a
band representing NAL, whereas the negative control, IgG, doesn't. This shows that
WT1 and NAL must have interacted for it to be present in the WT1
immunoprecipitate track. An identical blot (not shown) had also been probed with
the secondary antibody only, without having first blotted with 474, to ensure that the
bands produced were not non-specific. This blot did not produce any signal at all,
showing that the bands seen in figure 5.10 were representing NAL. This in vivo
experiment therefore shows that WT1 and NAL can interact under physiologically
relevant conditions. Unfortunately there are no antibodies that reliably distinguish
between the different WT1 isoforms, and therefore this in vivo experiment cannot be
used to determine whether NAL binds preferentially to any of the four isoforms.
5.5 Conclusion
NAL had been shown to bind to WT1 in the yeast two hybrid system and this
interaction had to be confirmed by using both in vitro and in vivo assays. This
chapter has shown, after overcoming several problems due to the insolubility of
WT1, that in an in vitro situation, NAL can bind to WT1 in conditions ranging from
low to high stringency, suggesting that the interaction between the two proteins must
be fairly strong. The in vitro data agreed with the results produced in the yeast two
hybrid system, in that exons 1 and 2 of WT1 are not needed for the interaction
between NAL and WT1 to occur, as the deletion construct Nco5' did not bind to
NAL, whereas the deletion constructs of Nco3' did. The in vitro experiments did not
show any apparent difference in binding affinities between the different WT1
isoforms.
The interactions found in the yeast two hybrid system and in vitro may not reflect
what is going on at the cellular level because the two proteins are overexpressed in
these assays. The binding assays therefore had to be carried out in vivo, to ensure
that the interaction was occurring at the cellular level. Initially these experiments
could not be carried out using endogenous NAL because there were no antibodies
available to detect this protein. For this reason transient transfections of HA
epitope-tagged NAL had to be carried out. Antibodies to the HA tag were then used
to assess whether HA-NAL was found in WT1 complexes. Unfortunately the
experiment did not show any HA-NAL present in WT1 complexes. This was
probably because under transient transfection conditions, relatively few cells would
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be expressing the HA-NAL and so even if HA-NAL was found in WT1 complexes in
these cells, the levels may have been below detection.
Since the transient transfections were not adequate, an antibody to NAL had to be
produced to ensure that the in vivo assays, with endogenous NAL, could be carried
out. A polyclonal antibody was produced, 474, and it proved to be very specific to
NAL, giving very clean Western blots. The antibody made was also able to
immunoprecipitate NAL. This antibody was therefore used for the in vivo
experiments, which now showed that endogenous NAL could be found in complexes
co-immunoprecipitated with WT1. These experiments all show that WT1 can bind
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Chapter 6: Expression and Cellular Localisation Studies
NAL was isolated due to its ability to bind to WT1 in the yeast two hybrid system.
The association between the two proteins was also shown to occur in vivo and thus it
was important to find out more about the novel protein to understand its role at the
molecular level and why it was binding to WT1. At this stage not much was known
about NAL as its protein sequence provided no clues towards its possible function
due to a lack of known motifs within it. The mouse homologue of NAL was isolated,
and it was seen that the sequence was highly conserved between mouse and human,
suggesting that the structure of the protein is likely to be important for function. As
discussed in chapter 4, mapping studies on both human and mouse NAL were
carried out and it was found that the human NAL mapped to human chromosome
6q26-27, and the mouse Nal mapped to chromosome 17, very close to the
centromere. Although the data are interesting, especially as the human NAL could
be mapping to a site where there is thought to be a tumour suppressor gene, it does
not provide any clues as to its possible function and why it binds to WT1. Studies
were therefore carried out to try to further characterise this novel protein, and these
included expression studies to determine whether the gene is expressed only in
certain tissues, as WT1 is, or whether it is ubiquitously expressed and therefore
perhaps carries out a housekeeping function in every cell. Localisation studies
within the cell were also carried out to determine whether the protein is nuclear or
cytoplasmic and from this knowledge, further experiments could then be devised to
start to decipher its role.
6.1 Determining the expression pattern using RT-PCR
RT-PCR was used to determine which tissues expressed NAL. The experiment was
carried out on RNA that had been isolated from tissues of an adult female mouse as
is discussed in section 2.4.2. The primer pair used to carry out the amplification
were primers L342, starting at base 416 of NAL, and M718 starting at base 1113-
the primer sequences used can be found in the appendix.
Figure 6.1 shows that NAL is expressed in all tissues that were studied and these
included: brain; thymus; heart; lung; liver; spleen; kidney; and muscle. The results
show that the main RT-PCR product was about 700 bases as expected but some
tissues have other smaller bands present too. These bands could represent
alternative transcripts, which vary between different tissues as the lung and the
thymus both have a band at about 550 bases, and although very faint, traces of the
same band appear in the brain, spleen and kidney samples whereas the heart and
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possibly the lung on the other hand, seem to have a product in the 300 base range.
The idea that there could be alternative transcripts of NAL was already discussed in
section 4.2, as an EST was found in the database which seems to be an alternative
transcript of NAL. Whether these other bands really represent alternative transcripts
is not known as the products could have been derived non-specifically, or they may
also represent transcripts from a closely related gene. As an approach to obtain more
specific PCR products, nested PCR could have been carried out. Alternatively, to
determine unequivocally whether the smaller amplified PCR products are alternative
transcripts of NAL, the amplified bands should have been cloned and sequenced.
Figure 6.1: Expression studies for NAL using RT-PCR. Tissues from an adult
mouse were used to test the expression pattern of NAL. The figure shows the
products amplified using primers L342 and M718. The expected 700 base
product is amplified in all tissues and not in the negative controls. The RT control
lane is a negative control, where RNA from the kidney had been used but no
reverse transcriptase had been added so that no cDNA could have been produced.
This control therefore shows that the PCR products are not being amplified from
contaminating genomic DNA. Apart from the main 700bp band, other smaller
bands, possibly representing alternative transcripts can be seen for the thymus and
lung (550 bp) as well as for the heart (300 bp). The nature of these smaller
products was not looked at and so they could equally be non-specific bands which
are being amplified.
These RT-PCR experiments show that NAL is expressed in a wide range of tissues
of the adult mouse. This is unlike WT1, which in the adult seems to be expressed
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al., 1993; Buckler et al., 1991). NAL is therefore not tissue specific and so its
expression is not confined to organs which express WT1. This suggests that NAL
and WT1 could be interacting in organs where both proteins are expressed but
because NAL is also expressed in organs where WT1 is not found, it is likely to also
function independently of WT1.
6.2 Immunofluorescence on sections through the kidney and testes
The RT-PCR experiment shows that NAL is expressed in the adult kidney. It was of
interest to examine whether NAL is also expressed in the developing kidney and if
so whether, like WT1, it is confined to the developing nephros - in other words, is
NAL localising within the kidney just to areas where it can interact with WT1? To
examine this, kidneys from mice at E=17.5d were used, as at this age the kidney has
reached a stage in development where all the structures leading to the formation of a
nephron can be seen. Section 1.7.1 described the expression pattern of WT1 within
the developing kidney, and the structures expressing WT1 are depicted in figure 1.2 .
Immunohistochemistry was performed on cryosections of kidneys at E=17.5d (as
detailed in section 2.9.2). The kidney sections were stained for WT1, using antibody
H2, and for NAL, using antibody 474 (see chapter 5 for details of this antibody).
Figure 6.2, panels (A) and (B), shows the expression seen for NAL and WT1 in
sections through the kidney. The expression pattern obtained for WT1 was as
expected, as the WT1 expression was seen in the condensing mesenchyme on the
outer most layer of the section, which is at an early developmental stage compared to
the inner layers of the kidney. As the glomerulus develops further, the expression of
WT1 can be seen in the Comma shaped bodies, followed by the S-shaped bodies and
finally being confined to the podocytes of the glomerulus (see figure 6.2 C). In
contrast to the confined expression pattern of WT1, NAL is shown to be expressed
throughout the whole kidney, including those areas where WT1 is expressed (seen as
a yellow output in the merged panel in figure 6.2 A and B). The expression of NAL
is therefore not confined to the structures within the kidney that express WT1.
The expression of NAL was also looked at in the testes as shown in figure 6.2 D.
The testes were dissected out from the E=17.5d mice and immunohistochemistry
was performed using the same antibodies as were used for the kidneys. The
expression pattern for WT1 was again as expected, with WT1 being expressed
mainly in the Sertoli cells, and not in the germ cells. The expression of NAL again
is ubiquitous within the testes. The expression overlapped with WT1 within the
Sertoli cells, but NAL was also expressed in the germ cells and throughout the rest of
the testes.
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These immunofluorescence studies therefore show that NAL is expressed within the
kidney and testes, but rather than having a restricted expression pattern within the
developing nephron and Sertoli cells like WT1, NAL is expressed throughout the









Figure 6.2: Immunofluorescence on sections through the kidney and testis. Panels
(A) and (B) show sections through the kidney at lower and higher magnification
respectively. The immunofluorescence produced using antibodies against WTl
(antibody H2: red output) and NAL (antibody 474; green output) is shown, as is their
merged output to see where they co-localise. Panel (C) highlights those areas within the
developing nephros where WTl is expressed, as is described in figure 1.2. Panel (D)
shows the expression pattern of WTl and NAL, together with their merged output,
within a section through the testis.
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6.3.1 Whole mount in situ hybridisation
The RT-PCR experiments provided some idea as to the type of tissues where NAL is
expressed, but for a more detailed study of both temporal and spatial expression,
whole mount in situ hybridisation experiments were carried out. Whole mount in
situ hybridisation is a technique used to detect the presence of the RNA of the gene
of interest in the context of whole embryos. It uses an antisense RNA probe, which
in this case was transcribed from the mouse Nal clone isolated (see section 4.4), that
is labelled with digoxigenin (DIG) as described in section 2.4.3. The embryos are
then hybridised with this antisense Nal probe, as discussed fully in section 2.5.1.
The antisense Nal probe will hybridise with endogenous Nal RNA wherever it is
expressed. Any probe which has not hybridised with endogenous Nal RNA, will be
washed away in the subsequent steps of the protocol. The hybridised probe can be
detected by enzyme-linked immunoassays using an anti-digoxigenin alkaline
phosphatase conjugate (anti-DIG-AP). A subsequent enzyme-catalysed colour
reaction with 5-bromo-4-chloro-3-indolyl-phosphate (BCIP) and nitroblue
tetrazolium salt (NBT) produces an insoluble blue precipitate, thus enabling
detection of the hybrid molecules. As a control, this experiment can be carried out
with a sense RNA Nal probe. This sense probe cannot hybridise to the endogenous
Nal RNA in the embryo, and so is removed during the washing steps. Thus any non
specific signal detected will also show up on this negative control.
Mouse embryos between embryonic ages E= 9.5d-12.5d were used for these studies,
and both sense and antisense Nal RNA probes were used for all ages except the
E— 11,5d where only the antisense probe was used. The results produced are shown
in figure 6.3, in which a whole mount in situ for an antisense WT1 probe at E=9d is
also shown (taken from Jacob Hecksher-Sprensen and Adrian Moore). Although
only one embryo for each of the probes is shown at each stage, a total of 3 embryos
were stained for each probe used at the different embryonal stages to ensure that the
signal obtained was real. What is immediately obvious from these results is that Nal
seems to be expressed throughout the embryo at all the ages tested. As the sense
control was used, it can be seen that the expression observed for Nal is real and is
not just background staining of the embryo (apart from a few areas in the E=10.5d
embryo where there is a little 'trapping' of the probe in the brain and neck). Apart
from being ubiquitously expressed, there are a few other areas where the expression
levels seem to be slightly higher, as is the case for the limbs; at the tip of the tail end;
and in the E=9.5d in the nasal process and mandibular component of the first
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branchial arch, which in the older embryos the tissues derived from these
components also have a higher expression level.
Antisense Sense Control Antisense
WT1 at E=9d Nal atE=9.5d
Sense Control Antisense
Nal at E=10.5d
Antisense Antisense Sense Control
Nal at E=11.5d Nal at E=12.5d
Figure 6.3: Whole Mount In Situ Hybridisation. These whole mount
in situ hybridisations show the RNA expression pattern of WT1 and
NAL. The WT1 expression is only shown for E=9d (taken from Moore et
al 1998). Embryonic ages between 9.5d-12.5d were used to see if there is
any variation in the expression pattern at the different developmental
stages.
- 133-
Ch 6 Expression and Cellular Localisation Studies
Although these areas could simply be sites to which the probe has easier access and
therefore produce a stronger signal, they could be genuine sites of higher NAL
expression. The reason for this possible elevated expression of NAL is not known,
but perhaps these regions of the embryo are undergoing a lot of cellular
proliferation, although this has not been demonstrated, and thus a possible link
between cellular proliferation and NAL could be studied in the future.
6.3.2 In situ hybridisation on sections
The whole mount in situ hybridisation of WT1 shows that the RNA is found mainly
in the mesonephric ridge (figure 6.3). It is hard to tell whether Nal shows a stronger
expression at the mesonephric ridge compared to the expression levels for the rest of
the embryo. In situ hybridisation studies were thus performed on cryosections
through embryos, so that the expression pattern on cross-sections of embryos could
be carried out and the levels of expression on the mesonephric ridge determined. By
carrying out the hybridisation on sections means that there will be no problem of
accessibility to the probe and so it will be easier to determine whether Nal
expression is elevated in particular areas.
Embryos of E=10.5d were dissected out and immediately fixed, then mounted in
agarose blocks and frozen. The embryos were sectioned (10pm thickness) using a
cryostat machine and the hybridisation was carried out by Liz Graham, as explained
fully in section 2.5.2. Unfortunately this experiment was only carried out once due
to lack of time, and thus the conditions had not been optimised. Nevertheless, the
preliminary results obtained are shown in figure 6.4. Sections close to the tail-end of
the embryo are shown for the three probes: Wtl antisense; Nal antisense; and Nal
sense. The Wtl section shows that Wtl expression is confined to the urogenital ridge
and mesothelium. The Nal antisense section shows that the Nal expression pattern
is very different to that seen for Wtl, as Nal is found to be ubiquitously expressed.
There appears to be no increased expression in the urogenital ridge compared to the
expression seen for the rest of the section, and thus it seems that Nal expression is
not upregulated in areas which express Wtl. On these sections there does not appear
to be any stronger expression of Nal in the limbs and so this suggests that the
stronger expression levels in the limbs and in the posterior end of the tail seen in the
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6.4 NAL is a nuclear protein
The cellular localisation of NAL was looked at to determine in which compartments
NAL was mainly present. It was important to know whether at least some of the
protein was nuclear, as if it is to interact with WT1, then both proteins should be in
the same cellular localisation. Immunocytochemistry was thus carried out on M15
cells, as these cells express both NAL and WT1 - which was required for direct
comparisons between the endogenous localisation of WT1 and NAL. Figure 6.5
(panel A) shows that NAL, like WT1, is a totally nuclear protein. This was an
encouraging finding as it shows that WT1 and NAL are present in the same cellular
localisation and thus are able to interact.
6.5 NAL co-localises with splicing factors
Closer inspection of the immunofluorescence signal produced for NAL in figure 6.5
A, shows that the pattern within the nucleus appears to be speckled together with an
overall diffuse stain which excludes the nucleolus. This was the pattern also seen for
WT1 and which had previously been described by Larsson et al. (1995). They then
went on to show that the speckle structures in which WT1 was found corresponded
to sites which co-localised with splicing factors. It was therefore of interest to
determine whether the speckles in which NAL are found in are the same as those
speckles seen when the nucleus is stained for splicing factors, and thus
immunocytochemistry was carried out on Ml5 cells with the monoclonal antibody
3C5. This antibody detects proteins in interchromatin granule clusters (IGCs), the
structures in which splicing factors are stored (Misteli and Spector, 1998; Turner
and Franchi, 1987). The immunocytochemistry was also performed with the NAL
antibody, 474, to see if the speckles seen for NAL co-localise with those of splicing
factors.
Figure 6.5 B shows the immunocytochemistry results produced for 3C5 (green, FITC
signal) and NAL (Texas Red signal). The 3C5 panel shows large foci which are the
storage sites of splice factors, together with some diffuse staining. The NAL panel
shows that NAL is also present in the same speckled structures, which are seen as a
yellow output in the merged panel. The speckled staining of NAL is not as intense
as seen for 3C5, and this could perhaps reflect the fact that under these conditions,
NAL may be preferentially localising to the nucleoplasm instead of the speckles.
Nevertheless the speckles in which some of NAL are the same ones which contain
splicing factors.
Ch 6 Expression and Cellular Localisation Studies
I: No Treatment
(A) WT1 NAL Merge
3 *
&#
(B) NAL 3C5 Merge
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&
Figure 6.5: Immunofluorescence on M15 cells. Panel (A) shows that both WT1 (antibody H2; red
output) and NAL (antibody 474; green output) are nuclear. The staining pattern for both WT1 and
NAL seems to be speckled together with an overall diffuse stain. Panel (B) shows that the speckles
seen for NAL (red output) co-localise with those of 3C5 (green output) which stains interchromatin
granule clusters, where splicing factors are found. After actinomycin D treatment, NAL behaves
differently to WT1 as shown in panel (C). WT1 re-localises to a few, small foci around the remnants
of the nucleoli (red output), where as NAL goes into several larger foci (green output). Panel (D)
shows that the large foci where NAL is found in after actinomycin D treatment (red output), co-
localise witli the foci stained by 3C5 which contain the bulk of the splicing factors.
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6.6 NAL redistributes into large foci after actinomycin D treatment
The interchromatin granule clusters are thought to be sites where splicing factors are
stored and/or assembled until they are required for processing pre-mRNAs. At this
point they are recruited out of the speckles to the sites of active transcription at the
perichromatin fibrils (Misteli et al., 1997; Spector, 1996). The experiments
described in these two papers show that the speckles are very dynamic, as splicing
factors shuttle between the speckles and the site of active transcription. However
when transcription is inhibited, the splicing factors are not required and so remain in
the IGC, causing these structures to become larger and more uniform in shape. Not
all splicing factors return to the IGC when transcription is inhibited, as changes in
localisation are to a large extent splice factor dependent (Spector et al., 1991). For
instance U170K and U2AF65 are examples of splicing factors which instead of
being found in the large foci after inhibition of transcription, are present in small
foci around the remnants of the nucleolus (Carmo-Fonseca et al., 1992). The same
was seen to be true for WT1, as when M15 cells were treated with the transcription
inhibitor actinomycin D, WT1 localised to small foci which co-localised with
U170K and U2AF65, and not with the other snRNPs (Larsson et al., 1995).
The nuclear localisation of NAL was therefore looked at after M15 cells had been
treated with actinomycin D, to see if the treatment affected the nuclear distribution
of NAL. It was of interest to determine whether, if NAL did redistribute, it behaved
like WT1 and localised to small foci around the nucleolus, or whether it was found
in several large foci where most of the other snRNPs are present. Figures 6.5 C and
D, clearly show that when M15 cells are treated with actinomycin D, NAL re¬
distributes into large foci. Panel 6.5 C shows that WT1 is present in small foci
found around the remnants of the nucleolus, as seen previously by Larsson et al.,
1995. These foci are different to the large, abundant foci seen for NAL, and as the
merged output shows, the foci in which WT1 are found in do not co-localise with the
foci in which NAL are in. Panel 6.5 D on the other hand shows that the large foci in
which NAL are found in do co-localise with the large foci stained by 3C5. The
staining seen for NAL does vary to that seen for 3C5 in that even after actinomycin
D treatment, NAL does continue to have a substantial amount of nucleoplasm
staining, whereas for 3C5 there is hardly any nucleoplasm staining at all, as the
splicing factors are localised almost exclusively to the speckles.
These experiments have therefore shown that NAL is a nuclear protein which is
found to be present in speckles as well as being distributed throughout the
nucleoplasm. This nuclear pattern is what has been seen for WT1 (this study and
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(Larsson et al., 1995)). However, when the cells are treated with the transcription
inhibitor, actinomycin D, WT1 and NAL behave differently. WT1 becomes localised
to small foci around the remnants of the nucleolus, as is seen for U170K and
U2AF65, whereas NAL goes into large foci which co-localise with the other
snRNPs.
6.6 Conclusions
This chapter has investigated the expression pattern of NAL as well looking at the
cellular distribution of the protein. The expression of NAL was looked at and
compared to the expression pattern previously documented for WT1. Both RT-PCR
experiments and in situ hybridisation techniques have shown that NAL is
ubiquitously expressed, therefore being expressed in tissues where WT1 is not
found. The immunohistochemistry carried out on kidneys and testes showed that in
these organs, where both NAL and WT1 are expressed, the expression pattern of
NAL is not identical to that of WT1. While WT1 is confined to certain structures
within these organs, NAL is expressed throughout both organs. Thus NAL and WT1
seem to be co-expressed but only in certain tissues and within these, only in
particular structures. Due to its ubiquitous expression, NAL may have a
housekeeping role, and in cells which also express WT1, the function of NAL may
be altered due to its interaction with WT1, and/or NAL may in turn affect the
function of WT1.
Using immunocytochemistry NAL was shown to be a nuclear protein and within the
nucleus it was shown to have both a diffuse distribution throughout the nucleoplasm,
excluding the nucleolus, as well as a speckled localisation. This is what had
previously been reported for WT1 (Larsson et al., 1995). This was a very
encouraging finding as it means that WT1 and NAL are in the same cellular
compartments and are therefore able to interact. Moreover it was interesting to find
that NAL also had a speckled pattern within the diffuse staining in the nucleoplasm,
suggesting that perhaps it may interact with all the different WT1 isoforms.
However, WT1 and NAL differ in their response to treatment with the transcription
inhibitor actinomycin D. When transcription is inhibited, WT1 localises into small
foci which are found around the remnants of the nucleoli, just like U2AF65, whereas
NAL goes into larger speckles which were shown to be the interchromatin granule
clusters, where the bulk of the splicing factors are stored. Although NAL is found in
these large speckles, it does not confirm that it itself is a splicing factor. The
function of these speckles is not yet really understood, but it is thought that these
sites are where splicing factors are stored and perhaps assembled into spliceosomes
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before they are recruited to the sites where the splicing reactions occur (Misteli et al.,
1997). It is thought that apart from the components of the spliceosome, there may
be other proteins present within the speckles which could have nothing to do with
splicing per se, and perhaps NAL could be one of these. It has been noted that many
of the splicing factors that are recruited into the speckles have an arginine/serine
(RS) rich motif (Li and Bingham, 1991) or an RNA binding motif together with a
certain combination of other motifs (Caceres et al., 1997; Gama-Carvalho et al.,
1997). The exact combination of motifs required to send a protein into the speckles
is not really understood and thus it is of interest to note that NAL does not have an
RS motif or an RNA-binding motif but still localises to the speckles.
As the immunocytochemistry of NAL overlapped with that of 3C5, and therefore
with splicing factors, the possibility that NAL could play a role in splicing cannot be
ruled out. The role of WT1 in splicing is not yet known, and indeed the question of
whether WT1 is involved in splicing at all is still very controversial. However, if
NAL and WT1 do play a role in splicing, and since they have been shown to interact
in vivo, it is perhaps surprising that WT1 and NAL did not co-localise after
actinomycin D treatment. This need not be a problem when trying to determine
whether the interaction between NAL and WT1 is significant in a splicing context
because not much is known about the assembly of the spliceosome. For instance it
is not certain whether the spliceosome assembles in the speckles before being
recruited to the site where it is required, or whether splice factors are recruited
individually from the speckles as they are needed. Therefore if WT1 and NAL do
have a role in splicing, they do not necessarily have to be interacting within the
speckles, but only at the site where splicing occurs.
What is known about splicing is that the system requires several snRNPs and
accessory proteins, whose interaction leads to the removal of introns by sequentially
binding to the pre-mRNA. It is first the U1 snRNP which binds to the 5' splice site
of the pre-mRNA. The accessory factor U2AF65 then promotes the binding of the
U2 snRNP to the pre-mRNAs 3' branch point (Zamore et al., 1992). Once U2 is
bound to the branch point, which occurs only after U1 has bound to the 5' splice site,
it commits the pre-mRNA to splicing. The interaction between U1 and U2 brings
the two splice sites together. The trimeric complex of U5 and U4/U6 then completes
the assembly of the spliceosome and splicing can begin. The splicing reaction is
triggered by the release of U4 from the complex, which probably acts to sequester
U6 until it is required. The release of U4 now allows the RNA component of U6 to
hybridise to part of the RNA within U2, the other part being hybridised to the branch
point of the pre-mRNA. The U5 recognises the 3' splice site although it is not yet
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known if it does so directly. The splicing reaction then occurs by two
transesterification events, leading to the joining of the two exons through an
intermediate lariat structure.
Davies et al. speculate that perhaps WT1 influences 3' splice site selection by
binding to a 3' branch point through its RRM and presenting it to U2AF65 by
directly interacting with it (Davies et al., 1998). As NAL interacts with WT1, it
could have a role at the branch point too, perhaps stabilising the complex between
WT1, U2AF65 and U2. However, it has also been suggested that WT1 may act at
several different stages during splicing (Davies et al., 1998) and so NAL could be
interacting with WT1 at any of these points. There are several as yet unidentified
non-snRNP splicing factors within the spliceosome and therefore NAL could be one
of these, acting at any of the stages during splicing. Because NAL is ubiquitously
expressed, it is plausible that it is part of the spliceosome and that perhaps WT1
binds to NAL to somehow affect the outcome of the overall splicing event.
The immunocytochemistry showed that NAL, apart from being present in speckles,
also had a diffuse staining pattern. Splicing factors also have a slight diffuse pattern
as well as the speckled pattern, as the factors do get recruited out of the speckles to
the site of splicing. However, after treatment with actinomycin D, the splicing
factors tend to return to the speckles, thus not only enlarging these structures but
also removing most of the diffuse staining. On the other hand, even after treatment
with actinomycin D, NAL still showed a diffuse staining pattern as well as the
enlarged speckles suggesting that a lot of the protein is not involved with the
speckles. This could perhaps suggest that NAL could have two roles, such as
splicing and transcription as has been postulated for WT1. The different roles of
NAL could arise due to its potential alternative transcripts, which were mentioned
earlier and in chapter 4. The proteins derived from these different transcripts would
possibly be detected by the NAL antibody in the immunocytochemistry experiments
because it was raised against the whole protein as opposed to specific peptides.
The whole mount in situ hybridisation experiment carried out for NAL suggested
that perhaps NAL is expressed higher in areas which may be proliferating at an
increased rate. As described in section 1.6.4, WT1 plays a role in cell cycle
regulation. In the kidney WT1 is thought to inhibit cellular proliferation and to
induce cells to differentiate into epithelial cells. It may be that the role of NAL
could be associated with the cell cycle, and that perhaps WT1 interacts with NAL to
bring about the desired effect. Thus it would be of interest to determine whether
NAL does have a role in the cell cycle.
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Unfortunately due to lack of time, no real functional assays could be done, and so
the role of NAL at the molecular level is not yet clear. However, its distribution
within the nucleus suggests that perhaps NAL could be playing one than one role,
and these may be brought about by alternative transcripts. This study has raised
several speculative functions of NAL but its true role and the consequences of its
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Chapter 7: Summary and discussion
This project set out to identify WT1 interacting proteins, in the hope that the
function of WT1 at the molecular level would become clearer. Although WT1 is
known to be essential for kidney and gonad development, the mechanism by which
it influences cell growth and differentiation is not well understood. There is
considerable evidence suggesting that WT1 is a transcriptional regulator but this
may not be its only role as it may have additional post-transcriptional functions. The
complex nature of the gene, encoding 16 different isoforms, makes it particularly
difficult to dissect WT1 function. Therefore if WT1-protein partners of known
functions are found, then the molecular pathways in which WT1 is involved may
start to fall into place. If protein partners are found whose function are not yet
known, then studies could be done to try and identify their role before attempting to
analyse the consequences of their interaction with WT1. Hopefully these studies
may further our understanding of urogenital development and also how defects in
the pathway might contribute to tumourigenesis.
7.1 A novel protein is identified which binds WT1 in the yeast two hybrid
system
The yeast two hybrid system was used as a tool to identify protein-protein
interactions. As discussed in chapter 3 WT1 +/+ was used to screen both an in-
house M15 cDNA library, which had been made for the purpose of this study, and a
Clontech foetal kidney library, in the hope of identifying proteins which bound to
WT1. The screen with the M15 library only pulled out a few clones, some of which
matched ESTs in the database. Unfortunately further analysis revealed that these
positives were probably false. As the M15 library was not of a high quality (the
insert sizes were small and the proportion of plasmids which were empty vectors was
fairly high) it was decided to screen a commercial kidney library. This library was
screened until it approached saturation. Clones were isolated which bound to WT1
but none of them originated from known proteins. No previously identified WT1
proteins were found. This could be because the particular library used does not
contain cDNA clones representing those proteins or perhaps the library does not
contain the full length clones, leading to lack of isolation if the clone does not
contain the WT1-binding domain.
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The Clontech screen isolated 5 clones that bound to WT1. Only one of these clones,
clone D, bound to WT1 specifically, whereas the other 4 clones also bound to the
negative control SNF1. Although these 4 clones could represent real WT1
interacting clones, they could equally be binding to WT1 due to a 'sticky' motif
which binds to several proteins. No further investigations were carried out on these
clones, which comprised out of frame fibrillin; 2 ESTs; and another clone which had
no matches in the database. Clone D was chosen for further study as it bound to
WT1 specifically from a range of factors tested and also bound to WT1 whether used
as the bait or the prey, suggesting that the interaction detected between the two
proteins is likely to be real. Clone D seemed to have a stronger association with the
-KTS isoforms of WT1, and as domain binding studies showed, it interacted with the
zinc finger region of WT1. As clone D was a novel WT1 binding protein, from then
on it was called NAL (Novel Associating Ligand).
The NAL clone isolated was sequenced fully and intriguingly NAL matched the EST
D14661 but only across the first 445 bases, after which there was a breakpoint where
there was virtually no homology for the remainder of the sequence. This finding
suggested that perhaps either NAL or the EST could have arisen from a chimaeric
clone. Thus RT-PCR experiments were carried out, using primers that spanned the
breakpoint, to determine which one of them was the true clone. It was shown that
NAL could be amplified across the breakpoint in several cell lines used, whereas the
EST could not, suggesting that the EST in the database had originated from a
chimaeric clone. However closer examination of the breakpoint sequence of the
EST suggested that there may be an exon-intron boundary and thus perhaps the EST
in the database may have arisen from an unspliced pre-mRNA. This could have been
verified by carrying out a PCR on genomic DNA. However as the EST also has a
stop codon and a poly-adenylation site at its 3'end, perhaps the EST did not arise
from a chimaeric clone or from unspliced pre-mRNA but could be an alternative
transcript of NAL. If this hypothesis is correct, then it is surprising that the RT-PCR
experiment carried out could not amplify the EST. However alternative splicing
may be cell type dependent and so this transcript may not have been present in the
particular cell lines used. Alternatively the transcript may be short lived or unstable
in these cells. Although not tested, this hypothesis could have been checked by
carrying out a Northern blot to see how many transcripts of NAL are present and
their tissue distribution. Additionally RT-PCR could have been repeated using the
original cell line from which the EST had been isolated. The C-terminus of NAL
also matched ESTs in the database, but unfortunately a contig of the ESTs found did
not extend sufficiently 5' to reach the breakpoint sequence.
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The NAL protein sequence showed no homology to any proteins in the Swissprot
database and the only motifs found within NAL were those of potential
phosphorylation sites. NAL is glutamine rich and as glutamine rich domains have
been found associated with transcription factors (Ladomery, 1997) this opens one
avenue for future investigation (see section 7.6). There are no NAL homologues
currently found in the invertebrate or fungi databases, suggesting that NAL, like
WT1, is present only in vertebrates. The GenBank database contained a mouse EST
homologous to NAL at its N-terminus. However, at the breakpoint, the mouse EST
matched the human EST D14661 and not NAL, and thus a mouse homologue of
NAL had to be isolated. A mouse library screen was performed to try to obtain the
homologue of NAL. A Clontech 11 day mouse cDNA library was screened with the
NAL probe and a clone was isolated which, when sequenced, was shown to be 94%
identical at the nucleotide level to human NAL. Such high sequence conservation at
the nucleotide level is not often seen, mainly because even if the amino acid
sequence conservation is high, at the nucleotide level there can be wobble of the
third base which frequently decreases the percentage identity to about 80%. This
high nucleotide conservation in NAL suggests that there may be constraints at the
RNA level, requiring the bases to be conserved. The fact that this mouse clone
matches NAL, even after the breakpoint, supports the results which show that NAL
was not produced from a chimaeric clone.
The human NAL clone isolated is not quite full length, but by comparing its
sequence to the D14661 EST in the database, it is known that the start site is 9 base
pairs further upstream. The isolated NAL clone is also only 14 base pairs short of
reaching the termination site as compared to the EST found to match the 3'end of
NAL. If a full length NAL clone were needed for future experiments, then the rapid
amplification of cDNA ends (RACE) technique could be used to isolate an
appropriate clone. The mouse Nal clone isolated is not full length either as it does
not have a start site but it does contain the stop codon and the 3' UTR.
7.2 NAL binds to WT1 both in vitro and in vivo
The yeast two hybrid system identified NAL as potentially binding to WT1. This
interaction had to be confirmed outside of the yeast two hybrid system to verify that
the two proteins really bind to each other. Chapter 5 shows the glutathione-S-
transferase (GST) in vitro assays used to provide additional evidence that WT1 and
NAL can interact. It was found that even under high salt conditions, which disrupts
complexes formed by weak interactions between two proteins, all four isoforms of in
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vitro translated WT1 could bind to the GST-NAL fusion protein. Thus both the
yeast two hybrid system and in vitro reactions show that WT1 and NAL can interact.
Despite these binding assays showing that the two proteins could bind, it was not
known whether the interaction was physiologically relevant. In order to test this, in
vivo co-immunoprecipitation assays were carried out. Transiently transfected HA-
tagged NAL could not be co-immunoprecipitated with endogenous WT1, possibly
because the levels of bound HA-NAL were too low to be detected. It was therefore
necessary to obtain anti-NAL antibodies so that the experiments could be carried out
using the endogenous protein.
A polyclonal antibody was raised against NAL by injecting GST-NAL fusion protein
into rabbits. The antibody was shown to specifically recognise NAL on Western
blots and so it could be used for the in vivo experiments. When the co-
immunoprecipitations were carried out, this time using the endogenous proteins and
detecting bound NAL with the polyclonal antibody, an interaction between NAL and
WT1 was seen. As the relative intensities of the detected NAL was similar when the
immunoprecipitation was carried out with anti-NAL antibody or with the anti-WTl
antibody it suggests that a high proportion of NAL is complexed with WT1. This
experiment therefore conclusively demonstrated that in addition to binding in the
yeast two hybrid system and in vitro, NAL and WT1 also bind in vivo.
7.3 Mapping the mouse and human NAL gene
The isolated mouse Nal cDNA was used to map the gene by FISH to mouse
chromosome 17, near the centromere. This position was confirmed by using the
EUCIB resource, which mapped Nal centromeric to the Brachyury (T) gene on
chromosome 17. Interestingly, this region is very close to the T-locus and mutations
within genes of the T-locus have profound effects on embryonal development
(Bennett, 1975). So far no t-alleles have been found to map as close to the
centromere of chromosome 17 as NAL. It is not therefore clear whether Nal is part
of the T-locus and whether, by extrapolation, it plays an essential role in
development.
The human NAL gene was mapped by FISH to chromosome 6q26-27. This region
of human chromosome 6 shows conserved synteny with the centromeric region of
murine chromosome 17, as shown by linkage maps. Interestingly this region of
chromosome 6 has been associated with several malignancies and it is thought that
perhaps a tumour suppressor gene may lie within this region (Theile et al., 1996).
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7.4 NAL is ubiquitously expressed and may have alternative transcripts
The expression pattern of NAL was examined to see if, like WT1, it was tissue
specific - being expressed mainly in the urogenital system - or whether it was more
ubiquitously expressed. RT-PCR experiments carried out on adult mouse tissues
showed that NAL was ubiquitously expressed in all tissues tested. Additionally the
RT-PCR experiment amplified other bands smaller than the expected product in
some tissues. Although these bands could be non-specific, this is unlikely as you
might expect to see these non-specific bands in all samples. The nature of the
shorter amplified bands was not investigated but it is possible that they could
represent alternative transcripts of NAL. Future experiments should be carried out to
determine whether NAL does have alternative transcripts. The RT-PCR experiments
should be repeated and the products probed with an internal oligonucleotide of NAL
to determine whether the shorter products are alternative transcripts of NAL, or
alternatively the RT-PCR products could be directly cloned and sequenced.
Whole mount in situ hybridisation experiments were used to determine the spatial
and temporal expression pattern of NAL. As presented in chapter 6, whole mount in
situ hybridisations showed that NAL is ubiquitously expressed perhaps with
increased expression seen in the tail extremity and the distal end of the limbs. The
expression of NAL is already on at E=9.5 days (the youngest embryos examined),
and remains on throughout the embryo at least until E=12.5d (the oldest embryos
examined) - and during adulthood as the RT-PCR experiments showed. The
expression pattern of NAL is therefore very different to that seen for WT1, as WT1
expression is localised to the urogenital ridge and the mesothelium and peaks at
E=11.5d (Armstrong et al., 1993). By looking at the whole embryo, it was hard to
tell whether the expression of NAL is increased in those areas that also express WT1,
and so in situ hybridisation was carried out on histological sections where the
internal regions of the embryo can be seen better. The preliminary data indicate that
NAL is not expressed at higher levels in those areas that also express WT1, the
staining pattern appearing uniform. These experiments also showed that, contrary to
the results from the whole mounts, expression of NAL is not increased in the tail end
or the distal end of the limbs, suggesting that these areas were more strongly stained
in the whole mounts due to better accessibility of the probe.
The RT-PCR experiment and whole mount in situ hybridisations respectively
showed that NAL was expressed in the adult kidney and in the developing urogenital
ridge. It was of interest to determine whether during kidney development NAL, like
WT1, was constrained to the developing nephros. Therefore immunohistochemistry
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was carried out on E=17.5d kidneys which display all stages of nephrogenesis. The
results showed that, unlike WT1 which is expressed only in the developing nephros,
NAL is expressed throughout the kidney. The same was true in the testis, where
NAL is ubiquitously expressed, while WT1 is confined to the Sertoli cells.
These expression studies therefore show that the pattern of NAL expression differs
to that of WT1, and suggests that although NAL can associate with WT1, it can only
do so in the tissues and cells where they are co-expressed. As NAL is ubiquitously
expressed, it is possible that it may have a housekeeping role and that perhaps WT1
binds to NAL to somehow alter its function.
7.5 Cellular localisation and possible functions of NAL
Immunocytochemical analysis showed that NAL, like WT1, is totally nuclear. This
is an important finding as if the two proteins are to interact then at least a portion of
the proteins should be in the same compartment. Interestingly the nuclear staining
pattern of NAL was shown to be speckled within a diffuse background. This is very
similar to the nuclear distribution of WT1 (figure 6.5 and Larsson et at. 1995). The
speckled structures of NAL were shown to overlap with the interchromatin granules
which are reported to be sites where splicing factors are stored. This finding
therefore suggested that NAL could have a role in splicing and so further tests were
carried out to determine whether NAL behaved as a classical splicing factor.
Actinomycin D treatment was used to investigate whether, like classical splicing
factors, NAL would re-distribute into large foci or alternatively whether NAL might
behave like WT1 and U2AF65 and re-distribute into small foci localised around the
remnants of the nucleolus (Larsson et at. 1995). The staining pattern of NAL did
alter after actinomycin D treatment, becoming incorporated into several large foci as
well as retaining some diffuse staining. These large foci overlapped with the large
splice factor containing foci, and not with the smaller foci in which WT1 was found.
Therefore NAL seems to be behaving as a more classical splicing factor in terms of
nuclear distribution. However although it is tempting to speculate that NAL could
have a role in splicing, caution should be exerted in the interpretation of these results
because the speckles may contain proteins other than splicing factors. Nevertheless,
if NAL and WT1 do play a role in splicing, and since they have been shown to
interact in vivo, it is perhaps surprising that WT1 and NAL did not co-localise after
actinomycin D treatment. However, since splicing does not occur after actinomycin
D treatment, the results suggest that the interaction between WT1 and NAL could be
important at the time when splicing occurs, but not during storage of the two
proteins. Not much is known about the assembly of the spliceosome prior to
- 149 -
Ch 7 Summary and Discussion
splicing. For instance it is not certain whether the spliceosome assembles in the
speckles before being recruited to the site where it is required, or whether splice
factors are recruited individually from the speckles as they are needed. Therefore if
WT1 and NAL do have a role in splicing, they do not necessarily have to be
interacting within the speckles, but only at the site where active splicing occurs.
Splicing requires several snRNPs and accessory proteins, whose interaction leads to
the removal of introns by sequentially binding to the pre-mRNA. The events leading
to fully spliced RNA include the stepwise assembly of the spliceosome via
intermediate complexes as follows: in the E complex the U1 snRNP initially binds to
the 5' splice site of the pre-mRNA and U2AF65 binds to the pyrimidine tract at the
3'splice site, both events requiring members of the SR family of splicing factors.
The accessory factor U2AF65 then promotes binding of the U2 snRNP to the pre-
mRNAs 3' branch point (Zamore et al., 1992) forming the A complex. The
interaction between U1 and U2 brings the two splice sites together, committing the
pre-mRNA to splicing. The trimeric complex of U5 and U4/U6 then completes the
assembly of the spliceosome and this is known as the B complex. The splicing
reaction is triggered by the release of U4 from the spliceosome complex, which
probably acts to sequester U6 until it is required. The release of U4 now allows the
RNA component of U6 to hybridise to part of the RNA within U2, the other part of
U2 being hybridised to the branch point of the pre-mRNA. Following RNA
rearrangement a transesterification occurs, cleaving the 5' exon from the intron
producing a lariat structure. U5 may then have a role re-aligning the exons for the
second transesterification event generating the mRNA.
The role of WT1 in splicing was examined by Davies et al (1998). They showed that
WT1 could interact with U2AF65 in vivo and by doing so it may influence 3'splice
site selection. They postulate that since WT1 has a putative RNA recognition motif
(Kennedy et al., 1996), it may bind to the 3'splice site of the pre-RNA and present it
to U2AF65, thus determining which 3' splice site is used. Since NAL localises to
the speckles and because it interacts with WT1, NAL may also play a role in the
3'splice site selection. By binding to WT1, NAL perhaps stabilises the complex
between WT1, U2AF65 and U2. This could be tested using the yeast two hybrid
system, to see if NAL also binds to U2AF65. However, it has also been suggested
that WT1 may act at several different stages during splicing (Davies et al., 1998) and
so NAL could be interacting with WT1 at any of these points. There are several as
yet unidentified non-snRNP splicing factors within the spliceosome and therefore
NAL could be one of these, acting at any of the stages during splicing. Because
NAL is ubiquitously expressed, it is plausible that it is part of the spliceosome and
-150-
Ch 7 Summary and Discussion
that perhaps WT1 binds to NAL to somehow affect the outcome of the overall
splicing event in a tissue specific manner.
7.6 Future directions
Although this study has not managed to find a WT1-binding protein which directly
helps to further our understanding of WT1, it has identified a novel protein, NAL,
which binds to WT1 in vivo. Several speculative functions of NAL have been
proposed but its true role and the consequences of its interaction with WT1 remains
to be investigated.
Does NAL play a role in splicing?
The studies carried out in chapter 6 showed the nuclear distribution of NAL. It was
shown that NAL had a speckled appearance within a diffuse background and that the
speckles overlapped with the speckles associated with splicing factors. This nuclear
distribution of NAL is thus suggestive of a role in splicing, which could be studied
in more detail.
One way of determining whether NAL acts like a splicing factor is by looking at its
dynamic properties. The movement of splicing factors within the nucleus has been
looked at and seen to leave the speckles in peripheral extensions and accumulate at
sites of active transcription (Misteli et al.1997). This movement of splicing factors
can be blocked when transcription inhibitors are used. Thus to investigate whether
NAL can move and behave in a splice factor-like manner, a GFP-NAL fusion protein
can be made and the dynamics of NAL visualised in living cells.
Immunofluorescent studies under a variety of different conditions have provided
preliminary ways of classifying splice factors. For example RNase A treatment of
cells affects snRNPs and non-snRNP splice factors differently. After treatment with
RNase A, snRNPs leave the speckles and adopt a diffuse localisation whereas non-
snRNPs stay in the speckles which become enlarged. This difference in behaviour is
probably due to snRNP particles requiring RNA-RNA or RNA-protein interactions
to be associated with the speckled region whereas non-snRNP splice factors require
protein-protein interactions (Spector et al., 1991). Thus these experiments could
also be carried out for NAL and they may show what interactions are keeping NAL
in the speckles and whether NAL is acting more like an snRNP or non-snRNP splice
factor. Alternatively cells could be micro-injected with antisense oligonucleotides.
The assembly of snRNPs on pre-mRNA is dependent on several RNA-RNA
interactions. Thus antisense oligonucleotides which disrupts such interactions, like
those which are complementary to the 5'end of the U1 snRNA, can be injected into
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cells disrupting the spliceosomes (Larsson et al., 1995). Following this treatment the
snRNPs assemble in large foci with little diffuse staining. If the sub-nuclear
localisation of NAL is dependent on spliceosome assembly, then NAL should also
redistribute into these large foci. Although this type of immunofluorescence analysis
can give important clues as to potential function, ultimately more direct assays
would be required to determine whether NAL is part of the spliceosome.
To ascertain whether NAL is part of the spliceosome, co-immunoprecipitations
could be carried out. If NAL is part of the spliceosome, then the 474 anti-NAL
antibody should be able to immunoprecipitate spliceosomes assembled in vitro. If
NAL is found to be associated with spliceosomes, then immunodepletion
experiments could also be carried out, where nuclear extracts would be incubated
with the NAL antibody to remove NAL. These NAL-depleted extracts could then be
tested for their ability to splice exogenously added pre-mRNA. If splicing cannot
occur, it would be suggestive of an essential role for NAL in splicing. Purified NAL
could be added back to the NAL-depleted extracts and if NAL is in some way
involved in splicing, the splicing activity may be restored.
If the previous assays all point towards NAL being a splicing factor, then the role of
NAL in splicing could be investigated. The postulated involvement of WT1 at the
3'splice site makes an analysis of NAL at similar sites particularly appealing. To
determine whether NAL is present in early stages of spliceosome assembly,
biotinylated pre-mRNA containing only a 5' or a 3' splice site could be prepared.
Following incubation with nuclear extracts from NAL expressing cells, streptavidin
beads are used to purify the pre-mRNA. A Western blot is then carried out to
investigate whether NAL is incorporated into the earliest splicing complexes present
exclusively at the 5' or 3' splice sites. To study whether NAL affects splice site
selection during alternative splicing, splicing assays using reporter genes can be
carried out. Minigenes containing different alternative splice sites can be transfected
into cells either with or without NAL. The harvested RNA is then used for RT-PCR
and according to the products of the PCR, the effect of NAL can be determined.
Similar assays could be carried out to see if NAL has any antagonistic effects on
splicing factors known to affect splice site selection. The yeast two hybrid method
and immunoprecipitation assays could be carried out to determine with which
components of the splicing machinery NAL is interacting, and thus start gaining
some idea as to which splicing events NAL is involved in.
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Does NAL play a role in transcription?
The immunocytochemistry showed that apart from being present in the speckles,
NAL also had a diffuse staining pattern. This similar staining pattern is seen for
WT1, and probably represents those isoforms which lack the KTS insert and whose
main role is proposed to be transcriptional (Larsson et al., 1995). As NAL has a
glutamine rich, a motif commonly found in transcription regulators, then perhaps a
potential role of NAL in transcription should be investigated.
Transcription factors typically have two domains, a DNA binding domain and an
activation domain. The motif search within NAL did not reveal any DNA-binding
domains, but this does not exclude the possibility that NAL could perhaps bind to
DNA especially if it does play a role in transcription. Thus a general DNA binding
assay could be carried out using DNA-cellulose columns to see whether NAL is able
to bind to DNA. If NAL is found to bind to DNA, then the specific sequence it
binds to could be investigated by using DNA selection assays. Band shift assays
could also be carried out to verify that NAL interacts directly with the isolated target.
If NAL does not bind to DNA directly then it could still be acting as a co-activator
or repressor. The role of NAL in transcriptional control could be examined by fusing
NAL to the yeast Gal4 DNA binding domain. The construct would then be co-
transfected into cells with a Gal4-dependent reporter, and activation or repression of
the reporter gene looked at. It may be that NAL itself is not an activator or repressor
of transcription, but perhaps it could affect the transcriptional activity of WT1. The
yeast two hybrid system showed that NAL bound better to the -KTS isoform of WT1
and so it may do so to affect the transcriptional activity of WT1. Transcriptional
reporter assays could therefore be used to determine whether NAL has any effect on
the transcriptional activity of WT1. If NAL itself has a transcriptional activity then
the effect of WT1 on NAL could also be looked at.
Does NAL play a role in proliferation?
As mentioned previously, the whole mount in situ hybridisation data showed a
tenuous link between NAL and proliferation, hence experiments could be carried out
to determine whether NAL may play a role in cell cycle regulation. The levels of
NAL could be looked at during the cycle to see if they are altered at any particular
stage. Of course it could be that the levels of NAL itself are not altered but its
activity is. Alternatively NAL could be overexpressed in cells to see if this causes
any effect - either promoting growth or apoptosis. The importance of the WT1
function in suppression of cell growth was shown when WT1 was identified as a
tumour suppressor gene. In these experiments, wild type WT1 was reintroduced into
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a Wilms' tumour cell line expressing an aberrantly spliced WT1 transcript, and
shown that it could suppress cell growth (Haber et al., 1993). It would be of interest
to determine whether NAL itself stimulates or inhibits growth, or whether it
interferes with this aspect of WT1 function.
Does NAL play a role in development or disease?
The studies carried out in chapter 4 mapped the mouse Nal gene to chromosome 17,
centromeric to the Brachyury gene. Nal therefore maps very close to the T-locus.
Mutations within genes of the T-locus have profound effects on embryonal
development and as it is not yet clear whether Nal is part of the T-locus and
therefore whether it plays an essential role in development, it would be of interest to
make a Nal null mouse as the phenotype of such a mouse may help in understanding
the role of NAL.
The chromosomal mapping of human NAL is suggestive of a role in disease. NAL
was mapped to chromosome 6q26-27, a region which has been associated with
several malignancies and which is thought to contain a tumour suppressor gene.
Future work could therefore include looking at renal cell carcinomas and ovarian
cancers which have been shown to have deletions in this region of chromosome 6 to
see if NAL is perhaps deleted or mutated or whether its expression is altered
compared to normal tissue. These experiments might help to determine whether
NAL plays a role in these malignancies. It would also be of interest to see if the
expression of NAL is altered in Wilms' tumours compared to normal tissue, as NAL
may be regulated by WT1.
Does NAL have alternative transcripts?
Future work should also concentrate on determining whether NAL does have
alternative transcripts as indicated by both RT-PCR experiments and the EST
database matches. Initially the RT-PCR experiments ought to be repeated and the
products produced should be cloned and sequenced. If these products do seem to
originate from alternative transcripts, then perhaps a cDNA library should be
screened with NAL probes to see whether alternative transcripts can be isolated. A
genomic library could also be screened to be able to analyse the genomic
organisation of NAL and by doing so being able to follow which exons the
alternative transcripts contain. If alternative transcripts are found then it would be of
interest to know whether they carry out different roles, just like the different WT1
isoforms are proposed to do.
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Is NAL part ofa network?
Apart from the aforementioned ways of studying the role of NAL, perhaps the yeast
two hybrid screen could be used to identify NAL-binding proteins. In this way a
network of interactions between NAL, WT1 and other cellular proteins can start to
be built up so as to shed some light on the cellular pathways in which NAL and WT1
are involved.
This future work should therefore help in trying to understand the role of this novel
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Appendix: Primers used in this thesis
The following table contains all the primers used in the thesis, and a brief description
of why they were used.
Primer Sequence 5' -3' Purpose
H792 AGA GAT CTC TCG AGG ATC 5' primer for pGADIO vector.
H793 CAG TAT CTA CGA TTC ATA 3' primer for pGADIO vector
1163 TGG CTT ACC CAT ACG ATG Sequencing pAS vector
J782 TCC CCC GGG TCA GTA TCT
ACG ATT CAT AGA
3' primer adding extra restriction
sites to clone insert from pGADIO
into pAS.
J783 AAC CAT GCC ATG GAG ATC
TCT CGA GGA TCC
5' primer adding extra restriction
sites to clone insert from pGADIO
into pAS.
L55 AGC TGT TGG AGG ACT TAT
TAC
Primer starting at position 941 bp to
sequence NAL in reverse direction.
L56 AGA GAT GCA AGA GTG TAC
TAC
Primer starting at position 248bp of
NAL to sequence the clone further.
L342 CTG AGT GGC TGG AAG TTT
AC
Primer starting at position 416bp of
NAL to sequence the clone further
L343 CTG GCG TGT CTC CTT CAG
CTG
Primer starting at position 694bp of
NAL to sequence the clone in the
reverse direction
L344 TTC TAG GAA GGA TAG AGT
GTA
Primer used to sequence clone B
L345 TTC CAA GGA CCT CCA GGA
TAT
Primer used to further sequence
clone B
L497 CGT ACC TCA GGA AGC AGG
TTT
3' primer used to sequence clone A
L957 AAC CAC TGT CACCTG GTT
GGA
pGADIO primer upstream of H792,
to check the frame of clones.
M715 CGG AAT TCT CAT TGG CTA
TCA GGC GTA AAC TT
3' primer adding EcoRI site and
stop codons in frame at position
428bp to subclone the N-terminal
half of NAL back into pGAD 10.
M716 GGA ATT CAC AGG GAA
AAA GTT ATT AAT GGC GAA
G
5' primer adding EcoRI site in
frame at position 450bp of NAL to
subclone the C-terminus back into
pGADKT
M717 CCC AAG AAG GTT CGA TTG
AGT AAA CAG ACT
5' primer starting at position 14bp
on NAL used for RT-PCR
-A 2-
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Primer Sequence 5' -3' Purpose
M718 ACT TCT GAA CGT GGC GGG
AAC CCA CAG TTC
3' primer starting at position
1142bp on NAL used for RT-PCR
M728 AAG TAA TAT AGA GCC CCA
AAC TAA ATG GTT
3' primer starting at position
1271 bp of EST D14661 used for
RT-PCR
M729 TGCCCA ACT GAG ATC AAC
AAT GGT AGA CCC
5' primer starting at position
306bp of NAL used for RT-PCR
M730 TAC CAA GCT GGA CAG TGT
AAG AAT GTG GCT
3' primer starting at position
724bp of the EST D14661 used
for RT-PCR
M731 TCC TGA CTG CTT TTA AGC
TCC TCA CTG TAT
3' primer starting at position
597bp of NAL used for RT-PCR
N842 GCT CTA GAG AAG AAC CTC
TTC CC
5' primer used to subclone NAL
out of pGADIO and into pCIneo-
HA
N845 ACG CGT CGA CCT AGC CTC
GAC TGT CA T
3' primer used to subclone NAL
out of pGADIO and into pCIneo-
HA
N966 ATT AAC CCT CAC TAA AGG
GA
T3 primer to sequence the pCIneo-
HA-NAL vector
N967 TAA TAC GAC TCA CTA TAG
G
T7 primer to sequence the pCIneo-
HA-NAL vector
P475 TAA TGG CGA AGT GTC GAA
TGC
5' primer used to sequence Nal
from 418bp
P725 AAA GAC TGC AGT CGT CTG 5' primer to sequence Nal from
751bp
Q13 GTT CAG AAT GGC TTG GAC
TCA
5' primer starting at position
1132bp on NAL
Q147 TCA GTG CGG GGT ATG AAA
GTG
5' primer starting at position
987bp on NAL
Q148 ATT CAG ACT TGT TAG AGT
AGA
5' primer starting at position
1497bp on Nal
R385 GTC AAA AAA TTA ATG CAT
AC
5' primer starting at position
1194bp of Nal, used for EUCIB
mapping
R386 CAG TAC AGG TGA GAT ATA
C
3' primer starting at position
1743bp of Nal used for EUCIB
mapping
-A3-
